Clinical trial NCT03175367
Conditions: Hypercholesterolemia
Sponsor: Regeneron Pharmaceuticals
Start date: 2017-11-10; Completion date: 2020-12-14
Enrollment: 272 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.

Detailed description:

Arms: arm 1: SC Evinacumab QW for 16 weeks arm 2: SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks) arm 3: SC Evinacumab QW for 16 weeks arm 4: Placebo SC QW for 16 weeks arm 5: Intravenous (IV) Evinacumab Q4W for 24 weeks arm 6: IV Evinacumab Q4W for 24 weeks arm 7: Placebo IV Q4W for 24 weeks
Interventions: intervention 1: Evinacumab intervention 2: Matching placebo intervention 3: Background Lipid Modifying Therapy (LMT)
Intervention descriptions: intervention 1: SC or IV administration intervention 2: SC or IV administration intervention 3: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Protocol documents:
Prot_000.pdf: 
IND Number: 116398 
EudraCT: 2017-001508-31 
Regeneron Pharmaceuticals, Inc. 
 
Clinical Study Protocol 
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 
Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent 
Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy 
 
 
 
Compound: 
Evinacumab/REGN1500 
Clinical Phase: 
2 
 
 
Protocol Number: 
R1500-CL-1643 
Protocol Version: 
R1500-CL-1643 Amendment 5 
Amendment 5 Date of Issue: 
See appended electronic signature page 
Amendment 4 Date of Issue: 
09 Oct 2018 
Amendment 3 Date of Issue: 
01 Mar 2018 
Amendment 2 Date of Issue: 
29 Sep 2017 
Amendment 1 Date of Issue: 
22 Jun 2017 
Original Date of Issue: 
03 May 2017 
Scientific/Medical Monitor: 
  
 
 Clinical Development & 
Regulatory Affairs 
 
Regeneron Pharmaceuticals, Inc. 
777 Old Saw Mill River Road 
Tarrytown, NY 10591 
 
 
 
 
 
. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 2 of 97 
 
CONFIDENTIAL 
AMENDMENT HISTORY 
Amendment 5 
The protocol was amended in response to recent nonclinical findings in the rabbit. The table 
below summarizes the changes and the affected sections:  
Change 
Sections Changed  
In an embryofetal development toxicology 
study in rabbits, incomplete ossification of 
the 15th vertebra was observed in some 
fetuses resulting from the mating of male 
rabbits exposed to evinacumab with female 
rabbits not exposed to evinacumab. In male 
rabbits, there were measurable levels of 
evinacumab in seminal fluid and, as a safety 
measure, the current clinical study is 
amended to require consistent use of a 
condom for all sexually active males.  
Section 6.2.3 Exclusion Criteria #28 
Table 1 Screening Schedule of Events – Patients 
Requiring Medication Change or Daily Statin 
Stabilization at Study Entry 
Table 2 Screening Schedule of Events – Patients on 
Stable Statin, PCSK9 Inhibitor Antobody and Lipid 
Modifying Therapy Regimen at Study Entry 
Table 3 Schedule of Events for SC Treatment Group A 
Table 4 Schedule of Events for IV Treatment Group B 
Table 5 Schedule of Events for IV Treatment Group B 
(Continued for Open-Label) 
Table 6 Follow-up Schedule of Events for SC Treatment 
Group A 
Table 7 Follow-up Schedule of Events for IV Treatment 
Group B 
Updated Scientific/Medical Monitor 
Title page 
 
Amendment 4 
The primary purpose of this amendment is to update the study population and entry criteria to: 
 Allow patients with heterozygous familial hypercholesterolemia (HeFH) who are not 
taking a background statin due to intolerability to at least 2 statins.  This change is 
being made to include a patient population with high unmet medical need that 
requires further low-density lipoprotein cholesterol (LDL-C) lowering. 
 Change the inclusion LDL-C threshold for all patients with a history of clinical 
atherosclerotic cardiovascular disease (ASCVD) from 100 mg/dL (2.59 mmol/L) to 
70 mg/dL (1.81 mmol/L).  This change aligns with clinical practice and dyslipidemia 
treatment guidelines.  The study population enrolled in this study consists of high-risk 
patients, who are recommended to achieve an LDL-C <70 mg/dL (1.81 mmol/L). 
Additional major changes include increasing the duration of the open-label treatment period for 
Group B from 24 weeks to 48 weeks.  This change has been made to increase the amount of 
long-term safety information obtained on the evinacumab 15 mg/kg Q4W dose regimen, ensuring 
at least 52 weeks of continuous exposure with this regimen for all patients randomized to the 
intravenous (IV) treatment groups. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 3 of 97 
 
CONFIDENTIAL 
Additionally, the protocol is revised to state that patients may have the opportunity to enroll in an 
open-label extension or safety study. 
Change 
Sections Changed  
Allow patients with HeFH who are taking no 
statin(s) to enter the study.  This change is 
being made to include a patient population 
with high unmet medical need that requires 
furthers LDL-C lowering. 
Section 1 Introduction 
Section 3.2.1 Rationale for Study Design 
Section 3.2.3 Benefit / Risk Assessment 
Section 5.1 Study Description and Duration 
Section 6.2.2 Inclusion Criteria 
Section 7.3 Background Treatment 
Change the inclusion LDL-C threshold for 
all patients from 100 mg/dL (2.59 mmol/L) 
to 70 mg/dL (1.81 mmol/L).  This change 
aligns with clinical practice and dyslipidemia 
treatment guidelines.  The study population 
enrolled in this study consists of high-risk 
patients, who are recommended to achieve 
an 
LDL-C 
<70 mg/dL 
(1.81 mmol/L).  
Includes clarification of definition of 
persistent hypercholesterolemia, ACVSD, 
and of intolerance to satins. 
Section 1 Introduction 
Section 2.1 Primary Objective 
Section 3.2.1 Rationale for Study Design 
Section 3.2.3 Benefit / Risk Assessment 
Section 5.1 Study Description and Duration 
Section 6.2 Study Population 
Section 6.2.1 Rescreening of Patients 
Section 6.2.2 Inclusion Criteria 
Section 10.4.3.4 Subgroup Analysis 
The open-label treatment period for Group B 
has been increased from 24 weeks to 
48 weeks.  This change has been made to 
increase the amount of long-term safety 
information obtained on the evinacumab 
15 mg/kg Q4W dose regimen, ensuring at 
least 52 weeks of continuous exposure with 
this regimen for all patients randomized to 
the IV treatment groups. 
Clinical Study Protocol Synopsis (Study Design) 
Section 5.1 Study Description and Duration (including 
Figure 1) 
Section 5.1.2 Follow-up 
Table 4, Table 5, and Table 7 
Section 10.4.1 Patient Disposition 
Section 10.4.9.3 Third Step: Final Safety Analysis 
Note that patients may have the opportunity 
to enroll in an open-label extension or safety 
study. 
Section 3.2.1 Rationale for Study Design 
Section 3.2.3 Benefit / Risk Assessment 
Section 5.1 Study Description and Duration 
Section 5.1.2 Follow-up 
Provide lipid results (but not treatment 
assignment) to patients during the open-label 
treatment period.  The rationale for this 
change is that since patients in Group B/IV 
treatment groups will be in the study for over 
a year, patients’ lipid values will be disclosed 
when at steady state on evinacumab 15 
Section 5.1 Study Description and Duration 
Section 7.6.1 Blinding 
Section 8.2.2 Efficacy Procedures 
Section 8.2.2.2 Specialty Lipid Panel 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 4 of 97 
 
CONFIDENTIAL 
Change 
Sections Changed  
mg/kg IV Q4W to allow patients and 
investigators to be aware of the patients’ 
lipid levels. 
Added a goal attainment threshold of 
50 mg/dL as a secondary endpoint, as current 
lipid treatment guidelines are expected to 
change 
Clinical Study Protocol Synopsis (Secondary Endpoints) 
Section 4.2.2 Secondary Efficacy Endpoints 
For clarity, included the numbers of patients 
enrolled into each treatment group. 
Section 6.1 Number of Patients Planned 
Revised the target population to allow 
patients up to 80 years of age (because they 
should respond similarly in terms of both 
efficacy and safety).  Clarified the target 
population to state that the study will aim to 
enroll, at a minimum, 25% of patients with 
LDL-C 
≥130 mg/dL 
(3.37 mmol/L) 
to 
understand efficacy and safety in patients 
with higher baseline LDL-C levels. 
Clinical Study Protocol Synopsis (Target Population) 
Section 6.2 Study Population 
Section 6.2.2 Inclusion Criteria 
To be consistent with the recommendations 
from the Clinical Trial Facilitation Group 
(CTFG) on contraception and pregnancy 
testing in clinical trials, clarified sexual 
abstinence as “True abstinence: When this is 
in line with the preferred and usual lifestyle 
of the patient. Periodic abstinence (calendar, 
symptothermal, post-ovulation methods), 
withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method 
(LAM) are not acceptable methods of 
contraception.” 
Also included prohibiting oocyte donation. 
Section 6.2.3 Exclusion Criteria 
Removed exclusion criterion prohibiting 
insulin usage, because uncontrolled diabetes, 
defined as HbA1c > 9%, is already an 
exclusion criterion and is sufficient to 
exclude patients with diabetes that might 
confound the safety results. 
Section 6.2.3 Exclusion Criteria 
Clarified that the IV dose should be prepared 
using the patient’s most recent weight 
Section 7.1 Investigational Treatments and Reference 
Treatments 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 5 of 97 
 
CONFIDENTIAL 
Change 
Sections Changed  
Clarified fasting procedures 
Section 8.2.2 Efficacy Procedures 
Minor editorial/formatting changes 
Section 1 Introduction 
Section 3.1 Hypothesis 
Section 3.2.1 Rationale for Study Design 
Section 3.2.2 Rationale for Dose Selection 
Section 3.2.3 Benefit / Risk Assessment 
Section 4.2.2 Secondary Efficacy Endpoints 
Section 5.1 Study Description and Duration 
Section 5.1.1 Description of Study Treatment Groups 
Section 6.2 Study Population 
Section 6.2.2 Inclusion Criteria 
Section 7.1 Investigational Treatments and Reference 
Treatments 
Section 7.3 Background Treatment 
Section 7.5.1.2 Termination of the Infusion 
Section 7.6 Method of Treatment Assignment 
Table 1 Screening Schedule of Events 
Table 4 Schedule of Events for IV Treatment Groups 
Section 9.4.3 Other Events that Require Accelerated 
Reporting to Sponsor 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 6 of 97 
 
CONFIDENTIAL 
Amendment 3 
The table below summarizes the changes to the protocol and the affected sections: 
Change 
Sections Changed  
Added a 24-week open-label treatment 
period after the 24-week double-blind 
treatment period for the IV groups. The 
purpose of this change was to obtain long-
term safety information with continuous 
exposure of evinacumab IV for up to 48 
weeks. 
As a result, the mandatory 24-week follow-
up period for the IV treatment groups was 
removed to allow patients to go directly into 
a separate OL study after completing the 
double-blind treatment period and open-
label treatment period.  Patients who do not 
participate in the OL study would enter a 24-
week follow up period.  
Synopsis: Study Design, Study Duration, Treatments 
Section 3.2.1 Rationale for Study Design 
Section 3.2.2 Rationale for Dose Selection 
Section 3.2.3 Benefit/Risk Assessment 
Section 5.1 Study Description and Duration 
Figure 1 Study Flow Diagram 
Section 5.1.1 Description of Study Treatment Groups 
Section 5.1.2 Follow-up 
Table 3 Schedule of Events for SC Treatment Group A 
Table 4 Schedule of Events for IV Treatment Group B 
Table 7 Follow-up Schedule of Events for IV Treatment 
Group B  
Section 10.3.1.2 Modified Intent-to-Treat 
Section 10.3.2.1 Double-Blind Safety Analysis Set 
Section 10.3.2.2 Open-Label Safety Analysis Set 
Section 10.4.1 Patient Disposition 
Section 10.4.2 Demography and Baseline Characteristics 
Section 10.4.3.1 Primary Efficacy Analysis 
Section 10.4.3.2 Secondary Efficacy Endpoint Analysis 
Section 10.4.3.3 Dose-Response Analysis 
Section 10.4.3.4 Subgroup Analysis 
Section 10.4.3.5 Multiplicity Considerations 
Section 10.4.4 Safety Analysis 
Section 10.4.4.1 Adverse Events 
Section 10.4.4.2 Other Safety 
Section 10.4.4.3 Treatment Exposure 
Section 10.4.4.4 Treatment Compliance 
Section 10.4.9.1 First Step: Group B Main Efficacy and 
Safety Analysis 
Section 10.4.9.2 Second Step: Group A Main Efficacy and 
Safety Analysis 
Section 10.4.9.3 Third Step: Final Safety Analysis 
Removed PK sample at week 12 and week 
20 for IV treatment Group B 
Table 4 Schedule of Events for IV Treatment Group B 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 7 of 97 
 
CONFIDENTIAL 
Change 
Sections Changed  
For Group A, the ADA at week 12 was 
removed because ADA is tested at week 4 
and week 16 and, therefore, an additional 
evaluation at week 12 was not considered 
necessary. 
Table 3 Schedule of Events for SC Treatment Group A 
Edits/Clarifications 
Synopsis:  Endpoint(s) 
Section 3.2.1 Rationale for Study Design 
Section 4.2.1 Primary Efficacy Endpoint 
Section 5.1 Study Description and Duration 
Section 10 Statistical Plan 
Section 10.3.1.1 Intent-to-Treat 
 
Amendment 2 
The table below summarizes the changes to the protocol and the affected sections: 
Change 
Sections Changed  
Specified that enrollment of intravenous (IV) 
cohorts 
will 
precede 
enrollment 
of 
subcutaneous (SC) cohorts. 
Modified run-in period 
Synopsis: Treatments, Study Duration, Statistical Plan 
Section 5.1 Study Description and Duration 
Section 6.1 Number of Patients Planned 
Section 7.2 Run-in Treatment(s) 
Section 7.6 Method of Treatment Assignment 
Section 10.1 Statistical Hypothesis 
Section 10.2 Justification of Sample Size 
Section 10.4.3.1 Primary Efficacy Analysis 
Section 10.4.3.1 Secondary Efficacy Endpoint Analysis 
Section 10.4.3.3 Dose Response Analysis 
Section 10.4.3.4 Subgroup Analysis 
Section 10.4.3.5 Multiplicity Considerations 
Section 10.4.4 Safety Analysis 
Section 10.4.9.1 First Step: Group B Main Efficacy and 
Safety Analysis 
Section 10.4.9.2 Second Step: Group A Main Efficacy and 
Safety Analysis 
Section 10.4.9.3 Third Step: Final Safety Analysis (section 
added)  
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 8 of 97 
 
CONFIDENTIAL 
Change 
Sections Changed  
Removed query for compliance to proprotein 
convertase subtilisin/kexin type 9 (PCSK9) 
inhibitor from the Schedule of Events tables 
Table 1 Screening Schedule of Events - Patients Requiring 
Medication Change or Daily Statin Stabilization at Study 
Entry 
Table 2 Screening Schedule of Events - Patients on Stable 
Statin, PCSK9 Inhibitor and Lipid Modifying Therapy 
Regimen at Study Entry 
Table 3 Schedule of Events for SC Treatment Group A 
Table 4 Schedule of Events for IV Treatment Group B 
Table 6 Follow-up Schedule of Events for SC Treatment 
Group A 
Table 7 Follow-up Schedule of Events for IV Treatment 
Group B 
Updated anti-drug antibody (ADA) variables 
and added a sentence for follow-up of 
patients whose last sample was positive in 
the ADA assay  
Added collection of a sample for ADA at 
week 4 (visit 6) and 12 (visit 14) for SC 
group A and week 4 (visit 4) and 24 (visit 10) 
for IV group B 
Section 4.4 Anti-Drug Antibody Variables 
Section 8.2.4.2 Anti-Drug Antibody Measurements and 
Samples 
Table 3 Schedule of Events for SC Treatment Group A 
Table 4 Schedule of Events for IV Treatment Group B 
Section 10.3.3 Pharmacokinetic and Anti-Drug Antibody 
Analysis Sets 
Section 10.4.6 Analysis of Anti-Drug Antibody Data 
Added a section Benefit Risk 
Section 3.2.3 Benefit / Risk Assessment 
Added assessment for HbA1c during 
prescreening 
Added PK sample at week 4 
Table 1 Screening Schedule of Events – Patients Requiring 
Medication Change or Daily Statin Stabilization at Study 
Entry 
Table 3 Schedule of Events for SC Treatment Group A 
Expanded list of adverse events of special 
interest (AESIs) for evinacumab 
Section 9.4.3 Other Events that Require Accelerated 
Reporting to Sponsor 
Removed exclusion for doxycycline 
Section 6.2.3  Exclusion Criteria (old Exclusion Criterion 
#23) 
Added instruction for maximally tolerated 
regimen of lipid-modifying therapy (LMT) 
Section 5.1 Study Description and Duration 
Section 7.3 Background Treatment(s) 
Updated blinding text 
Section 7.6.1 Blinding 
Edited PCSK9 inhibitor to PCSK9 inhibitor 
antibody 
Throughout 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 9 of 97 
 
CONFIDENTIAL 
Amendment 1 
The protocol is amended primarily to update post-dose monitoring to standardize across the 
evinacumab program. 
The table below summarizes the changes to the protocol and the affected sections: 
Change 
Sections Changed  
Updated 
post-dose 
and 
vital 
signs 
monitoring 
Section 8.1.1 Footnotes for Schedule of Events Tables, 
footnote #7, footnote #11 
Section 8.2.3.1  Vital Signs 
Clarified measurement of LDL-C  
Section 8.2.2  Efficacy Procedures 
Added definition of new onset of diabetes 
Section 9.4.3 Other Events that Require Accelerated 
Reporting to Sponsor 
Updated ADA variables and sampling times  Section 4.4 Anti-Drug Antibody Variables 
Section 8.1 Schedule of Events Table 3 and Table 4 
Section 10.4.6 Analysis of Anti-Drug Antibody Data 
Specified that lipid results after the 
randomization visit will be blinded 
Section 5.1 Study Description and Duration 
Section 7.6.1 Blinding 
Section 8.2.2.1 Core Lipid Panel 
Section 8.2.2.2 Specialty Lipid Panel 
Added an exclusion criterion 
Section 6.2.3 Exclusion Criteria 
Minor clarifications/corrections 
Section 5.1.3 End of Study Definition 
Section 6.2.2 Inclusion Criteria #3 
Section 8.1 Schedule of Events 
Section 10.1 Statistical Hypothesis 
 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 10 of 97 
 
CONFIDENTIAL 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL SYNOPSIS.............................................................................16 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................20 
1. 
INTRODUCTION ......................................................................................................23 
2. 
STUDY OBJECTIVES ..............................................................................................25 
2.1. 
Primary Objective .......................................................................................................25 
2.2. 
Secondary Objective(s) ...............................................................................................25 
3. 
HYPOTHESIS AND RATIONALE ..........................................................................26 
3.1. 
Hypothesis ..................................................................................................................26 
3.2. 
Rationale .....................................................................................................................26 
3.2.1. 
Rationale for Study Design .........................................................................................26 
3.2.2. 
Rationale for Dose Selection ......................................................................................28 
3.2.3 
Benefit / Risk Assessment ..........................................................................................29 
4. 
STUDY VARIABLES................................................................................................30 
4.1. 
Demographic and Baseline Characteristics ................................................................30 
4.2. 
Primary and Secondary Efficacy Endpoints ...............................................................30 
4.2.1. 
Primary Efficacy Endpoint .........................................................................................30 
4.2.2. 
Secondary Efficacy Endpoints ....................................................................................30 
4.3. 
Pharmacokinetic Variable ...........................................................................................31 
4.4. 
Anti-Drug Antibody Variables ...................................................................................31 
5. 
STUDY DESIGN .......................................................................................................31 
5.1. 
Study Description and Duration .................................................................................31 
5.1.1. 
Description of Study Treatment Groups .....................................................................34 
5.1.2. 
Follow-up ....................................................................................................................34 
5.1.3. 
End of Study Definition ..............................................................................................35 
5.2. 
Planned Interim Analysis ............................................................................................35 
5.3. 
Study Committees .......................................................................................................35 
5.3.1. 
Independent Data Monitoring Committee ..................................................................35 
5.3.2. 
Clinical Events Committee .........................................................................................35 
6. 
SELECTION, WITHDRAWAL, AND REPLACEMENT OF PATIENTS ..............36 
6.1. 
Number of Patients Planned .......................................................................................36 
6.2. 
Study Population .........................................................................................................36 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 11 of 97 
 
CONFIDENTIAL 
6.2.1. 
Rescreening of Patients ...............................................................................................36 
6.2.2. 
Inclusion Criteria ........................................................................................................37 
6.2.3. 
Exclusion Criteria .......................................................................................................38 
6.3. 
Premature Withdrawal from the Study .......................................................................41 
6.4. 
Replacement of Patients .............................................................................................42 
7. 
STUDY TREATMENTS............................................................................................42 
7.1. 
Investigational Treatments and Reference Treatments ...............................................42 
7.2. 
Run-in Treatment(s) ....................................................................................................42 
7.3. 
Background Treatment(s) ...........................................................................................43 
7.4. 
Dose Modification and Study Treatment Discontinuation Rules ...............................43 
7.4.1. 
Dose Modification ......................................................................................................43 
7.4.2. 
Study Drug Discontinuation .......................................................................................43 
7.4.2.1. 
Reasons for Permanent Discontinuation of Study Drug .............................................44 
7.5. 
Management of Acute Reactions ................................................................................44 
7.5.1. 
Acute Infusion Reactions ............................................................................................44 
7.5.1.1. 
Interruption of the Infusion .........................................................................................44 
7.5.1.2. 
Termination of the Infusion ........................................................................................45 
7.5.2. 
Acute Injection Reactions ...........................................................................................45 
7.5.2.1. 
Systemic Injection Reactions ......................................................................................45 
7.5.2.2. 
Local Injection Site Reactions ....................................................................................45 
7.6. 
Method of Treatment Assignment ..............................................................................46 
7.6.1. 
Blinding ......................................................................................................................46 
7.6.2. 
Emergency Unblinding ...............................................................................................46 
7.7. 
Treatment Logistics and Accountability .....................................................................47 
7.7.1. 
Packaging, Labeling, and Storage ..............................................................................47 
7.7.2. 
Supply and Disposition of Treatments .......................................................................47 
7.7.3. 
Treatment Accountability ...........................................................................................47 
7.7.4. 
Treatment Compliance ................................................................................................47 
7.8. 
Concomitant Medications and Procedures .................................................................48 
7.8.1. 
Prohibited Medications and Procedures .....................................................................48 
7.8.2. 
Permitted Medications and Procedures ......................................................................48 
8. 
STUDY SCHEDULE OF EVENTS AND PROCEDURES ......................................48 
8.1. 
Schedule of Events .....................................................................................................48 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 12 of 97 
 
CONFIDENTIAL 
8.1.1. 
Footnotes for the Schedule of Events Tables .............................................................58 
8.1.2. 
Early Termination Visit ..............................................................................................58 
8.1.3. 
Unscheduled Visits .....................................................................................................59 
8.2. 
Study Procedures ........................................................................................................59 
8.2.1. 
Procedures Performed Only at the Screening/Baseline Visit .....................................59 
8.2.2. 
Efficacy Procedures ....................................................................................................59 
8.2.2.1. 
Core Lipid Panel .........................................................................................................60 
8.2.2.2. 
Specialty Lipid Panel ..................................................................................................60 
8.2.3. 
Safety Procedures .......................................................................................................60 
8.2.3.1. 
Vital Signs ..................................................................................................................60 
8.2.3.2. 
Physical Examination .................................................................................................61 
8.2.3.3. 
Electrocardiogram .......................................................................................................61 
8.2.3.4. 
Laboratory Testing ......................................................................................................61 
8.2.3.5. 
Pregnancy Testing ......................................................................................................62 
8.2.4. 
Pharmacokinetic and Anti-Drug Antibody Procedures ..............................................63 
8.2.4.1. 
Drug Concentration Measurements and Samples .......................................................63 
8.2.4.2. 
Anti-Drug Antibody Measurements and Samples ......................................................63 
8.2.5. 
Pharmacodynamic Procedures ....................................................................................63 
8.2.6. 
Other Assessments ......................................................................................................63 
8.2.7. 
Review of Diet ............................................................................................................63 
8.2.8. 
Low Density Lipid-Receptor Function .......................................................................63 
8.2.9. 
Future Biomedical Research .......................................................................................63 
 
 
9. 
SAFETY DEFINITIONS, REPORTING, AND MONITORING .............................64 
9.1. 
Obligations of Investigator .........................................................................................64 
9.2. 
Obligations of Sponsor ...............................................................................................64 
9.3. 
Definitions ..................................................................................................................65 
9.3.1. 
Adverse Event .............................................................................................................65 
9.3.2. 
Serious Adverse Event ................................................................................................65 
9.3.3. 
Adverse Events of Special Interest .............................................................................65 
9.3.4. 
Infusion Reactions ......................................................................................................66 
9.4. 
Recording and Reporting Adverse Events ..................................................................66 
9.4.1. 
Adverse Events ...........................................................................................................66 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 13 of 97 
 
CONFIDENTIAL 
9.4.2. 
Serious Adverse Events ..............................................................................................66 
9.4.3. 
Other Events that Require Accelerated Reporting to Sponsor ...................................66 
9.4.4. 
Reporting Adverse Events Leading to Withdrawal from the Study ...........................68 
9.4.5. 
Abnormal Laboratory, Vital Signs, or Electrocardiogram Results .............................68 
9.4.6. 
Follow-up ....................................................................................................................68 
9.5. 
Evaluation of Severity and Causality .........................................................................69 
9.5.1. 
Evaluation of Severity ................................................................................................69 
9.5.2. 
Evaluation of Causality ...............................................................................................70 
9.6. 
Safety Monitoring .......................................................................................................71 
9.7. 
Investigator Alert Notification ....................................................................................71 
10. 
STATISTICAL PLAN................................................................................................71 
10.1. 
Statistical Hypothesis ..................................................................................................72 
10.2. 
Justification of Sample Size........................................................................................72 
10.3. 
Analysis Sets ...............................................................................................................73 
10.3.1. 
Efficacy Analysis Sets ................................................................................................73 
10.3.1.1. 
Intent-to-Treat .............................................................................................................73 
10.3.1.2. 
Modified Intent-to-Treat .............................................................................................73 
10.3.2. 
Safety Analysis Set .....................................................................................................74 
10.3.2.1. 
Double-Blind Safety Analysis Set ..............................................................................74 
10.3.2.2. 
Open-Label Safety Analysis Set .................................................................................74 
10.3.3. 
Pharmacokinetic and Anti-drug Antibody Analysis Sets ...........................................74 
10.3.4. 
Pharmacodynamic Analysis Set .................................................................................74 
10.4. 
Statistical Methods ......................................................................................................74 
10.4.1. 
Patient Disposition ......................................................................................................74 
10.4.2. 
Demography and Baseline Characteristics .................................................................75 
10.4.3. 
Efficacy Analyses .......................................................................................................76 
10.4.3.1. 
Primary Efficacy Analysis ..........................................................................................76 
10.4.3.2. 
Secondary Efficacy Endpoint Analysis ......................................................................76 
10.4.3.3. 
Dose-Response Analysis ............................................................................................78 
10.4.3.4. 
Subgroup Analysis ......................................................................................................78 
10.4.3.5. 
Multiplicity Considerations ........................................................................................78 
10.4.4. 
Safety Analysis ...........................................................................................................79 
10.4.4.1. 
Adverse Events ...........................................................................................................79 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 14 of 97 
 
CONFIDENTIAL 
10.4.4.2. 
Other Safety ................................................................................................................80 
10.4.4.3. 
Treatment Exposure ....................................................................................................81 
10.4.4.4. 
Treatment Compliance ................................................................................................82 
10.4.5. 
Analysis of Drug Concentration Data and Total ANGPTL3 Data .............................82 
10.4.6. 
Analysis of Anti-Drug Antibody Data ........................................................................82 
10.4.7. 
Analysis of Quality of Life Data ................................................................................82 
 
 
10.4.9. 
Timing of Statistical Analyses ....................................................................................83 
10.4.9.1. 
First Step: Group B Main Efficacy and Safety Analysis ............................................83 
10.4.9.2. 
Second Step: Group A Main Efficacy and Safety Analysis .......................................83 
10.4.9.3. 
Third Step: Final Safety Analysis ...............................................................................83 
10.5. 
Additional Statistical Data Handling Conventions .....................................................84 
10.6. 
Statistical Considerations Surrounding the Premature Termination of a Study .........84 
11. 
DATA MANAGEMENT AND ELECTRONIC SYSTEMS .....................................84 
11.1. 
Data Management .......................................................................................................84 
11.2. 
Electronic Systems ......................................................................................................84 
12. 
STUDY MONITORING ............................................................................................84 
12.1. 
Monitoring of Study Sites ...........................................................................................84 
12.2. 
Source Document Requirements ................................................................................84 
12.3. 
Case Report Form Requirements ................................................................................85 
13. 
AUDITS AND INSPECTIONS .................................................................................85 
14. 
ETHICAL AND REGULATORY CONSIDERATIONS ..........................................86 
14.1. 
Good Clinical Practice Statement ...............................................................................86 
14.2. 
Informed Consent .......................................................................................................86 
14.3. 
Patient Confidentiality and Data Protection ...............................................................87 
14.4. 
Institutional Review Board/Ethics Committee ...........................................................87 
15. 
PROTOCOL AMENDMENTS ..................................................................................88 
16. 
PREMATURE TERMINATION OF THE STUDY OR CLOSE-OUT OF A 
SITE ............................................................................................................................88 
16.1. 
Premature Termination of the Study ...........................................................................88 
16.2. 
Close-out of a Site ......................................................................................................88 
17. 
STUDY DOCUMENTATION ...................................................................................89 
17.1. 
Certification of Accuracy of Data ...............................................................................89 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 15 of 97 
 
CONFIDENTIAL 
17.2. 
Retention of Records ..................................................................................................89 
18. 
CONFIDENTIALITY ................................................................................................89 
19. 
FINANCING AND INSURANCE .............................................................................89 
20. 
PUBLICATION POLICY ..........................................................................................89 
21. 
REFERENCES ...........................................................................................................90 
22. 
INVESTIGATOR’S AGREEMENT ..........................................................................92 
SIGNATURE OF SPONSOR’S RESPONSIBLE OFFICERS .....................................................97 
 
LIST OF TABLES 
Table 1: 
Screening Schedule of Events – Patients Requiring Medication Change or 
Daily Statin Stabilization at Study Entry ....................................................................49 
Table 2: 
Screening Schedule of Events – Patients on Stable Statin, PCSK9 Inhibitor 
Antibody and Lipid Modifying Therapy Regimen at Study Entry .............................50 
Table 3: 
Schedule of Events for SC Treatment Group A .........................................................51 
Table 4: 
Schedule of Events for IV Treatment Group B ..........................................................53 
Table 5: 
Schedule of Events for IV Treatment Group B (Continued for Open-Label) ............55 
Table 6: 
Follow-up Schedule of Events for SC Treatment Group A ........................................56 
Table 7: 
Follow-up Schedule of Events for IV Treatment Group B .........................................57 
 
LIST OF FIGURES 
Figure 1: 
Study Flow Diagram ...................................................................................................32 
 
LIST OF APPENDICES 
Appendix 1: Factors to Consider in Assessing the Relationship of Adverse Events to 
Study Drug and Study Conduct or Injection Procedure, Study Procedure, or 
Background Treatment, etc. ........................................................................................93 
Appendix 2: Simon Broome Register Diagnostic Criteria for Heterozygous Familial 
Hypercholesterolemia .................................................................................................94 
Appendix 3: WHO Criteria (Dutch Lipid Network clinical criteria) for Diagnosis of 
Heterozygous Familial Hypercholesterolemia (HeFH) ..............................................95 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 16 of 97 
 
CONFIDENTIAL 
CLINICAL STUDY PROTOCOL SYNOPSIS 
Title 
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and 
Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients 
with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid 
Modifying Therapy 
Site Location(s) 
 
Principal Investigator 
Multi-national (US and globally) 
Multi-center 
Objective(s) 
The primary objective of the study is to evaluate the reduction of 
low-density lipoprotein cholesterol (LDL-C) by evinacumab in comparison 
to placebo after 16 weeks in patients with primary hypercholesterolemia 
(heterozygous familial hypercholesterolemia [HeFH], or non-HeFH with a 
history of clinical atherosclerotic cardiovascular disease [clinical ASCVD]) 
with persistent hypercholesterolemia despite receiving maximally-tolerated 
lipid-modifying treatment (LMT).  Persistent hypercholesterolemia is 
defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical 
ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without 
clinical ASCVD. 
Secondary objectives of the study are: 
 
To evaluate the dose-response effect of evinacumab on other lipid 
parameters (ie, apolipoprotein [Apo] B, non-high-density 
lipoprotein cholesterol [non-HDL-C], total cholesterol [TC], 
Lp(a), HDL-C, triglycerides [TGs], ApoA1, apolipoprotein CIII 
[ApoCIII], and total Angiopoietin-like 3 [ANGPTL3]) in patients 
with primary hypercholesterolemia 
 
To evaluate the safety and tolerability of subcutaneous (SC) and 
intravenous (IV) doses of evinacumab in patients with primary 
hypercholesterolemia 
 
To assess systemic serum concentrations of evinacumab in patients 
with primary hypercholesterolemia 
 
To evaluate the potential development of anti-evinacumab 
antibodies 
Study Design 
This is a phase 2, randomized, double-blind, placebo-controlled, 
dose-ranging study to assess varying doses of SC and IV regimens of 
evinacumab in patients diagnosed with primary hypercholesterolemia 
(HeFH, or non-HeFH with a history of clinical ASCVD) with persistent 
hypercholesterolemia 
despite 
receiving 
maximally-tolerated 
LMT.  
Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL 
(1.81 mmol/L) for those patients with clinical ASCVD and LDL-C 
≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 17 of 97 
 
CONFIDENTIAL 
The study consists of 4 (for Group A [SC treatment groups]) or 5 (for 
Group B [IV treatment groups) periods: run-in period (for patients whose 
background LMT has not been stable prior to screening, who are not already 
receiving a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor 
antibody, or whose background LMT has not been optimized), a 2-week 
screening period, a 16-week double-blind treatment period for the SC dose 
groups or a 24-week double-blind treatment period for the IV dose groups, 
an approximately 48-week open-label treatment period for the IV dose 
groups, and a follow-up period that lasts 24 weeks after the last dose of study 
drug. 
Study Duration 
The duration of the study for a patient is approximately 41 or 90 weeks, for 
the SC and IV groups, respectively.  This includes the screening, 
double-blind treatment, open-label treatment (for IV group), and follow-up 
periods.  All patients who successfully complete this study (or successfully 
complete the double-blind treatment period and open-label treatment period 
for patients in the IV treatment groups) may have the opportunity to enroll 
in an open-label extension or safety study. All patients who enroll in the 
open-label extension or safety study will continue to receive evinacumab. 
Population 
 
 
Sample Size: 
Expected total number of patients is 252 (Group A 144; Group B 108). 
 
Target Population: 
Adult men and women, ages 18 to 80, with primary hypercholesterolemia 
(HeFH*, or non-HeFH with a history of clinical ASCVD) with LDL-C 
≥70** mg/dL (1.81 mmol/L), despite receiving maximally-tolerated LMT.  
Background LMT would include a stable maximally-tolerated statin and 
stable PCSK9 inhibitor antibody for patients who are HeFH or non-HeFH 
with a history of clinical ASCVD.  Patients with HeFH not on a statin are 
allowed to participate if there is documentation of inability to tolerate at least 
2 statins. 
*HeFH may be diagnosed by at least 1 of the following: 
1. Genotyping 
2. World Health Organization/Dutch Lipid Network or Simon 
Broome criteria. 
** Efforts will be made to enroll, at a minimum, 25% of patients with 
LDL-C ≥ 130 mg/dL (3.37 mmol/L).  Approximately 25% of the population 
is targeted to have a baseline LDL-C ≥100 mg/dL (2.59 mmol/L). 
Please note: To ensure an adequate number of patients with HeFH, 
randomization will be stratified 2:1 (HeFH:non-HeFH; 24:12) within each 
treatment group. 
Treatment(s) 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 18 of 97 
 
CONFIDENTIAL 
 
Dose/Route/Schedule: 
Patients will be randomized to either Group A or Group B. Completing 
enrollment and randomizing patients into Group B will occur prior to 
commencing enrollment into Group A.  The evinacumab dose regimens for 
Group A and Group B are as follows: 
Group A 
 
Evinacumab 300 mg SC once every week (QW), for 16 weeks, or  
 
Evinacumab 300 mg SC once every 2 weeks (Q2W), for 16 weeks 
(alternating with placebo on opposite weeks), or 
 
Evinacumab 450 mg SC QW, for 16 weeks 
Group B 
 
Evinacumab 5 mg/kg IV once every 4 weeks (Q4W), for 24 weeks, 
or 
 
Evinacumab 15 mg/kg IV Q4W, for 24 weeks 
In the open-label treatment period, patients in Group B will receive 
15 mg/kg IV of evinacumab Q4W for 48 weeks 
 
Placebo 
 
Route/Schedule: 
 
Group A:  Placebo SC QW, for 16 weeks 
 
Group B:  Placebo IV Q4W, for 24 weeks 
 
Background Treatment 
Statin (HMG CoA reductase inhibitor) 
PCSK9 inhibitor antibody 
Endpoint(s) 
 
 
Primary: 
The primary efficacy endpoint is the percent change in calculated LDL-C 
from baseline to week 16 in the intent-to-treat (ITT) population, using all 
LDL-C values regardless of adherence to treatment and subsequent 
therapies. 
 
Secondary: 
The secondary efficacy endpoints are: 
 
Percent change in ApoB from baseline to week 16 
 
Percent change in non-HDL-C from baseline to week 16 
 
Percent change in TC from baseline to week 16 
 
Proportion of patients with ≥ 30% reduction in calculated LDL-C 
at week 16 
 
Proportion of patients with ≥ 50% reduction in calculated LDL-C 
at week 16 
 
Percent change in TGs from baseline to week 16 
 
Percent change in Lp(a) from baseline to week 16 
 
Proportion of patients with calculated LDL-C < 100 mg/dL 
(2.59 mmol/L) at week 16 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 19 of 97 
 
CONFIDENTIAL 
 
Proportion of patients with calculated LDL-C < 70 mg/dL 
(1.81 mmol/L) at week 16 
 
Proportion of patients with calculated LDL-C < 50 mg/dL 
(1.30 mmol/L) at week 16 
 
Percent change in calculated LDL-C, ApoB, non-HDL-C, TC, TG, 
and Lp(a) from baseline to week 24 (only applicable to those 
patients receiving IV route of study treatment administration) 
Procedures and Assessments 
The efficacy of evinacumab will be assessed by clinical laboratory 
evaluation of lipid levels at pre-specified time points throughout the study.  
Lipid parameters include: TC, calculated LDL-C, HDL-C, TG, non-HDL-
C, Lp(a), ApoA1, ApoB, and ApoCIII. 
Safety and tolerability will be assessed by clinical evaluation of 
treatment-emergent adverse events (TEAEs), physical examination, vital 
signs, electrocardiogram (ECG), and clinical laboratory tests.  Patients will 
be monitored for all TEAEs experienced from the time of informed consent 
until their end of study visit. 
Pharmacokinetics will be assessed by analysis of evinacumab drug 
concentrations. 
Immunogenicity will be assessed by analysis for anti-drug antibodies to 
evinacumab. 
Additional pharmacodynamic effects will be assessed by analysis of total 
ANGPTL3. 
Statistical Plan 
Justification of the sample size 
Four pairwise comparisons of evinacumab to a placebo control arm 
corresponding to the route of administration (Group A or Group B) are 
hypothesized for the primary efficacy analysis of this study.  A total of 216 
patients are planned for assessing the primary measure at week 16.  
Specifically, a sample size of 36 patients per treatment arm will have 90% 
power to detect a treatment group difference in mean percent change LDL-C 
of 20% in any 1 pairwise comparison (ie, evinacumab mean = 27% and 
control mean = 7%), assuming that the common standard deviation (SD) is 
25 using an independent group t-test.  This sample size has been adjusted 
for a 5% dropout rate.  The alpha level for each of the 4 pairwise 
comparisons is 0.05 (2-sided), and assumes control of the overall type-1 
error rate using a pre-specified hierarchical inferential approach. 
Further, the evinacumab 5 mg/kg IV Q4W regimen has been added to 
Group B, allowing for an assessment of dose-response in the IV route of 
administration. The additional 36 patients for this second IV dose regimen 
culminate in a total of 252 patients planned for the study. 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 20 of 97 
 
CONFIDENTIAL 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
ADA 
Anti-drug antibody  
AE 
Adverse event 
ALT 
Alanine aminotransferase 
ANGPTL3 
Angiopoietin-like 3 
ApoA-1 
Apolipoprotein A-1 
ApoB 
Apolipoprotein B 
ApoCIII 
Apolipoprotein CIII 
ASCVD 
Atherosclerotic cardiovascular disease 
AST 
Aspartate aminotransferase 
BUN 
Blood urea nitrogen 
CABG  
Coronary artery bypass graft 
CAD 
Coronary artery disease 
CHD 
Coronary heart disease 
CPK 
Creatine phosphokinase 
CRF 
Case report form (electronic or paper) 
CRO 
Contract research organization 
CVD 
Cardiovascular disease 
CV 
Cardiovascular 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
EDC 
Electronic data capture 
EOS 
End of study 
EOT 
End of treatment 
FAS 
Full analysis set 
FSH 
Follicle-stimulating hormone 
EL 
Endothelial lipase 
FDA 
Food and Drug Administration 
FH 
Familial hypercholesterolemia 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HDL 
High-density lipoprotein 
HDL-C 
High-density lipoprotein cholesterol 
HeFH 
Heterozygous familial hypercholesterolemia 
HoFH 
Homozygous familial hypercholesterolemia 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 21 of 97 
 
CONFIDENTIAL 
hs-CRP 
High-sensitivity C-reactive protein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
IDMC 
Independent Data Monitoring Committee 
IMP 
Investigational medicinal product 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IV 
Intravenous 
LDH 
Lactate dehydrogenase 
LDL 
Low-density lipoprotein 
LDL-C 
Low-density lipoprotein cholesterol 
LDL-R 
Low-density lipoprotein receptor 
LOF 
Loss-of-function 
LMT 
Lipid modifying therapy 
Lp(a) 
Lipoprotein(a) 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
Myocardial infarction 
MMRM 
Mixed-effect model with repeated measures 
mITT 
Modified intent-to-treat 
Non-HDL-C 
Non High-density lipoprotein cholesterol 
PCSK9 
Proprotein convertase subtilisin/kexin type 9 
PCI 
Percutaneous coronary intervention 
PCSV 
Potentially clinically significant value 
PD 
Pharmacodynamic 
PK 
Pharmacokinetic 
POC 
Proof-of-concept 
PT 
Preferred term 
QW 
Every week 
Q2W 
Every 2 weeks 
Q4W 
Every 4 weeks 
RBC 
Red blood cell 
Regeneron 
Regeneron Pharmaceuticals, Inc. 
RNA 
Ribonucleic acid 
SAE 
Serious adverse event 
SAF 
Safety analysis set 
SAP 
Statistical analysis plan 
SAS 
Statistical Analysis System 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 22 of 97 
 
CONFIDENTIAL 
SC 
Subcutaneous 
SD 
Standard deviation 
SOC 
System organ class 
TIA 
Transient ischemic attack 
TC 
Total cholesterol 
TEAE 
Treatment-emergent adverse event 
TG 
Triglyceride 
TSH 
Thyroid stimulating hormone 
WBC 
White blood cell 
WOCBP 
Women of childbearing potential 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 23 of 97 
 
CONFIDENTIAL 
1. 
INTRODUCTION  
Current medications for lowering low-density lipoprotein cholesterol (LDL-C) include statins, 
cholesterol absorption inhibitors, fibrates, niacin, bile acid sequestrants, and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitor antibodies.  Statins are the most commonly prescribed 
medications because they are inexpensive and have demonstrated the ability to reduce coronary 
heart disease (CHD) events.  However, even with statin therapy, many patients still have residual 
cardiovascular (CV) risk (Ridker 2009).  Twenty-two percent (22%) of patients with a history of 
prior cardiovascular disease (CVD) and 10% of patients without a history of prior CVD experience 
a CV event in statin trials (Baigent 2005, Baigent 2010).   
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to lower 
LDL-C by approximately 60% in patients with heterozygous familial hypercholesterolemia 
(HeFH) on maximally tolerated statin therapy (Kastelein 2015), and have recently been approved 
as adjunct to statins in patients with HeFH who require additional LDL-C lowering 
(Praluent® and Repatha® 
Product 
Information). 
 
In 
the 
recent 
Odyssey 
familial 
hypercholesterolemia (FH) 1 and FH 2 studies comparing alirocumab on top of maximally 
tolerated statin therapy (with or without ezetimibe) in patients with HeFH and LDL-C ≥ 70 mg/dL 
with a history of myocardial infarction (MI)/stroke or LDL-C ≥ 100 mg/dL without a history of 
MI/stroke, treatment with alirocumab reduced LDL-C by up to a mean of 48.8% after 24 weeks 
(Kastelein 2015).  Although the majority of patients achieved their target LDL-C goal, up to 19% 
and 28% in the FH 1 and FH 2 studies, respectively, did not meet their LDL-C target after 24 weeks 
of treatment. 
One group of patients recognized to remain far from their LDL-C goal are those patients with 
severe HeFH, often defined as having an on-treatment LDL-C > 200 mg/dL.  However, only 
approximately 2% of patients with severe elevations in LDL-C, despite statin therapy, have an 
identified FH-causing mutation (low-density lipoprotein receptor [LDL-R], apolipoprotein B 
[ApoB], PCSK9) (Khera 2016, Abul-Husn 2016).  Further, those patients with severely elevated 
LDL-C, but without evidence of an FH-causing mutation have a 6-fold increased risk of coronary 
artery disease (CAD), compared with those non-FH patients with an LDL-C <130 mg/dL 
(Khera 2016). 
 
Thus, 
patients 
who 
require 
additional 
LDL-C 
lowering, 
despite 
maximally tolerated statin and PCSK9 inhibitor antibody therapy, include not only those patients 
with HeFH, but also those with polygenic etiologies. 
Data generated with both alirocumab and evolocumab in patients not able to tolerate a statin due 
to muscle-related symptoms highlight another group of patients not able to achieve their LDL-C 
goal who require additional LDL-C lowering despite available treatment options.  The Odyssey 
Alternative study evaluated the effect of alirocumab in patients at moderate to high CV risk who 
were unable to tolerate a statin due to muscle symptoms.  At week 24, 41.9% of patients on 
alirocumab 
achieved 
their 
treatment 
goal 
(LDL-C 
<70 mg/dL 
[1.81 mmol/L] 
in 
very-high-cardiovascular-risk patients, or <100 mg/dL [<2.59 mmol/L] in moderate-to-high-risk 
patients) (Moriarty 2015).  Similarly, evolocumab was also evaluated in patients unable to tolerate 
a statin due to muscle-related symptoms.  In GAUSS-3, approximately 32% of the study 
population was able to achieve an LDL-C of <70 mg/dL (1.81 mmol/L) at week 24 (Nissen 2016).  
Over 50% of the study populations in these trials were not able to achieve their target LDL-C goal.  
Despite treatment with potent agents like PCSK9 inhibitor antibodies, a sizeable proportion of the 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 24 of 97 
 
CONFIDENTIAL 
patients not able to tolerate a statin will not achieve their LDL-C goal and will require additional 
lipid-lowering therapies. 
Angiopoietin-like 3 (ANGPTL3) has recently emerged as an attractive target for the treatment of 
elevated levels of LDL-C and triglycerides (TGs), both factors for the development of CVD.  
Subjects who are homozygous for loss-of-function (LOF) mutations in ANGPTL3 have 
significantly lower levels of TGs as compared to non-carrier controls.  Those with ANGPTL3 LOF 
mutations also exhibit lower LDL-C levels (mean difference of 48% versus non-carriers for the 
mutations).  The mechanism by which ANGPTL3 LOF mutations result in lower LDL-C levels is 
not fully understood, but appears to be independent of the effects on TGs, and occurs through a 
pathway independent of the LDL-R.  It is noteworthy that patients with 1 or 2 ANGPTL3 LOF 
alleles also have reported reductions in serum high-density lipoprotein cholesterol (HDL-C) levels.  
The mechanism for this appears to be related to the inhibitory effect of ANGPTL3 on endothelial 
lipase (EL), which is involved in the hydrolysis of HDL phospholipids.  No health deficits have 
been reported in the (relatively small number of) patients who are homozygous for ANGPTL3 
LOF mutations.  Importantly, population genetic studies indicate that patients heterozygous for 
ANGPTL3 LOF mutations have reduced CV risk.  These data suggest that inhibiting ANGPTL3 
may be a meaningful strategy for lowering serum lipids in patients whose elevated LDL-C levels 
place them at significant residual CV risk, despite otherwise optimized lipid-lowering therapy. 
REGN1500, also known as evinacumab, is a fully human monoclonal antibody that specifically 
binds to and inhibits ANGPTL3.  Preclinical and early clinical studies have demonstrated that the 
administration of evinacumab results in a reduction of serum LDL-C and serum TGs.  
Non-clinical experiments performed in animals demonstrate the in vivo effects of ANGPTL3, and 
ANGPTL3 blockade with evinacumab.  Angiopoietin-like 3 knockout mice, including those fed a 
western or high-fat diet, have lower levels of LDL-C and TGs than those of wild-type mice.  In 
several mouse models, administration of evinacumab induced reductions in both LDL-C (up to 
46% in ApoE-/- mice) and TGs (up to 72% in ApoE-/- mice).  Reductions in HDL-C of 
approximately 35% were also observed in ApoE-/- mice.  In hyperlipidemic LDL-R-deficient 
(LDL-R-/-) mice, a single dose of 10 mg/kg of evinacumab reduced LDL-C levels by up to 23%, 
supporting the hypothesis that the reductions in LDL-C likely occurs through a pathway 
independent of the LDL-R. 
In a phase 1, first-in-human, placebo-controlled, double-blind, single ascending dose study 
(R1500-HV-1214) of the safety, tolerability, and bioeffect of varying dose levels of evinacumab 
administered subcutaneously (SC) or intravenously (IV) to patients with TGs 150-450 mg/dL 
and/or LDL-C ≥ 100 mg/dL, administration of evinacumab was associated with dose-dependent 
reductions in LDL-C.  The maximal mean percent LDL-C decrease from baseline of 27.8% was 
observed on day 15 in the 20 mg/kg IV group (n=11) compared to a decrease of 4.5% in the placebo 
IV group (n= 12).  The duration of LDL-C reduction was dose-dependent and appeared to extend 
at least 64 days after administration of evinacumab 20 mg/kg IV.  Evinacumab was well-tolerated 
at all dose levels up to 20 mg/kg IV. 
In a randomized, double-blind, placebo-controlled, multiple ascending dose study 
(study R1500-CL-1321) of the safety, tolerability, pharmacokinetic (PK), immunogenicity, and 
pharmacodynamic (PD) effects of evinacumab in otherwise healthy patients with mixed 
dyslipidemia (TGs 150-500 mg/dL and LDL-C ≥ 100 mg/dL), repeated administration of 
evinacumab over the 8-week double-blind treatment period was associated with continuous, 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 25 of 97 
 
CONFIDENTIAL 
dose-dependent reductions in LDL-C up to approximately 40%.  The duration of LDL-C reduction 
with evinacumab administration was dose-dependent.  It took approximately 6 weeks for the 
LDL-C level to return to baseline for all SC doses and 9 weeks for the IV dose group. Evinacumab 
was well-tolerated at all dose levels up to 20 mg/kg IV. 
In an ongoing open-label, single-arm, proof-of-concept (POC) study in 9 patients with 
homozygous familial hypercholesterolemia (HoFH) (Study R1500-CL-1331), evinacumab 
demonstrated a mean percent change from baseline in LDL-C at week 4 of 49%, with a duration 
of effect approximately 10 weeks after a single 15 mg/kg IV dose.  In this study, evinacumab, at 
doses up to 15 mg/kg IV, has exhibited an acceptable safety profile. 
The primary objective of the current study is to assess the PD effect of varying doses/dose regimens 
of SC and IV administered evinacumab on serum LDL-C in patients with primary 
hypercholesterolemia (HeFH [heterozygous familial hypercholesterolemia], or non-HeFH with a 
history of clinical atherosclerotic cardiovascular disease [ASCVD]) with persistent 
hypercholesterolemia despite receiving maximally-tolerated lipid-modifying treatment (LMT).  
Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients 
with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical 
ASCVD. 
Additional background information on the study drug and development program can be found in 
the Investigator’s Brochure. 
2. 
STUDY OBJECTIVES  
2.1. 
Primary Objective 
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in 
comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or 
non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite 
receiving maximally-tolerated LMT.  Persistent hypercholesterolemia is defined as LDL-C 
≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL 
(2.59 mmol/L) for those patients without clinical ASCVD. 
2.2. 
Secondary Objective(s) 
The secondary objectives of the study are: 
 To evaluate the dose-response effect of evinacumab on other lipid parameters (ie, 
ApoB, non-high-density lipoprotein cholesterol [non-HDL-C], total cholesterol [TC], 
Lp (a), triglycerides [TGs], ApoCIII), and total ANGPTL3 in patients with primary 
hypercholesterolemia 
 To evaluate the safety and tolerability of SC and IV doses of evinacumab in patients 
with primary hypercholesterolemia 
 To assess systemic serum concentrations of evinacumab in patients with primary 
hypercholesterolemia  
 To evaluate the potential development of anti-evinacumab antibodies  
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 26 of 97 
 
CONFIDENTIAL 
3. 
HYPOTHESIS AND RATIONALE  
3.1. 
Hypothesis 
It is hypothesized that evinacumab will reduce LDL-C in patients who need further LDL-C 
lowering, despite standard of care treatment, including maximally-tolerated statin and PCSK9 
inhibitor antibody therapy. 
3.2. 
Rationale  
3.2.1. 
Rationale for Study Design 
No randomized placebo-controlled clinical CV outcome trials of statin treatment have been 
conducted in patients with HeFH due to ethical concerns of withholding recommended therapy in 
this population.  Clinical management of HeFH is largely based on extrapolation from the results 
of clinical outcomes trials conducted in patients with polygenic hypercholesterolemia, from studies 
in FH patients that used carotid intima-media thickness as a surrogate outcome, and from a small 
number of prospective observational studies in patients with FH.  In 4 observational studies, statin 
therapy was shown to reduce the risk of CHD by 50% to 80% in patients with FH 
(Harada-Shiba 2010, Huijgen 2010, Vermissen 2008).  Unfortunately, even after treatment, the 
risk in HeFH can still be almost 2-fold higher than the general population (Neil 2008). 
Proprotein convertase subtilisin/kexin type 9 inhibitor antibodies have been recently approved as 
adjunct to statins in patients with HeFH who require additional LDL-C-lowering 
(Praluent® and Repatha® Product Information).  The PCSK9 inhibitors have been shown to lower 
LDL-C by approximately 60% in patients with HeFH on maximally tolerated statin therapy 
(Kastelein 2015).  In the recent Odyssey FH 1 and FH 2 studies comparing alirocumab (Praluent®) 
on top of maximally tolerated statins (with or without ezetimibe) in patients with HeFH and LDL-C 
≥70 mg/dL with a history of MI/stroke or LDL-C ≥ 100 mg/dL without a history of MI/stroke, 
treatment with alirocumab reduced LDL-C by up to a mean of 48.8% after 24 weeks 
(Kastelein 2015).  Moreover, these significant reductions in LDL-C by PCSK9 inhibitors also 
result in risk reductions in CV events.  Topline results from the FOURIER study with Repatha® 
(Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated 
Risk) demonstrated a 15% risk reduction in a composite endpoint of CV events (CV death, 
non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or coronary revascularization) 
in patients with clinical ASCVD treated with evolocumab (Sabatine 2017).  Similarly, topline 
results from the Odyssey Outcomes study with alirocumab demonstrated a 15% risk reduction in 
the composite endpoint of major cardiac events (CHD death, non-fatal MI, ischemic stroke, or 
unstable angina requiring hospitalization) (Schwartz 2018).  Both studies highlight the CV 
outcome benefits associated with lowering LDL-C to target levels or even lower. 
Although the majority of patients in the Odyssey FH1 and FH2 studies achieved their target LDL-C 
goal, up to 19% and 28%, respectively, did not meet their LDL-C target after 24 weeks of 
treatment.  One group of patients recognized to remain far from their LDL-C goal are those patients 
with severe HeFH, often defined as having a treated (statin) LDL-C >200 mg/dL.  Approximately 
2% of patients with severe elevations in LDL-C have an identified FH-causing mutation 
(Khera 2016).  Those patients with severely elevated LDL-C, but without evidence of an 
FH-causing mutation, have a 6-fold increased risk of CAD compared with non-FH patients with 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 27 of 97 
 
CONFIDENTIAL 
an LDL-C < 130 mg/dL (Khera 2016).  Thus, patients with significant residual CV risk who require 
additional LDL-C lowering, despite maximally tolerated statin and PCSK9 inhibitor therapy, 
include not only those patients with HeFH, but also those with polygenic etiologies.  It is important 
for all of these patients to achieve their target LDL-C goal, because the body of evidence from the 
statin literature shows that the relationship between LDL-C reduction and CV event reduction is 
approximately linear and for every 1 mmol/L (38.7 mg/dL) reduction in LDL-C, there is a 
corresponding 22% risk reduction in CV events (Cholesterol Treatment Trialists’ Collaboration 
2010). 
Another population not able to achieve their LDL-C goal with the available treatment options and 
require additional LDL-C lowering is those patients with FH  not able to tolerate any statin 
regimen.  Even in studies conducted with potent lipid-lowering agents such as PCSK9 inhibitor 
antibodies, >50% of the study population was not able to achieve their target LDL-C 
(Moriarty 2015) (Nissen 2016), highlighting the high unmet medical need in these patients and the 
need for additional lipid-lowering therapies. 
This present study is a phase 2, double-blind, randomized, placebo-controlled, dose-ranging study 
to assess varying doses of subcutaneous (SC) and intravenous (IV) regimens of evinacumab in 
patients who need further LDL-C reductions, defined as those patients diagnosed with 
hypercholesterolemia (HeFH, or non-HeFH with clinical ASCVD) who have an LDL-C 
≥70 mg/dL (1.81 mmol/L), despite receiving a stable maximally-tolerated lipid-lowering regimen.  
This regimen is defined as including a maximally-tolerated dose of a statin and a PCSK9 inhibitor 
antibody at the top recommended doses for all patients.  Patients with HeFH on no statin will be 
allowed as long as they were treated previously with statins and have the associated documentation 
demonstrating inability to tolerate at least 2 statin regimens. 
The primary endpoint in this study is the percent change in LDL-C from baseline to week 16.  As 
described above, LDL-C is an accepted surrogate endpoint for CV risk, and has repeatedly been 
used as the primary endpoint for other lipid lowering treatments.  The primary endpoint will be 
assessed at week 16 because that treatment duration will allow all patients in both Group A 
(SC treatment groups) and Group B (IV treatment groups) to achieve steady state and maximum 
LDL-C lowering.  As such, 16 weeks is an adequate treatment duration to obtain sufficient PK and 
PD information to guide dose selection. 
In addition to providing key information to understand the effect of evinacumab in patients with 
refractory hypercholesterolemia and to help with dose selection for future studies, long-term safety 
of IV administrations of evinacumab will be evaluated in Group B patients. For this reason, the 
double-blind treatment period for Group B is 8 weeks longer than for Group A (24 weeks vs 16 
weeks) and a 48-week open-label treatment period will occur for patients in Group B. This 
additional exposure to evinacumab will help to define further the safety profile for evinacumab.  
Long-term safety of SC administration will not be obtained in this study, but patients in Group A 
may have the opportunity to enroll in an open-label extension or safety study. The SC treatment 
period in this study is shorter due to the high burden of up to 3 weekly injections, which are 
administered by study staff at each clinic visit.  Therefore, beyond the primary endpoint at 
week 16, patients will not be required to continue receiving evinacumab injections. 
The study design includes a run-in period of variable duration.  This run-in period will ensure 
patients have enough time to become stabilized on their background medications (if they need 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 28 of 97 
 
CONFIDENTIAL 
stabilization). Since this can vary from patient to patient, depending on the potential changes 
needed to their background lipid modifying therapy (LMT), the upper limit of the run-in period is 
variable.  Additionally, for all patients not on a PCSK9 inhibitor antibody that will require 
alirocumab to be provided to them, this change will allow patients to enroll into the study in 
advance of randomization and start to receive a beneficial lipid lowering therapy. 
All patients receiving study treatment will enter a 24-week follow-up period, beginning at the time 
of the last study treatment administration (double-blind or open-label study treatment). 
3.2.2. 
Rationale for Dose Selection  
The doses proposed for this current study are 300 mg SC every week (QW), 300 mg SC every 
2 weeks (Q2W) (alternating with placebo on opposite weeks), 450 mg SC QW, 5 mg/kg IV every 
4 weeks (Q4W), and 15 mg/kg IV Q4W.  These doses have been evaluated in the study 
R1500-CL-1321, in patients with modestly elevated LDL-C and were shown to have an acceptable 
safety profile. Effects in lowering LDL-C have been observed with all of the proposed SC doses.  
The 15 mg/kg IV dose has been studied in the HoFH POC study.  The maximal LDL-C reduction 
from baseline ranged from approximately 15-35% during the 8-week treatment period in the 
R1500-CL-1321 study, whereas mean percent change in LDL-C in the HoFH POC study was 
approximately -49% at 2 weeks following a single 15 mg/kg IV dose.  
Available data show evinacumab PK is nonlinear and dose-dependent, consistent with 
target-mediated elimination. Steady-state concentrations of evinacumab are predicted to be 
achieved after approximately 16 weeks of weekly SC administration.  Target saturation with 
limited duration was observed at evinacumab concentrations of 100 mg/L and above.  In study 
R1500-CL-1321, the PK profiles of 300 mg SC QW, 300 mg SC Q2W and 450 mg SC QW were 
clearly separated in a dose-dependent manner.  Total ANGPTL3 concentrations increased with 
increasing doses, indicating dose-dependent target engagement.  Evidence of target saturation with 
limited duration was observed following 8 weeks of treatment at doses of 20 mg/kg IV Q4W and 
450 mg SC QW.  Target saturation for the duration of the dosing interval is expected with the 15 
mg/kg IV dose.  Based on available data, the dosing regimens to be evaluated in the current study 
are expected to provide therapeutic benefit to patients with primary hypercholesterolemia, and will 
enable comprehensive characterization of evinacumab exposure at dose levels ranging from low 
to high in this patient population.  Varying PD responses at each dose level, including change in 
total ANGPTL3 and LDL-C, can also be obtained to further inform evinacumab exposure-response 
relationship in this particular patient population.  Data collected from this study are expected to 
have a wide dynamic range and support dose selection for phase 3 studies in patients with 
hypercholesterolemia, including, but not limited to, HeFH and non-HeFH. 
Five (5) mg/kg IV Q4W is selected as the alternative lower dose as it is expected to differentiate 
from 15 mg/kg in evinacumab exposure, ANGPTL3 binding, TG reduction and possibly, LDL-C 
reduction in patients with HeFH.  In otherwise healthy subjects with elevated TGs and LDL-C in 
study R1500-HV-1214, single-dose administrations of evinacumab 75, 150, and 250 mg SC and 
5, 10, and 20 mg/kg IV led to dose-dependent target engagement and reductions in LDL-C and 
TGs.  The total exposure (AUC) of evinacumab after 5 mg/kg IV is 4- to 5-fold lower than the 
predicted area under curve for 15 mg/kg IV, due to non-linearity in PK.  In addition, the serum 
concentration of evinacumab in the single-dose study (R1500-HV-1214) after 5 mg/kg IV was 
above 100 mg/L for 2-3 days.  Inclusion of this dose will inform whether ANGPTL3 saturation is 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 29 of 97 
 
CONFIDENTIAL 
needed for maximal LDL-C reduction in patients with HeFH.  On the other hand, 5 mg/kg IV Q4W 
is expected to provide some benefit in decreasing LDL-C in patients with HeFH, as evinacumab 
concentration after 5 mg/kg IV was much greater than that after the 250 mg SC dose, which has 
shown to reduce LDL-C to a varying degree in patients with HoFH (study R1500-CL-1331).  
Low-density lipoprotein response, although observed to lag behind drug exposure, is expected to 
be stabilized following 8 weeks of treatment with a Q4W dosing interval.  
For the open-label phase, 15 mg/kg IV Q4W will be administered.  Target saturation is expected 
during the 4-week dosing interval and patients are most likely to have a sustained, maximal LDL-C 
reduction compared to lower doses.  In addition, safety information can be collected at the highest 
dose of evinacumab and provide the most relevant information to characterize the benefit-risk 
profile of evinacumab over long-term use. 
3.2.3 Benefit / Risk Assessment  
Of the current medications for lowering LDL-C, statins are the most commonly prescribed because 
they are inexpensive and have demonstrated the ability to reduce CHD events.  Proprotein 
convertase subtilisin/kexin type 9 inhibitor antibodies are a newer class of agents that significantly 
lower LDL-C and recently demonstrated a reduction in the risk of CV events (Sabatine 2017). 
Despite all of the available treatment options, particularly statins and PCSK9 inhibitor antibodies, 
some patients still do not reach their LDL-C goal, and continue to have residual CV risk.  In the 
Odyssey FH 1 and FH 2 studies, up to 19% and 28% in FH1 and FH2, respectively, did not meet 
their LDL-C target despite 24 weeks of treatment with alirocumab.  Additionally, some patients 
are not able to tolerate a statin, despite trials with multiple agents and regimens.  In previous studies 
of PCSK9 inhibitor antibodies in patients who are not able to tolerate statin therapy, over 50% of 
patients do not achieve their LDL-C goal. 
Patient populations that continue to need additional LDL-C lowering include those with severe 
HeFH, as well as patients without a mutation identified as causing FH, with polygenic etiologies 
of their disease. It is important for all patients to achieve their LDL-C target because the body of 
evidence from the statin literature shows that the relationship between LDL-C reduction and CHD 
event reduction is approximately linear and for every 1 mmol/L (38.7 mg/dL) reduction in LDL-C, 
there is a corresponding 22% risk reduction in CHD events (CTT study). Moreover, the results 
from recent outcomes trials with ezetimibe (IMPROVE-IT), evolocumab (FOURIER), and 
alirocumab (Odyssey Outcomes) reinforce this concept, providing additional evidence for the 
relationship between LDL-C lowering and reduction in risks for CV events, thereby emphasizing 
the importance for patients to achieve their target LDL-C.  
Evinacumab is a new treatment option that could get patients to their target LDL-C when added to 
a stable lipid-lowering regimen, including statins and a PCSK9 inhibitor antibody. In the early 
clinical studies in healthy subjects, monotherapy treatment with evinacumab resulted in up to 40% 
reduction in LDL-C and up to 80% reduction in TG. In the R1500-CL-1331 study in patients with 
HoFH, treatment with evinacumab on top of a stable lipid lowering regimen resulted in peak mean 
LDL-C reductions of approximately 58%.  
It is expected that treatment with evinacumab will be well tolerated and have an acceptable safety 
profile.  The accumulated safety information from the completed and ongoing clinical studies is 
marked by the absence of any important identified risks. There are potential risks that include 
systemic hypersensitivity reactions, immunogenicity, and embryofetal toxicity. These risks will be 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 30 of 97 
 
CONFIDENTIAL 
managed through careful patient selection and monitoring. For the potential embryofetal toxicity 
risk, there is a strict risk mitigation plan, including requirements for consistent use of contraception 
for sexually active male study participants and sexually active female study participants of child 
bearing potential.  
Taken together, these data show the positive benefit/risk assessment of treatment with evinacumab 
in patients with HeFH, or non-HeFH with clinical ASCVD with persistent hypercholesterolemia 
despite receiving maximally-tolerated LMT.  Persistent hypercholesterolemia is defined as LDL-C 
≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL 
(2.59 mmol/L) for those patients without clinical ASCVD. 
To obtain long-term safety data with evinacumab, all patients in Group B will receive IV study 
drug for 48 weeks. Due to the injection burden of weekly SC administration, Group A patients will 
not be required to receive study drug for 48 weeks. After the 16-week double-blind treatment 
period, Group A patients who wish to receive treatment with evinacumab may have the opportunity 
to enroll in an open-label extension or safety study. Therefore, this study design took into 
consideration the objective of obtaining long-term safety data and providing potential benefit to 
patients with continued treatment with evinacumab while balancing the burden of frequent study 
visits and SC injections. 
4. 
STUDY VARIABLES 
4.1. 
Demographic and Baseline Characteristics 
Baseline characteristics will include standard demography (eg, age, race, weight, and height), 
medical history, and medication history for each patient. 
4.2. 
Primary and Secondary Efficacy Endpoints 
4.2.1. 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the percent change in calculated LDL-C from baseline to week 
16 in the intent-to-treat (ITT) population, using all LDL-C values regardless of adherence to 
treatment and subsequent therapies. 
The primary endpoint is defined as:  100 x (calculated LDL-C value at week 16 - calculated LDL-C 
value at baseline)/calculated LDL-C value at baseline.  The baseline calculated LDL-C value will 
be the last LDL-C level obtained before the first dose of study drug.  The calculated LDL-C at 
week 16 will be the LDL-C level obtained within the week 16 analysis window. 
All calculated LDL-C values (scheduled or unscheduled) may be used to provide a value for the 
primary efficacy endpoint, if appropriate, according to the above definition.  The analysis window 
used to allocate a time point to a measurement will be defined in the statistical analysis plan (SAP). 
4.2.2. 
Secondary Efficacy Endpoints 
The secondary endpoints are: 
 Percent change in ApoB from baseline to week 16 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 31 of 97 
 
CONFIDENTIAL 
 Percent change in non-HDL-C from baseline to week 16 
 Percent change in TC from baseline to week 16 
 Proportion of patients with ≥ 30% reduction in calculated LDL-C at week 16 
 Proportion of patients with ≥ 50% reduction in calculated LDL-C at week 16 
 Percent change in TGs from baseline to week 16 
 Percent change in Lp(a) from baseline to week 16 
 Proportion of patients with calculated LDL-C < 100 mg/dL (2.59 mmol/L) at week 16 
 Proportion of patients with calculated LDL-C < 70 mg/dL (1.81 mmol/L) at week 16 
 Proportion of patients with calculated LDL-C < 50 mg/dL (1.30 mmol/L) at week 16 
 Percent change in calculated LDL-C, Apo B, non-HDL-C, TC, TG, and Lp(a) from 
baseline to week 24 (only applicable to those patients receiving IV route of study 
treatment administration) 
4.3. 
Pharmacokinetic Variable 
The PK variable is evinacumab concentrations at sampling times specified in the visit schedule 
(Table 3 and Table 4). 
4.4. 
Anti-Drug Antibody Variables 
Anti-drug antibody (ADA) variables include ADA status and titer as follows: 
 Treatment-emergent response - defined as a positive response post first dose in the 
ADA assay when baseline results are negative or missing 
 Treatment-boosted response - defined as a positive response post first dose in the ADA 
assay that is at least 9-fold over baseline titer levels, when baselines results are positive 
The definition of persistent and transient ADA will be defined a priori in the SAP. 
 Titer category 
 Low (titer <1,000) 
 Moderate (1,000 ≤ titer ≤10,000) 
 High (titer >10,000) 
Samples positive in the ADA assay will be assessed for neutralizing activity. 
5. 
STUDY DESIGN  
5.1. 
Study Description and Duration 
This is a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to assess 
varying doses of SC and IV regimens of evinacumab in patients diagnosed with primary 
hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) who have an 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 32 of 97 
 
CONFIDENTIAL 
LDL-C ≥70 mg/dL (1.81 mmol/L), despite receiving a stable maximally-tolerated LMT.  The LMT 
would include a stable, maximally-tolerated statin and stable PCSK9 inhibitor antibody for patients 
who are HeFH or non-HeFH with a history of clinical ASCVD.  Patients with HeFH not on a statin 
are eligible if there is documentation of inability to tolerate at least 2 statins (see Section 7.3 
Background Treatments for further information). 
The study consists of 4 (for Group A [SC treatment groups]) or 5 (for Group B [IV treatment 
groups]) periods: a run-in period (for patients whose background LMT has not been stable prior to 
screening, who are not already receiving a PCSK9 inhibitor antibody, or whose background LMT 
is not optimized), a 2-week screening period, a 16-week double-blind treatment period for the SC 
dose groups or 24-week double-blind treatment period for the IV dose groups, an approximately 
48-week open-label treatment period for the IV dose groups, and a follow-up period lasting 24 
weeks after the last dose of study drug (Figure 1). 
All patients in Group B who have successfully completed the double-blind treatment period and 
the open-label treatment period, and all patients in Group A who have successfully completed the 
double-blind treatment period and follow-up period in this study may have the opportunity to 
enroll in an open-label extension or safety study.  All patients who enroll in the separate open-label 
extension study will continue to receive evinacumab. 
Figure 1: 
Study Flow Diagram 
 
Run-in 
Screening 
Double-Blind 
Treatment 
Open-Label 
Treatment  
Follow-Up Period 
 
 
 
 
Group A: SC x 16 weeks  
Group B: IV x 24 weeks 
Group B: IV x 
48 weeks 
Group A: 23 weeks 
Group B: 20 weeks 
 
 
 
 
Baseline 
 
End of Double-Blind  
End of Open-Label 
End of Study  
Variable 
(Day –14) 
 
(Day 1) 
(Day 113/ Day 169) 
(Approx Day 505) 
(Day 274/ Day 
645) 
Run-in: 
There will be a run-in period for: 
 Patients who are not receiving the maximal dose of a PCSK9 inhibitor antibody or 
whose dose has not been stable for at least 8 weeks before the screening visit  
 Patients whose maximally tolerated statin has not been stable for at least 4 weeks before 
the screening visit 
 Patients whose background LMT (other than statin or PCSK9 inhibitor antibody) has 
not been stable for at least 4 weeks (6 weeks for fibrates) before the screening visit 
During this run-in period, patients will be stabilized on their statin, PCSK9 inhibitor antibody, and 
other background LMT (as applicable), and patients receiving alirocumab 75 mg SC Q2W will 
have their dose up-titrated to the maximum dose of either 150 mg SC Q2W or 300 mg SC Q4W. 
The duration of the run-in period will depend on the time needed for the patient to stabilize on 
their background LMT. 
Whether or not a patient is considered to be on a maximum tolerated regimen of LMT (statin, 
PCSK9 inhibitor, ezetimibe, etc) and reasons why the patient is not taking the various treatments 
(eg, due to intolerance, lack of efficacy, etc) will need to be documented in the case report form 
(CRF). 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 33 of 97 
 
CONFIDENTIAL 
Screening:  
Patients who have been receiving a stable maximally tolerated statin regimen for at least 4 weeks 
and a stable PCSK9 inhibitor antibody regimen (alirocumab 150 mg SC Q2W, or 300 mg SC 
Q4W, or evolocumab 140 mg SC Q2W or 420 mg SC Q4W) for at least 8 weeks before screening, 
and whose additional LMT (as applicable) has been stable for at least 4 weeks (6 weeks for 
fibrates) before screening, will enter a 2-week screening period.  
Double-blind Treatment: 
Patients who meet all inclusion criteria and who meet none of the exclusion criteria will be 
randomized within  either Group A (1:1:1:1) or Group B (1:1:1) to receive: 
Group A 
 Evinacumab 300 mg SCQW, for 16 weeks, or  
 Evinacumab 300 mg SC Q2W, for 16 weeks (alternating with placebo on opposite 
weeks), or 
 Evinacumab 450 mg SCQW, for 16 weeks, or  
 Placebo SC QW, for 16 weeks 
Group B 
 Evinacumab 5 mg/kg IV Q4W, for 24 weeks, or  
 Evinacumab 15 mg/kg IV Q4W, for 24 weeks, or 
 Placebo IV Q4W, for 24 weeks 
Enrollment of IV cohorts will occur before enrollment of SC cohorts, accordingly, enrollment of 
Group A will not begin until Group B enrollment is completed. 
Patients randomized within either the SC (Group A) and IV (Group B) treatment groups will have 
different visit schedules because of the differences in dosing frequency.   
Randomization will be stratified by high-intensity statin (Yes/No) and HeFH (Yes/No) at baseline.  
High-intensity statin is defined as rosuvastatin 20 mg or 40 mg daily, atorvastatin 40 mg or 80 mg 
daily, or simvastatin 80 mg daily (if already on this dose for >1 year).  To ensure an adequate 
number of patients with HeFH are included in this study and exposed to each dose, randomization 
will be stratified 2:1 (HeFH:non-HeFH; 24:12) within each treatment group.  
Investigational medicinal product (IMP) administration during the double-blind treatment period 
will take place at the site and possibly, by visiting home nurses (only for the SC group).  The IMP 
will be administered at the site on the day of randomization, after all samples for clinical laboratory 
evaluation have been obtained.  In order to ease burden for those patients randomized to receive 
SC IMP, visiting home nurses may be utilized to administer SC IMP on odd visit dates, eg. Week 1, 
week 3, and week 5. 
Open-Label Treatment Period (Group B only) 
Patients in Group B (the IV treatment groups) will enter a 48-week open-label treatment period 
and all patients will receive evinacumab 15 mg/kg IV Q4W. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 34 of 97 
 
CONFIDENTIAL 
Follow-Up Period (Groups A and B) 
All patients will be followed for 24 weeks after the last dose of study drug. 
Patients should maintain their stable background LMT regimen from screening through the end of 
study (EOS) visit. 
Patients will be reminded to adhere to a heart-healthy diet at screening, and continuing through the 
EOS visit.  Patients should maintain a stable exercise level for the duration of the study, and avoid 
rigorous exercise 24 hours before each study visit. All lipid results will be blinded from after 
randomization until the week 36 visit for the IV cohorts, and until database lock for the SC cohorts. 
5.1.1. 
Description of Study Treatment Groups 
Group A double-blind treatment period (16 weeks):  
 Evinacumab 300 mg SC QW, or  
 Evinacumab 300 mg SC Q2W (alternating with placebo on opposite weeks), or 
 Evinacumab 450 mg SC QW, or  
 Placebo SC QW, for 16 weeks 
Group B double-blind treatment period (24 weeks): 
 Evinacumab 5 mg/kg IV Q4W, or  
 Evinacumab 15 mg/kg IV Q4W, or  
 Placebo IV Q4W, for 24 weeks 
Group B open-label treatment period (48 weeks): 
 Evinacumab 15 mg/kg IV Q4W 
5.1.2. 
Follow-up 
All patients will be followed for 24 weeks after the last dose of study drug.  Thus, for IV cohorts 
in which the dosing interval is Q4W, patients will be followed for an additional 20 weeks after end 
of treatment (EOT).  For SC cohorts, in which the shortest dosing interval is QW, patients will be 
followed for an additional 23 weeks after the EOT visit.Patients in Group B may have the option 
of joining an open-label extension or safety study after successfully completing the treatment 
period (48 weeks). Patients in Group A may have the option of joining an open-label extension or 
safety study after successfully completing the treatment period (16 weeks) and follow-up period 
(24 weeks). Those patients that do not enroll in the separate open-label study will enter a follow-up 
period, which lasts 20 weeks for IV groups after the last dose of study drug.  It takes approximately 
24 weeks for evinacumab concentration to be below lower limit of quantitation.   
Sexually active patients should be reminded at the EOT visit to maintain highly effective 
contraceptive measures for 24 weeks after the last dose of study drug.  At this visit, women of 
childbearing potential (WOCBP) may be provided urine pregnancy tests to perform at home with 
instructions to test for pregnancy 4 weeks after this visit and Q4W thereafter.  The patient should 
also be notified of Q4W follow-up phone calls to confirm contraception use, provide a reminder 
of pregnancy reporting, and to obtain the results of the pregnancy test. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 35 of 97 
 
CONFIDENTIAL 
5.1.3. 
End of Study Definition 
The EOS for this study is defined as the last visit of the last patient. 
5.2. 
Planned Interim Analysis  
No interim analysis is planned. 
5.3. 
Study Committees 
5.3.1. 
Independent Data Monitoring Committee 
An Independent Data Monitoring Committee (IDMC), composed of members who are 
independent from the sponsor and the study investigators, will monitor patient safety by 
conducting formal reviews of accumulated safety data that will be blinded by treatment group; if 
requested, the IDMC may have access to the treatment allocation code or any other requested data 
for the purposes of a risk-benefit assessment. 
The IDMC will provide the sponsor with appropriate recommendations on the conduct of the 
clinical study to ensure the protection and safety of the patients enrolled in the study.  The IDMC 
will also institute any measures that may be required for ensuring the integrity of the study results 
during the study execution. 
All activities and responsibilities of the IDMC are described in the IDMC charter. 
5.3.2. 
Clinical Events Committee 
The Clinical Events Committee is composed of experts in the field of cardiovascular disease, 
independent from the sponsor and the investigators.  This committee will be responsible for 
defining, validating, and classifying (in a blinded fashion) pre-specified cardiovascular events, and 
all deaths.  
Patients with suspected or confirmed CV events, which occur during the time period from 
randomization until the follow-up visit, will have a corresponding adjudication package prepared 
and submitted to the CEC.  The events should also be reported as serious adverse events (SAEs), 
as appropriate.  Adjudicated CV events include all CV adverse events (AEs) positively 
adjudicated. The adjudication categories include: 
 CHD death 
 Non-fatal MI 
 Fatal and non-fatal ischemic stroke 
 Unstable angina requiring hospitalization 
 Congestive heart failure requiring hospitalization 
In addition, deaths will be classified by the CEC.  All coronary revascularizations (percutaneous 
coronary intervention [PCI], coronary artery bypass graft [CABG]) will be submitted to the CEC, 
and analyzed. 
A charter and an adjudication operational manual will specify additional details regarding the 
procedures, criteria, and classification used for adjudication of these events. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 36 of 97 
 
CONFIDENTIAL 
6. 
SELECTION, WITHDRAWAL, AND REPLACEMENT OF 
PATIENTS 
6.1. 
Number of Patients Planned 
Approximately 252 patients, at approximately 80 sites in the US and globally, will be randomized 
within either Group A (evinacumab 300 mg SC QW: evinacumab 300 mg SC Q2W: evinacumab 
450 mg SC QW: placebo SC) or Group B (evinacumab 5 mg/kg IV Q4W: evinacumab 15 mg/kg 
IV Q4W: placebo IV).  There will be 144 patients randomized to Group A (36 patients per 
treatment group), with 108 patients exposed to SC evinacumab and 36 exposed to SC placebo.  
There will be 108 patients randomized to Group B (36 patients per treatment group), with 72 
patients exposed to IV evinacumab and 36 exposed to IV placebo. 
6.2. 
Study Population  
Adult men and women, ages 18 to 80, with primary hypercholesterolemia (HeFH, or non-HeFH 
with clinical ASCVD), with persistent hypercholesterolemia despite receiving maximally-
tolerated LMT.  Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) 
for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients 
without clinical ASCVD.  Background LMT would include a stable maximally-tolerated statin and 
stable PCSK9 inhibitor antibody for patients who are HeFH or non-HeFH with a history of clinical 
ASCVD.  Patients with HeFH not on a statin are allowed to participate if there is documentation 
of inability to tolerate at least 2 statins due to muscle symptoms.  Inability to tolerate a statin should 
be due to skeletal muscle-related symptoms, other than those due to strain or trauma, such as pain, 
aches, weakness, or cramping, that began or increased during statin therapy and stopped when 
statin therapy was discontinued. 
Randomization will be stratified 2:1 (HeFH:non-HeFH; 24:12) within each treatment group to 
ensure an adequate number of patients with HeFH are appropriately represented at each dose.  This 
will ensure that there is a proportionate distribution of patients with HeFH in each cohort to 
adequately assess the safety and efficacy of evinacumab in patients with HeFH.   
Approximately 25% of the population is targeted to have a baseline LDL-C ≥100 mg/dL 
(2.59 mmol/L) and approximately 25% of the population should have a baseline LDL-C 
≥130 mg/dL (3.37 mmol/L).  The baseline value is defined as the last available value before the 
first dose of study drug. 
6.2.1. 
Rescreening of Patients  
Patients who do not meet eligibility criteria during the initial screening may rescreen only once.  
Patients who are rescreened after the screening window ends must re-consent for study 
participation and repeat all screening procedures. 
Patients who do not meet all eligibility criteria during the initial screening, and are still within the 
screening window, may retest once the assessments that did not meet eligibility criteria. 
Patients with a history of ASCVD who previously failed screening due to the LDL-C threshold of 
100 mg/dL (2.59 mmol/L) will be eligible to rescreen once based on the eligibility criterion being 
amended to 70 mg/dL (1.81 mmol/L). 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 37 of 97 
 
CONFIDENTIAL 
6.2.2. 
Inclusion Criteria  
A patient must meet the following criteria to be eligible for inclusion in the study: 
1. Men and women, ages 18 through 80 at the screening visit 
2. Body mass index ≥ 18.0 and ≤ 40.0 kg/m2 
3. Diagnosis of primary hypercholesterolemia, either HeFH* or non-HeFH with clinical 
ASCVD 
*Diagnosis of heFH must be made either by genotyping or by clinical criteria.  For those 
patients not genotyped, the clinical diagnosis may be based on either the Simon Broome 
criteria for definite FH (Appendix 2) or the World Health Organization/Dutch Lipid 
Network criteria with a score of >8 points (Appendix 3). 
4. A history of clinical ASCVD, for those patients who are non-HeFH.  Clinical ASCVD is 
defined as: acute coronary syndrome, or a history of MI, stable or unstable angina, coronary 
or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral 
arterial disease presumed to be of atherosclerotic origin (Stone 2014) 
5. Receiving a stable maximally tolerated* statin (± ezetimibe) for at least 4 weeks at 
screening 
*Patients not able to be on a high-intensity statin/statin dose should be treated with a 
regimen considered appropriate for the patient, according to the investigator's judgment.  
Some examples of acceptable reasons for a patient taking a lower statin dose or no statin 
include, but are not limited to: adverse effects, advanced age, low body mass index, 
regional practices, local prescribing information, concomitant medications, co-morbid 
conditions such as impaired glucose tolerance/impaired fasting glucose.  The reason(s) for 
not receiving a high-intensity statin will be documented in the CRF. 
“High-intensity statin” is defined as (any of the following are acceptable): 
 Rosuvastatin 20 mg or 40 mg daily  
 Atorvastatin 40 mg or 80 mg daily  
 Simvastatin 80 mg daily (if already on this dose for > 1 year) 
6. For those patients with HeFH who are not receiving a statin at screening, documentation 
of inability to tolerate at least 2 statins.  Inability to tolerate a statin should be due to skeletal 
muscle-related symptoms, other than those due to strain or trauma, such as pain, aches, 
weakness, or cramping, that began or increased during statin therapy and stopped when 
statin therapy was discontinued. 
7. Receiving alirocumab 150 mg SC Q2W or 300 mg SC Q4W, OR evolocumab 140 mg SC 
Q2W or 420 mg SC Q4W for at least 8 weeks prior to the screening visit 
8. For those patients with a history of clinical ASCVD, serum LDL-C ≥70 mg/dL 
(1.81 mmol/L) at screening (1 repeat lab is allowed).  ASCVD is defined as:  acute coronary 
syndrome, or a history of MI, stable or unstable angina, coronary or other arterial 
revascularization, stroke, TIA, or peripheral arterial disease presumed to be of 
atherosclerotic origin (Stone 2014).  Patients with a history of ASCVD who previously 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 38 of 97 
 
CONFIDENTIAL 
failed screening due to the LDL-C threshold of 100 mg/dL (2.59 mmol/L) will be eligible 
to rescreen once based on the change to 70 mg/dL (1.81 mmol/L). 
9. For those patients without a history of clinical ASCVD, serum LDL-C ≥100 mg/dL 
(2.59 mmol/L) at screening (1 repeat lab is allowed).  Clinical ASCVD is defined as: acute 
coronary syndrome, or a history of MI, stable or unstable angina, coronary or other arterial 
revascularization, stroke, TIA, or peripheral arterial disease presumed to be of 
atherosclerotic origin (Stone 2014) 
10. Stable heart-healthy diet, starting at screening and willing to continue through the EOS 
visit  
11. Willing and able to comply with clinic visits and study-related procedures 
12. Provide signed informed consent 
6.2.3. 
Exclusion Criteria  
A patient who meets any of the following criteria will be excluded from the study: 
1. Known history of homozygous FH (clinically, or by previous genotyping) 
2. Use of any medication or nutraceutical (other than a statin or PCSK9 inhibitor antibody) 
known to alter serum lipids and which has not be stable for at least 4 weeks (6 weeks for 
fibrates) before screening. 
3. Unwilling to maintain current exercise regimen and/or general physical activity level for 
the duration of the study 
4. Presence of any clinically significant uncontrolled endocrine disease known to influence 
serum lipids or lipoproteins 
Note:  Patients on thyroid replacement therapy can be included if the dosage of the 
replacement therapy has been stable for at least 12 weeks prior to screening and the thyroid 
stimulating hormone (TSH) level is within the normal range of the central laboratory at the 
screening visit. 
5. Use of thyroid medications (except for replacement therapy which has been stable for at 
least 12 weeks before screening) 
6. Newly-diagnosed (within 3 months prior to screening visit) or poorly-controlled 
(hemoglobin A1c [HbA1c] > 9%) diabetes 
7. Daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg (except 
for patients on simvastatin 80 mg for > 1 year) 
8. Use of estrogen or testosterone therapy unless the regimen has been stable in the past 
6 weeks prior to the screening visit and there are no plans to change the regimen during the 
study 
9. Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal 
disease with a stable regimen for at least 6 weeks prior to randomization 
Note:  Topical, intra-articular, nasal, inhaled and ophthalmic steroid therapies are not 
considered as ‘systemic’ and are allowed. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 39 of 97 
 
CONFIDENTIAL 
10. Initiation of a new diet or major change to a previous diet within 4 weeks prior to screening 
11. Conditions/situations such as: 
a. Any clinically significant abnormality identified at the time of screening that, in the 
judgment of the investigator or any sub-investigator, would preclude safe completion 
of the study or constrain endpoints assessment; eg, major systemic diseases, patients 
with short life expectancy 
b. Considered by the investigator or any sub-investigator as inappropriate for this study 
for any reason, eg: 
 Deemed unable to meet specific protocol requirements, such as scheduled visits 
 Deemed unable to tolerate injections, as per the patient or the investigator 
 Investigator or any sub-investigator, pharmacist, study coordinator, other study 
staff or relative thereof directly involved in the conduct of the protocol, etc. 
 Presence of any other conditions (eg, geographic or social), either actual or 
anticipated, that the investigator feels would restrict or limit the patient’s 
participation for the duration of the study 
12. Laboratory findings during screening period (not including randomization labs): 
a. Triglycerides >400 mg/dL (>4.52 mmol/L) for patients without a known history of 
diabetes mellitus (1 repeat lab is allowed);  
OR 
Triglycerides >300 mg/dL (>3.39 mmol/L) for patients with a known history of 
diabetes mellitus (1 repeat lab is allowed) 
b. Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody (associated 
with a positive HCV ribonucleic acid [RNA] polymerase chain reaction) 
c. Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women 
of childbearing potential 
d. Estimated glomerular filtration rate <30 mL/min/1.73 m2 according to 4-variable 
MDRD study equation (calculated by central lab) 
e. TSH >1.5 x upper limit of normal (ULN) (1 repeat lab is allowed) for patients not on 
thyroid replacement therapy 
f. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN at 
screening (1 repeat lab is allowed) 
g. Creatine phosphokinase (CPK) > 3 x ULN at screening (1 repeat lab is allowed) 
13. Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at the 
screening visit or time of randomization (1 repeat allowed) 
14. History of heart failure (New York Heart Association [NYHA] Class III-IV) within 
12 months before screening  
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 40 of 97 
 
CONFIDENTIAL 
15. History of MI, unstable angina leading to hospitalization, CABG surgery, PCI, 
uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, TIA, carotid 
revascularization, endovascular procedure or surgical intervention for peripheral vascular 
disease within 3 months prior screening  
16. Having received LDL apheresis within 2 months before screening  
17. Evidence of clinically significant intestinal malabsorption, or a history of ileal bypass, 
gastric bypass, or other bariatric surgery within 12 months before screening  
18. Unstable weight (variation > 5 kg) within 2 months prior to screening visit 
19. Significant concomitant illness including, but not limited to: cardiac, renal, neurological, 
endocrinological, hepatic, metabolic, or lymphatic disease, that would adversely affect the 
patient’s participation in the study  
20. History of cancer within the past 5 years, except for adequately treated basal cell skin 
cancer, squamous cell skin cancer, or in situ cervical cancer  
21. Known hypersensitivity to monoclonal antibody therapeutics  
22. History of a hypersensitivity reaction to PCSK9 inhibitor antibodies 
23. Participation in a clinical research study evaluating an investigational drug within 30 days, 
or at least 5 half-lives of the investigational drug, before screening, whichever is longer  
24. History or evidence of drug or alcohol abuse within 12 months before screening  
25. History of noncompliance to medical treatments  
26. Pregnant or breast-feeding women 
27. Women of childbearing potential* who are unwilling to practice a highly effective birth 
control method prior to the initial dose, during the study, and for 24 weeks after the last 
administration of study drug.  Highly effective contraception measures include: 
 Stable use of combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to 
screening: 
 oral 
 intravaginal 
 transdermal 
 Stable use of progestogen-only hormonal contraception associated with inhibition of 
ovulation initiated 2 or more menstrual cycles prior to screening: 
 oral 
 injectable 
 implantable  
 Intrauterine device  
 Intrauterine hormone-releasing system  
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 41 of 97 
 
CONFIDENTIAL 
 Bilateral tubal ligation  
 Vasectomized partner.  Note: Vasectomized partner is a highly effective birth control 
method provided that the partner is the sole sexual partner of the WOCBP study 
participant and that the vasectomized partner has received medical assessment of the 
surgical success. 
 Sexual abstinence.  Note:  Sexual abstinence is considered a highly effective method 
only if defined as refraining from heterosexual intercourse during the entire period of 
risk associated with study treatments. 
True abstinence: When this is in line with the preferred and usual lifestyle of the patient.  
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are 
not acceptable methods of contraception 
*Postmenopausal women must be amenorrheic for at least 12 months in order not to be 
considered of childbearing potential.  Postmenopausal status will be confirmed by 
measurement of follicle-stimulating hormone (FSH).  Pregnancy testing and contraception 
are not required for women with documented hysterectomy and/or oophorectomy.  
Oocyte donation is prohibited during the study and for 24 weeks after the last 
administration of study drug. 
28. Men who are sexually active with WOCBP and are unwilling to consistently use 
condoms during the study drug treatment period and for 24 weeks after the last 
administration of study drug, regardless of vasectomy status.  Sperm donation is 
prohibited during the study and for up to 24 weeks after the last administration of study 
drug. 
29. Member of the clinical site study team and/or his/her immediate family. 
6.3. 
Premature Withdrawal from the Study  
A patient has the right to withdraw from the study at any time, for any reason, and without 
repercussion. 
The investigator and/or sponsor have the right to withdraw a patient from the study if it is no longer 
in the interest of the patient to continue in the study, or if the patient’s continuation in the study 
places the scientific outcome of the study at risk (eg, if a patient does not or cannot follow study 
procedures).  An excessive rate of withdrawals would render the study uninterpretable; therefore, 
unnecessary withdrawal of patients should be avoided. 
Patients who are withdrawn prematurely from the study will be asked to complete study 
assessments, as described in Section 8.1.2. 
Rules for discontinuation of study drug (permanent or temporary) are discussed in Section 7.4.2. 
Early Termination from the Study 
If for any reason the patient refuses to continue the study, the patient should undergo an 
unscheduled visit with assessments normally planned at the EOT visit (it should take place within 
5 days of treatment discontinuation, if possible). 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 42 of 97 
 
CONFIDENTIAL 
For patients that discontinue the study prematurely, the patient should be followed for at least 
24 weeks from the last dose of study drug or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last.  A final EOS visit should take 
place with assessments as specified in the EOS visit (ie, follow-up visit) at 24 weeks after the last 
dose of study drug. 
Sexually active patients who discontinue the study prematurely should be reminded at the 
unscheduled visit following treatment discontinuation to maintain highly effective contraceptive 
measures for 24 weeks after the last dose of study drug.  At this visit, WOCBP will be provided 5 
urine pregnancy tests with instructions to test for pregnancy 4 weeks after this visit and Q4W 
thereafter.  All patients should also be notified of Q4W follow-up phone calls to confirm 
contraception use, remind them of pregnancy reporting, and to obtain the results of the urine 
pregnancy test. 
The investigator or study staff should make the best effort to contact any patient (eg, contacting 
patient’s family or private physician, review available registries or health care database) who fails 
to return to the site, and to determine health status, including at least vital status.  Attempts to 
contact such patients must be documented in the patient’s records (eg, times and dates of attempted 
telephone contact, receipt for sending a registered letter).  The site will be provided a retention 
manual outlining the best practices for patient retention.  
6.4. 
Replacement of Patients 
Patients who prematurely discontinue from the study will not be replaced. 
7. 
STUDY TREATMENTS  
7.1. 
Investigational Treatments and Reference Treatments 
Evinacumab or placebo will be supplied for SC or IV administration.  Study treatment groups are 
defined in Section 5.1.1.   
For patients who are not receiving a PCSK9 inhibitor antibody, sterile alirocumab drug product 
will be supplied at a concentration of 150 mg/mL in a prefilled pen. 
All SC injections will be administered in the abdomen, thigh, or outer area of the upper arm with 
rotating sites of injection.  Instructions for management of acute injection site and infusion 
reactions are provided in Section 7.5. 
For SC QW regimen the dose should be administered ± 3 days; if ≥4 days have passed, skip the 
dose and return to the original schedule.  For IV Q4W regimen the dose should be administered 
± 14 days; if >14 days have passed, skip the dose and return to the original schedule. 
The IV dose should be prepared using the patient’s most recent weight.  Further instructions on 
dose preparation are provided in the pharmacy manual. 
7.2. 
Run-in Treatment(s) 
There will be a run-in period for: 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 43 of 97 
 
CONFIDENTIAL 
 Patients who are not receiving the maximal dose of a PCSK9 inhibitor antibody or 
whose dose has not been stable for at least 8 weeks before the screening visit  
 Patients whose maximally tolerated statin has not been stable for at least 4 weeks before 
the screening visit 
 Patients whose background LMT (other than statin or PCSK9 inhibitor antibody) has 
not been stable for at least 4 weeks (6 weeks for fibrates) before the screening visit 
During this run-in period, patients will be stabilized on their statin, PCSK9 inhibitor antibody, and 
other background LMT (as applicable), and patients receiving alirocumab 75 mg SC Q2W will 
have their dose up-titrated to 150 mg SC Q2W or 300 mg SC Q4W.  The duration of the run-in 
period will depend on the time needed for the patient to stabilize on their background LMT. 
Patients have to be consented prior to entering the run-in period. 
7.3. 
Background Treatment(s) 
All patients should be on a stable, maximally-tolerated LMT regimen throughout the duration of 
the study.   
All patients should be on maximal background LMT, which includes a stable maximally tolerated 
statin and stable PCSK9 inhibitor antibody.  Patients with HeFH who are not on a statin are allowed 
to participate if there is documentation of inability to tolerate at least 2 statins due to muscle 
symptoms.  Inability to tolerate a statin should be due to skeletal muscle-related symptoms, other 
than those due to strain or trauma, such as pain, aches, weakness, or cramping, that began or 
increased during statin therapy and stopped when statin therapy was discontinued. 
For the background LMT, sites must follow the national product label for patient safety monitoring 
and management.  The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, 
as well as other LMT (if applicable), should remain stable throughout the study duration, from 
screening through the EOS visit.  If a patient is not considered to be on a maximum tolerated LMT 
regimen (high-intensity statin, PCSK9 inhibitor antibody, ezetimibe, etc) at the start of the run-in 
or at screening, reasons why or why not (eg, due to intolerance, lack of efficacy, not marketed in 
the region) the patient is taking/not taking the various treatments will need to be documented in 
the CRF. 
7.4. 
Dose Modification and Study Treatment Discontinuation Rules 
7.4.1. 
Dose Modification 
Dose modification for an individual patient is not allowed. 
7.4.2. 
Study Drug Discontinuation 
Study treatment should be continued whenever possible.  In the event study drug dosing is stopped, 
it should be determined if the stop can be made temporarily; permanent discontinuation should be 
a last resort.  Regardless, the patient should remain in the study treatment period as long as 
possible. 
Patients who prematurely discontinue study drug should remain in the study and undergo all study 
visits and procedures, with the exception of dosing with study drug.  At the time of study drug 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 44 of 97 
 
CONFIDENTIAL 
discontinuation, the patient should have, as soon as possible, an unscheduled visit with assessments 
normally planned at EOT visit (this should take place within 5 days of discontinuation of study 
drug, if possible), and then resume the original study schedule until the EOS visit.  In case of early 
discontinuation before week 16, all efforts should be made to perform EOT assessments as soon 
as possible. 
Patients who permanently discontinue from study drug, and who opt to withdraw from the study, 
will be asked to complete study assessments, per Section 6.3. 
7.4.2.1. 
Reasons for Permanent Discontinuation of Study Drug 
Study drug dosing will be permanently stopped in a patient in the event of the following, but not 
limited to: 
 Evidence of pregnancy 
 Acute systemic injection/infusion reactions with AEs including, but not limited to, 
anaphylaxis, laryngeal/pharyngeal edema, severe bronchospasm, chest pain, seizure, or 
severe hypotension 
 Patient requires a prohibited concomitant medication during the study.  The principal 
investigator should contact the Regeneron study monitor.  Based on the discussion, 
study drug may be continued, or may be temporarily or permanently discontinued 
 Patient withdraws consent 
The investigator may permanently discontinue dosing with study drug at any time, even without 
consultation with the medical monitor, if the urgency of the situation requires immediate action 
and if this is determined to be in the patient’s best interest.  However, the medical monitor should 
be contacted as soon as possible in any case of permanent study drug discontinuation. 
7.5. 
Management of Acute Reactions  
7.5.1. 
Acute Infusion Reactions 
Emergency equipment and medication for the treatment of infusion reactions must be available 
for immediate use.  All infusion reactions must be reported as AEs (as defined in Section 9.4.1) 
and graded using the grading scales, as instructed in Section 9.5.1. 
7.5.1.1. 
Interruption of the Infusion 
The infusion should be interrupted if any of the following AEs are observed: 
 cough 
 rigors/chills 
 rash, pruritus (itching) 
 urticaria (hives, welts, wheals) 
 diaphoresis (sweating) 
 hypotension 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 45 of 97 
 
CONFIDENTIAL 
 dyspnea (shortness of breath) 
 vomiting 
 flushing 
The reaction(s) should be treated symptomatically, and the infusion may be restarted at 50% of the 
original rate. 
If investigators feel there is a medical need for treatment of the reaction or need for discontinuation 
of the infusion, other than described above, they should use clinical judgment to provide the 
appropriate response according to typical clinical practice. 
7.5.1.2. 
Termination of the Infusion 
The infusion should be terminated and NOT restarted if any of the following AEs occur: 
 anaphylaxis* 
 severe bronchospasm 
 chest pain 
 seizure 
 severe hypotension 
 other neurological symptoms (confusion, loss of consciousness, paresthesia, paralysis, 
etc.) 
 any other symptom or sign that, in the opinion of the investigator, warrants 
discontinuation of the infusion 
*Consider anaphylaxis if the following is observed (Sampson 2006):  acute onset of an 
illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, 
generalized hives, pruritus or ﬂushing, swollen lips-tongue-uvula) AND AT LEAST ONE 
OF THE FOLLOWING: 
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak 
expiratory flow, hypoxemia) 
b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence) 
7.5.2. 
Acute Injection Reactions 
7.5.2.1. 
Systemic Injection Reactions 
Acute systemic reactions following administration of study drug (IV or SC), should be treated 
using clinical judgment, based on standard clinical practice, in order to determine the appropriate 
response.  
7.5.2.2. 
Local Injection Site Reactions 
Local injection site reactions must be reported as AEs and graded according to the Food and Drug 
Administration (FDA) September 2007 Guidance for Industry, Toxicity Grading Scale for Healthy 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 46 of 97 
 
CONFIDENTIAL 
Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (provided in the 
study Regulatory Binder, also see Section 9.5.1). 
7.6. 
Method of Treatment Assignment  
Patients will be randomized within either Group A (SC treatment regimens) in a 1:1:1:1 ratio or 
Group B (IV treatment regimens) in a 1:1:1 ratio.  Enrollment of IV cohorts will occur before 
enrollment of SC cohorts; accordingly, enrollment of Group A will not begin until Group B 
enrollment is completed.  There will be 144 patients randomized to Group A (36 patients per 
treatment group), with 108 patients exposed to SC evinacumab and 36 exposed to SC placebo.  
There will be 108 patients randomized to Group B (36 patients per treatment group), with 
72 patients exposed to IV evinacumab and 36 exposed to IV placebo. 
Patients in Group A will receive treatment from day 1 through week 16 (last dose of study drug at 
week 15).  Patients in Group B will receive treatment from day 1 through week 24 (last dose of 
study drug week 20).  Patients will be randomized to a treatment group according to a central 
randomization scheme provided by an interactive voice response system (IVRS)/interactive web 
response system (IWRS) to the designated study pharmacist (or qualified designee).  
Randomization will be stratified by study treatment route of administration (Group A or B), 
high-intensity statin (Yes/No), and HeFH (Yes/No) at baseline.  High-intensity statin is defined as 
rosuvastatin 20 mg or 40 mg daily, atorvastatin 40 mg or 80 mg daily, or simvastatin 80 mg daily 
(if already on this dose for >1 year).  To ensure that an adequate number of patients with HeFH 
are included, randomization will be stratified 2:1 (HeFH:non-HeFH; 24:12) within each treatment 
group. 
7.6.1. 
Blinding  
Study patients, principal investigators, and study site personnel will remain blinded to all 
randomized study treatment group assignments throughout the study.  The Regeneron Study 
Director, Medical Monitor, Study Monitor, and any other Regeneron and contract research 
organization (CRO) personnel who are in regular contact with the study site will remain blinded 
to all patient randomization assignments.  All lipid results will be blinded from after randomization 
until the week 36 visit for the IV cohorts, and until database lock for the SC cohorts. 
Due to differences in the color of the study drug as compared to placebo, an unblinded pharmacist 
or qualified unblinded designee will  prepare the IV infusion bags and SC injections. Further details 
are provided in the pharmacy manual. 
7.6.2. 
Emergency Unblinding 
Unblinding of treatment assignment for a patient may be necessary due to a medical emergency or 
any other significant medical event (eg, pregnancy). 
If unblinding is required: 
 Only the investigator will make the decision to unblind the treatment assignment 
 Only the affected patient will be unblinded 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 47 of 97 
 
CONFIDENTIAL 
 The designated study pharmacist(s)/designee at the study site will provide the treatment 
assignment to the investigator.  If there is no study pharmacist, the investigator for the 
site will unblind the patient 
 The investigator will notify Regeneron and/or designee before unblinding the patient, 
whenever possible 
Treatment assignment is not to be provided to site personnel, other than the unblinded study 
pharmacist (when applicable), at any time during the conduct of the study, except in the case of a 
true emergency.  In the event that there is no study pharmacist, the individual at the site fulfilling 
that role will be the only unblinded member of the site personnel. 
7.7. 
Treatment Logistics and Accountability 
7.7.1. 
Packaging, Labeling, and Storage  
A medication numbering system will be used to label blinded investigational study drug.  Lists 
linking medication numbers with product lot numbers will be maintained by the groups (or 
companies) responsible for study drug packaging.  In order to maintain the blind, these lists will 
not be accessible to individuals involved in study conduct. 
Study drug will be stored at the site at a temperature of 2ºC to 8ºC; storage instructions will be 
provided in the pharmacy manual. 
7.7.2. 
Supply and Disposition of Treatments 
Study drug will be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study.  At specified time points during the study (eg, interim site 
monitoring visits), at the site close-out visit, and following drug reconciliation and documentation 
by the site monitor, all opened and unopened study drug will be destroyed, or returned to the 
sponsor or designee. 
7.7.3. 
Treatment Accountability 
All drug accountability records must be kept current. 
The investigator must be able to account for all opened and unopened study drug.  These records 
should contain the dates, quantity, and study medication 
 dispensed to each patient 
 returned from each patient (if applicable), and 
 disposed of at the site or returned to the sponsor or designee 
All accountability records must be made available for inspection by the sponsor and regulatory 
agency inspectors; photocopies must be provided to the sponsor at the conclusion of the study. 
7.7.4. 
Treatment Compliance 
All drug compliance records must be kept current and made available for inspection by the sponsor 
and regulatory agency inspectors. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 48 of 97 
 
CONFIDENTIAL 
7.8. 
Concomitant Medications and Procedures 
Any treatment administered from the time of informed consent to the final study visit will be 
considered concomitant medication.  This includes medications that were started before the study 
and are ongoing during the study. 
7.8.1. 
Prohibited Medications and Procedures 
Any background medical LMT, which has not been stable for at least 4 weeks prior to the screening 
visit, is prohibited. 
 Simvastatin 80 mg (unless having received for > 1 years), lomitapide, and mipomersen 
are prohibited. 
 LDL apheresis is a prohibited procedure. 
7.8.2. 
Permitted Medications and Procedures 
The use of all medications and nutritional supplements known to alter serum lipids, including (but 
not limited to) statins, ezetimibe, fibrates, niacin, bile acid resins, red yeast rice, and PCSK9 
inhibitor antibodies is permitted, as long as that therapy has been stable for at least 4 weeks 
(6 weeks for fibrates and 8 weeks for PCSK9 inhibitor antibodies) prior to the screening visit.  
Patients should continue taking their background medical LMT for the duration of the study, 
starting at screening and continuing through the EOS visit. 
Thyroid replacement therapy can be used, if the dosage of thyroxine has been stable for at least 12 
weeks prior to the screening visit (week -2). 
8. 
STUDY SCHEDULE OF EVENTS AND PROCEDURES 
8.1. 
Schedule of Events 
Study assessments and procedures are presented by study period and visit in Table 1, Table 2, 
Table 3, Table 4, Table 5, Table 6, and Table 7. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 49 of 97 
 
CONFIDENTIAL 
Table 1: 
Screening Schedule of Events – Patients Requiring Medication Change or 
Daily Statin Stabilization at Study Entry 
Visit Number 
Visit 1a 
Pre-Screening  
Visit 1 
Full Screening Visit 
Visit Window (Day) 
 
Day -14 to -1 
Week 
 
-2 
Screening/Baseline: 
 
Informed Consent 
X 
 
 
 
X 
Medication Adjustment 
X 
 
Inclusion/Exclusion 
X 
X 
Medical History/Surgical History, Alcohol Habits, Smoking 
Habits 
 
X 
Demographics 
 
X 
Treatment: 
 
Concomitant Medications 
X 
X 
Query LMT compliance 
X 
X 
Safety: 
 
Height 
 
X 
Weight 
 
X 
Vital Signs 
 
X 
Physical Examination 
 
X 
Electrocardiogram3 
 
X 
Contraception Use Reminder1 
X 
X 
Remind male patients to use condoms 
X 
X 
Adverse Events 
X 
X 
Laboratory Testing2: 
 
Hematology 
 
X 
Chemistry 
 
X 
Urinalysis 
 
X 
Core Lipid Panel (8-hour fasting sample) 
X 
X 
HbA1c 
X 
X 
Pregnancy Test 
Urine 
Serum 
Hepatitis B and C serology 
 
X 
TSH 
 
X 
FSH 
 
X 
PK and Ab Samples: 
 
Research Samples (biomarkers) 
 
X 
Other: 
 
 
Review of diet 
X 
X 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 50 of 97 
 
CONFIDENTIAL 
Table 2: 
Screening Schedule of Events – Patients on Stable Statin, PCSK9 Inhibitor 
Antibody and Lipid Modifying Therapy Regimen at Study Entry 
Visit Number 
Visit 1 
Screening Visit 
 
Day-14 to -1 
Screening/Baseline: 
 
Informed Consent 
X 
 
 
X 
Inclusion/Exclusion 
X 
Medical/Surgical History, Alcohol habits, Smoking habits 
X 
Demographics 
X 
Treatment: 
 
Concomitant Medications 
X 
Query LMT compliance 
X 
Safety: 
 
Height 
X 
Weight 
X 
Vital Signs 
X 
Physical Examination 
X 
Electrocardiogram3 
X 
Contraception Use Reminder1 
X 
Remind male patients to use condoms 
X 
Adverse Events 
X 
Laboratory Testing2: 
 
Hematology 
X 
Chemistry 
X 
Urinalysis 
X 
Core Lipid Panel (8-hour fasting sample) 
X 
HbA1c 
X 
Pregnancy Test 
Serum 
Hepatitis B and C serology 
X 
TSH 
X 
FSH 
X 
PK and Ab Samples: 
 
Research samples (biomarkers) 
X 
Other: 
 
Review of diet 
X 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 51 of 97 
 
CONFIDENTIAL 
Table 3: 
Schedule of Events for SC Treatment Group A 
  
Double-Blind Treatment Period 
  
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 
10 
Visit 
11 
Visit 
12 
Visit 
13 
Visit 
14 
Visit 
15 
Visit 
16 
Visit 
17 
Visit 18/ 
EOT 
Day 
1 
8 
15 
22 
29 
36 
43 
50 
57 
64 
71 
78 
85 
92 
99 
106 
113 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Screening/Baseline: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Randomization 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Treatment: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Administer SC Study Drug4, 7, 8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Weight 
X 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
X 
Vital Signs11 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical Examination 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
Electrocardiogram3 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Remind male patients to use 
condoms 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Laboratory Testing2: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Hematology 
X 
  
X 
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
Chemistry 
X 
  
X 
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
Urinalysis 
X 
  
X 
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
Core Lipid Panel  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 52 of 97 
 
CONFIDENTIAL 
  
Double-Blind Treatment Period 
  
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 
10 
Visit 
11 
Visit 
12 
Visit 
13 
Visit 
14 
Visit 
15 
Visit 
16 
Visit 
17 
Visit 18/ 
EOT 
Day 
1 
8 
15 
22 
29 
36 
43 
50 
57 
64 
71 
78 
85 
92 
99 
106 
113 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Specialty Lipid Panel  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
HbA1c 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
hs-CRP 
X 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
X 
Pregnancy Test 
U 
  
  
  
U 
  
  
  
U 
  
  
  
U 
  
  
  
U 
PK and Research Samples: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
PK (evinacumab, alirocumab)4, 
ANGPTL3, PCSK9 sample 
X 
 X  
X 
  
X 
  
  
  
X 
  
X 
  
X 
  
  
  
X 
Anti-evinacumab antibody sample 
X 
  
  
  
X 
  
  
  
  
  
  
  
 
  
  
  
X 
Research samples (biomarkers) 
X 
  
  
  
  
  
X 
  
  
  
  
  
X 
  
  
  
X 
LDL-R function sample5 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
X 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Other: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Review of low fat diet 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 53 of 97 
 
CONFIDENTIAL 
Table 4: 
Schedule of Events for IV Treatment Group B 
  
Double Blind Treatment Period 
Open-Label Treatment Period 
  
Visit 2 
Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 
Visit 9 
End of 
DBTP 
Visit 10 
Visit 11 Visit 12 Visit 13 Visit 14 Visit 15 Visit 16 
Day 
1 
15 
29 
43 
57 
85 
113 
141 
169 
197 
225 
253 
281 
309 
337 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
2 
4 
6 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
Screening/Baseline: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Randomization 
X 
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Treatment: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Administer Double-Blind IV Study Drug4,7 
X 
  
X 
  
X 
X 
X 
X 
 
 
 
 
 
 
 
Administer Open-Label IV Study Drug4,7 
 
 
 
 
 
 
 
 
X# 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital Signs11 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical Examination 
  
  
  
  
  
  
  
  
X 
 
 
 
 
 
 
Electrocardiogram3 
  
  
  
  
  
  
  
  
X 
 
 
 
 
 
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Remind male patients to use condoms 
X 
X 
X 
X 
x 
x 
X 
x 
X 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Laboratory Testing2: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Hematology 
X 
X 
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Chemistry 
X 
X 
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Core Lipid Panel  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Specialty Lipid Panel  
X 
  
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
HbA1c 
  
  
  
  
  
X 
  
  
X 
 
 
X 
 
 
X 
hs-CRP 
X 
  
  
  
  
X 
  
  
X 
 
 
X 
 
 
X 
Pregnancy Test 
U 
  
U 
  
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 54 of 97 
 
CONFIDENTIAL 
  
Double Blind Treatment Period 
Open-Label Treatment Period 
  
Visit 2 
Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 
Visit 9 
End of 
DBTP 
Visit 10 
Visit 11 Visit 12 Visit 13 Visit 14 Visit 15 Visit 16 
Day 
1 
15 
29 
43 
57 
85 
113 
141 
169 
197 
225 
253 
281 
309 
337 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
2 
4 
6 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
PK and Research Samples: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
PK (evinacumab, alirocumab)4, 
ANGPTL3, and PCSK9  
X 
X 
X 
X 
X 
  
X 
  
X 
 
 
X 
 
 
X 
Anti-evinacumab antibody sample 
X 
  
 X 
  
  
X 
  
  
X 
 
 
X 
 
 
X 
Research samples (biomarkers) 
X 
  
  
X 
  
X 
  
  
X 
 
 
X 
 
 
X 
LDL-R function sample5 
X 
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
X 
X 
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
X 
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Other: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Review of low fat diet 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 55 of 97 
 
CONFIDENTIAL 
Table 5: 
Schedule of Events for IV Treatment Group B (Continued for Open-Label) 
  
Open-Label Treatment Period - Continued (Group B) 
  
Visit 17 
Visit 18 
Visit 19 
Visit 20 
Visit 21 
End of 
Open-
Label 
Visit 22 
Day 
365 
398 
421 
449 
477 
505 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
52 
56 
60 
64 
68 
72 
Treatment: 
 
 
 
 
 
 
Administer Open-Label IV Study Drug4, 7 
X 
X 
X 
X 
X 
 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
Safety: 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
Vital Signs11 
X 
X 
X 
X 
X 
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
Remind male patients to use condoms 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
Laboratory Testing2: 
 
 
 
 
 
 
Hematology 
 
 
X 
 
 
X 
Chemistry 
 
 
X 
 
 
X 
Urinalysis 
 
 
X 
 
 
X 
Core Lipid Panel  
X 
X 
X 
X 
X 
X 
Specialty Lipid Panel  
 
 
X 
 
 
X 
HbA1c 
 
 
X 
 
 
X 
hs-CRP 
 
 
X 
 
 
X 
Pregnancy Test 
U 
U 
U 
U 
U 
U 
PK and Research Samples: 
 
 
 
 
 
 
PK (evinacumab, alirocumab)4, ANGPTL3, and PCSK9  
 
 
X 
 
 
X 
Anti-evinacumab antibody sample 
 
 
X 
 
 
X 
Research samples (biomarkers) 
 
 
X 
 
 
X 
Other: 
 
 
 
 
 
 
Review of low fat diet 
X 
X 
X 
X 
X 
X 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
 
Regeneron Pharmaceuticals, Inc. 
 
Page 56 of 97 
 
CONFIDENTIAL 
Table 6: 
Follow-up Schedule of Events for SC Treatment Group A 
  
Follow-up Period 
  
Phone10 
Visit 19 
Visit 20 
Phone10 
Visit 21 
Visit 22 
Phone10 
Visit 23 
Visit 24/ 
EOS 
Day 
141 
169 
197 
225 
253 
274 
Visit Window (Day) 
±7 
±7 
±7 
±7 
±7 
±7 
Week 
20 
24 
28 
32 
36 
39 
Treatment: 
  
  
  
  
  
  
Concomitant Medications 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
  
Weight 
  
  
  
  
  
X 
Vital Signs 
  
X 
  
X 
  
X 
Physical Examination 
  
  
  
  
  
X 
Electrocardiogram 
  
  
  
  
  
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
Remind male patients to use condoms 
X 
X 
X 
X 
X 
 
Adverse Events 
X 
X 
X 
X 
X 
X 
Laboratory Testing: 
  
  
  
  
  
  
Hematology 
  
X 
  
X 
  
X 
Chemistry 
  
X 
  
X 
  
X 
Urinalysis 
  
X 
  
X 
  
X 
Core Lipid Panel  
  
X 
  
X 
  
X 
Specialty Lipid Panel  
  
X 
  
X 
  
X 
HbA1c 
  
X 
  
X 
  
X 
hs-CRP 
  
  
  
  
  
X 
Pregnancy Test 
U (home) 9 
U 
U (home) 
9 
U 
U (home) 
9 
S 
PK and Research Samples: 
  
  
  
  
  
  
PK (evinacumab, alirocumab), ANGPTL3, 
PCSK9 sample 
  
X 
  
X 
  
X 
Anti-evinacumab antibody sample 
  
  
  
  
  
X 
Research samples (biomarkers) 
  
  
  
  
  
X 
Other: 
  
  
  
  
  
  
Review of low fat diet 
X 
X 
X 
X 
X 
X 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
 
Regeneron Pharmaceuticals, Inc. 
 
Page 57 of 97 
 
CONFIDENTIAL 
Table 7: 
Follow-up Schedule of Events for IV Treatment Group B 
  
Follow-up Period 
  
Visit 23 
Phone10 
Visit 24 
Visit 25 
Phone10 
Visit 26 
EOS 
Visit 27 
Day 
533 
561 
589 
617 
645 
Visit Window (Day) 
±7 
±7 
±7 
±7 
±7 
Week 
76 
80 
84 
88 
92 
Treatment: 
  
  
  
  
  
Concomitant Medications 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
Weight 
  
  
  
  
X 
Vital Signs 
X 
  
X 
  
X 
Physical Examination 
  
  
  
  
X 
Electrocardiogram 
  
  
  
  
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
Remind male patients to use condoms 
X 
X 
X 
X 
 
Adverse Events 
X 
X 
X 
X 
X 
Laboratory Testing: 
  
  
  
  
  
Hematology 
X 
  
X 
  
X 
Chemistry 
X 
  
X 
  
X 
Urinalysis 
X 
  
X 
  
X 
Core Lipid Panel  
X 
  
X 
  
X 
Specialty Lipid Panel  
X 
  
X 
  
X 
HbA1c 
  
  
X 
  
X 
hs-CRP 
  
  
  
  
X 
Pregnancy Test 
U 
U (home)9 
U 
U (home) 9 
S 
PK and Research Samples: 
  
  
  
  
  
PK (evinacumab, alirocumab), ANGPTL3, and 
PCSK9  
X 
  
X 
  
X 
Anti-evinacumab antibody sample 
  
  
  
  
X 
Research samples (biomarkers) 
  
  
  
  
X 
Other: 
  
  
  
  
  
Review of low fat diet 
X 
X 
X 
X 
X 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 58 of 97 
 
CONFIDENTIAL 
8.1.1. 
Footnotes for the Schedule of Events Tables  
EOS = end of study; EOT = end of treatment; U = urine; Core lipid panel = TC, calculated LDL-C, 
HDL-C, TGs, and non-HDL-C; Specialty lipid panel = ApoB, ApoA-1, ratio ApoB/ApoA-1, and 
Lp(a). 
1. All patients will be reminded of protocol-specified contraception use and pregnancy 
reporting. 
2. All laboratory samples should be collected before the administration of study drug. All 
samples should be collected following at least an 8-hour fast. 
3. Electrocardiograms should be performed before blood is drawn during visits requiring 
blood draws. 
4. On dosing days, PK collection should occur pre-dose for group A and prior to IV infusion 
and at the end of the IV infusion for group B. 
5. LDL-R function samples will be collected from a sub-set of patients based on enrollment 
and will be determined by IWRS. 
 
 
 
 
7. For SC dosing, patients will be observed at the clinical site for at least 30 minutes following 
each SC study drug administration.  For IV dosing, patients will be monitored for at least 
60 minutes following the end of each IV study drug administration. 
8. Starting at W1 and every odd visit week (ie, W3, W5, W7, etc) thereafter, visiting home 
nurses may administer study drug for those patients randomized to Group A. 
9. WOCBP will be provided urine pregnancy tests with instructions to test for pregnancy at 
home. 
10. All subjects will be contacted by phone to query LMT compliance, inquire about AEs or 
changes to concomitant medications, confirm required contraception use and remind 
patients of pregnancy reporting.  Women of childbearing potential will report the results of 
their home urine pregnancy test.  All patients will also be queried regarding their low fat 
diet.  
11. Vital signs should be recorded prior to SC injection or IV infusion, and 30 minutes and 
60 minutes post-IV infusion. 
8.1.2. 
Early Termination Visit 
Patients who withdraw or are withdrawn from the study before EOT visit 
Patients who withdraw or are withdrawn from the study before the week 16 visit, will be asked to 
return to the clinic for 2 visits:  once for an early termination/EOT visit, consisting of the EOT 
assessments described in Table 3 and Table 4, and again at the EOS visit.  The EOT visit should 
take place within 5 days of treatment discontinuation, if possible.  A final EOS visit should take 
place with assessments as specified in the EOS visit (ie, follow-up visit) at 24 weeks after the last 
dose of study drug (Table 6 and Table 7). 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 59 of 97 
 
CONFIDENTIAL 
Patients who withdraw or are withdrawn from the study after EOT Visit 
Patients who are withdrawn from the study after the EOT visit (week 16 for SC group or week 24 
for IV group) will be asked to return to the clinic for early termination assessments/EOS, only.  
The EOS visit should take place with assessments as specified in the EOS visit (ie, follow-up visit) 
at 24 weeks after the last dose of study drug. 
Sexually active patients who discontinue the study prematurely should have an unscheduled visit 
to remind patients to maintain highly effective contraceptive measures for 24 weeks after the last 
dose of study drug.  At this visit, WOCBP will be provided urine pregnancy tests with instructions 
to test for pregnancy Q4W until the EOS visit.  All patients should also be notified of Q4W 
follow-up phone calls to confirm contraception use, remind them of pregnancy reporting, and to 
obtain the results of the urine pregnancy test. 
8.1.3. 
Unscheduled Visits 
All attempts should be made to keep patients on the study schedule.  Unscheduled visits may be 
necessary to repeat testing following abnormal laboratory results, for follow-up of AEs, or for any 
other reason, as warranted. 
8.2. 
Study Procedures 
8.2.1. 
Procedures Performed Only at the Screening/Baseline Visit 
The following procedures will be performed for the sole purpose of determining study eligibility 
or characterizing the baseline population:  
 Demographics,  
 Past medical/surgical history, alcohol/smoking habits 
 Medication history,  
 Medication adjustments 
 Height, weight, vital signs, physical examination, ECG 
 Hepatitis B and C serology,  
 TSH,  
 FSH  
8.2.2. 
Efficacy Procedures  
All laboratory samples will be collected before the dose of study drug is administered. 
Blood samples for lipid panels should be collected in the morning, in fasting condition (ie, 
overnight, at least 8 hours fast, only water) for all clinic visits.  Alcohol consumption within 
48 hours, and smoking or intense physical exercise within 24 hours, preceding blood sampling are 
discouraged. 
Note:  If the patient is not in the fasting condition, the blood sample may not be collected and a 
new appointment can be scheduled the day after (or as close as possible to this date) with a 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 60 of 97 
 
CONFIDENTIAL 
reminder to be fasted.  Patients who are not fasted should 1) be reminded that they should fast, and 
2) should be seen by study staff the next day or close as possible in fasted state. 
Total-C, HDL-C, TG, ApoB, ApoA-1, Lp(a), and ApoCIII will be directly measured by the central 
laboratory.  LDL-C will be calculated using the Friedewald formula.  If TG values exceed 
400 mg/dL (4.52 mmol/L), LDL-C will be measured via the beta quantification method (rather 
than via the Friedewald formula).  If the LDL-C value is less than 25 mg/dL (0.65 mmol/L), LDL-C 
will be measured via the beta quantification method (rather than the Friedewald formula). 
Non-HDL-C will be calculated by subtracting HDL-C from TC.  Ratio ApoB/ApoA-1 will be 
calculated.  All lipid results will be blinded from after randomization until the week 36 visit for 
the IV cohorts, and until database lock for the SC cohorts.  No attempts should be made by the 
investigator or patient to have the patient’s lipid values independently evaluated after 
randomization and through the EOS visit. 
Detailed procedures of sample preparation, storage, and shipment are provided in the laboratory 
manual. 
8.2.2.1. 
Core Lipid Panel  
Fasting blood (at least 8 hours) samples for the core lipid panel (TC, TG, HDL-C, non-HDL-C, 
and calculated LDL-C) will be collected at time points described in Table 1, Table 2, Table 3, 
Table 4, Table 5, Table 6, and Table 7.  These samples will also be used for specialty lipid panel 
assessment when it is scheduled at the same time as the lipid panel assessment.  All lipid results 
after the randomization visit will be blinded. 
8.2.2.2. 
Specialty Lipid Panel  
Fasting (at least 8 hours) blood samples for the specialty lipid panel (ApoB, ApoA-1, 
ApoB/ApoA-1 ratio, and Lp[a]), as well as for ApoCIII will be collected at time points according 
to in Table 3, Table 4, Table 5, Table 6, and Table 7.  The specialty lipid panels will be assessed 
in the same sample that is collected for the lipid panel.  All lipid results will be blinded from after 
randomization until the week 36 visit for the IV cohorts, and until database lock for the SC cohorts 
. 
8.2.3. 
Safety Procedures  
8.2.3.1. 
Vital Signs 
Vital signs, including temperature, sitting blood pressure, pulse, and respiration rate, will be 
collected pre-dose at time points according to in Table 1, Table 2, Table 3, Table 4, Table 5, 
Table 6, and Table 7.  Post-dose vital signs consist of blood pressure and pulse rate and will be 
collected 30 minutes and 60 minutes after completion of the IV infusion. 
Blood pressure should be measured in the same arm throughout the study, after the patient has 
been resting quietly for at least 5 minutes.  Pulse rate will be measured at the time of the 
measurement of blood pressure. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 61 of 97 
 
CONFIDENTIAL 
8.2.3.2. 
Physical Examination 
A thorough and complete physical examination will be performed at time points according to in 
Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, and Table 7.  Care should be taken to examine 
and assess any abnormalities that may be present, as indicated by the patient’s medical history. 
8.2.3.3. 
Electrocardiogram 
A standard 12-lead electrocardiogram (ECG) will be performed at time points according to in 
Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, and Table 7.  Electrocardiograms should be 
performed before blood is drawn during visits that require blood draws. 
The 12-lead ECGs should be performed in the supine position after resting for at least 10 minutes.  
For each ECG recording throughout the study, the electrodes should be positioned at the same 
place as much as possible.  The ECG will be interpreted locally by the investigator.  Any new 
and/or clinically significant changes in ECG parameters should be immediately rechecked for 
confirmation before making any decision for the concerned patient. 
Any clinically significant abnormality should be documented as an AE/SAE, as applicable.  Each 
ECG tracing will be analyzed in comparison with the screening recorded trace.  All ECG tracings 
will be kept as source data (see Section 9.4.5). 
8.2.3.4. 
Laboratory Testing 
All laboratory samples will be collected before the dose of study drug is administered. 
Samples for laboratory testing will be collected at time points according to in Table 1, Table 2, 
Table 3, Table 4, Table 5, Table 6, and Table 7 and analyzed by a central laboratory during the 
study.  Detailed instructions for blood sample collection are in the laboratory manual provided to 
study sites and specific tests are listed below. 
Tests will include: 
Blood Chemistry 
Sodium 
Total protein, serum 
Total bilirubin* 
Potassium 
Creatinine 
Uric acid 
Chloride 
Blood urea nitrogen (BUN) 
Creatine phosphokinase 
(CPK) 
Bicarbonate 
Aspartate aminotransferase (AST) 
 
Calcium 
Alanine aminotransferase (ALT) 
 
Glucose 
Alkaline phosphatase 
 
Albumin 
Lactate dehydrogenase (LDH) 
 
 
Blood chemistry tests should be performed with fasting samples. 
* Samples with elevated values are automatically fractionated 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 62 of 97 
 
CONFIDENTIAL 
Hematology 
Hemoglobin 
Differential: 
Hematocrit 
 
Neutrophils 
Red blood cells (RBCs) 
 
Lymphocytes 
White blood cells (WBCs) 
 
Monocytes 
Platelet count 
 
Basophils 
Reticulocyte count 
 
Eosinophils 
Red blood cell distribution width 
(RDW) 
 
Urinalysis 
Color 
Glucose 
RBC 
Clarity 
Blood 
Hyaline and other casts 
pH 
Bilirubin 
Bacteria 
Specific gravity 
Leukocyte esterase 
Epithelial cells 
Ketones 
Nitrite 
Crystals 
Protein 
WBC 
Yeast 
Other Laboratory Tests 
Other laboratory tests will be performed at time points shown in Table 1, Table 2, Table 3, Table 4, 
Table 5, Table 6, and Table 7 are as follows:  FSH, TSH, hs-CRP, HbA1c, and serum and urine 
pregnancy test. 
Abnormal Laboratory Values and Laboratory Adverse Events 
 All laboratory values must be reviewed by the investigator or authorized designee. 
 Significantly abnormal test results that occur after start of treatment must be repeated 
to confirm the nature and degree of the abnormality.  When necessary, appropriate 
ancillary investigations should be initiated.  If the abnormality fails to resolve or cannot 
be explained by events or conditions unrelated to the study medication or its 
administration, the medical monitor must be consulted. 
 The clinical significance of an abnormal test value, within the context of the disease 
under study, must be determined by the investigator. 
Criteria for reporting laboratory values as an AE are provided in Section 9.4.5. 
8.2.3.5. 
Pregnancy Testing 
Women of childbearing potential will undergo pregnancy testing approximately every 4 weeks 
throughout the study from baseline through EOS.  Pregnancy testing will be via a urine pregnancy 
test, except for the screening visit and EOS visit, which will be via a serum pregnancy test.  During 
some follow-up visits, and in case of early termination, pregnancy testing may occur at home via 
a urine pregnancy test where the results will be reported to the clinical site by the patient. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 63 of 97 
 
CONFIDENTIAL 
8.2.4. 
Pharmacokinetic and Anti-Drug Antibody Procedures 
8.2.4.1. 
Drug Concentration Measurements and Samples 
Serum samples for assessment of evinacumab and alirocumab concentration will be collected at 
specified time points listed in Table 3, Table 4, Table 5, Table 6, and Table 7. 
Any unused samples collected for drug concentration measurements may be used for exploratory 
biomarker research or other investigations. 
8.2.4.2. 
Anti-Drug Antibody Measurements and Samples 
Serum samples for anti-evinacumab antibody (ADA) assessment will be collected at time points 
listed in Table 3, Table 4, Table 5, Table 6, and Table 7.  They will be collected pre-dose on days 
when study drug is administered. 
Patients who exhibit a treatment-emergent or treatment-boosted positive ADA assay response with 
a titer >240 in their last sample analyzed and who do not participate in an open-label study will be 
followed until the titers are <240 or have returned to within 2 dilution steps from their baseline 
titer levels. 
8.2.5. 
Pharmacodynamic Procedures 
Blood samples for measurement of total ANGPTL3, free and total PCSK9, and lipid profile (core 
lipid panel, specialty lipid panel) will be collected at specified time points listed in Table 1, 
Table 2, Table 3, Table 4, Table 5, Table 6, and Table 7.  ANGPTL3 concentration in serum will 
be measured from the PK samples collected at the time points listed in Table 1, Table 2, Table 3, 
Table 4, Table 5, Table 6, and Table 7. 
8.2.6. 
Other Assessments 
8.2.7. 
Review of Diet 
Patients will be following a heart-healthy diet at the screening visit and will be asked to continue 
the dietary plan until the last study visit.  Patients will be queried on compliance with the dietary 
plan during the double-blind treatment period, at time points according to Section 8.1. 
Details are provided in the study reference manual. 
8.2.8. 
Low Density Lipid-Receptor Function 
A blood sample for LDL-R function testing will be collected from a subset of patients at time 
points according to in Table 3, and Table 4 in order to characterize LDL-R function and explore 
potential differences in safety and efficacy. 
8.2.9. 
Future Biomedical Research 
Biomarker samples will be collected at time points according to Table 1, Table 2, Table 3, Table 4, 
Table 5, Table 6, and Table 7.  The biomarker samples unused for study-related research, as well 
as unused PK and ADA, will be stored for up to 15 years after the final date of the database lock.  
The unused samples may be utilized for future biomedical research of hyperlipidemia and other 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 64 of 97 
 
CONFIDENTIAL 
related diseases.  No additional samples will be collected for future biomedical research.  After 15 
years, any residual samples will be destroyed. 
 
 
 
  
 
  
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
9. 
SAFETY DEFINITIONS, REPORTING, AND MONITORING 
9.1. 
Obligations of Investigator 
The investigator must promptly report to the Institutional Review Board (IRB)/Ethics Committee 
(EC) all unanticipated problems involving risks to patients.  This includes death from any cause 
and all SAEs related to the use of the study drug.  It is recommended that all SAEs be reported to 
the IRB/EC, regardless of assessed causality. 
9.2. 
Obligations of Sponsor 
During the course of the study, the sponsor will report in an expedited manner as per national 
regulatory requirements in participating countries, all SAEs that are both unexpected and at least 
reasonably related to the study drug (suspected unexpected serious adverse reaction, to the health 
authorities, IECs/IRBs as appropriate, and to the investigators.  
Any AE not listed as an expected event in the Investigator’s Brochure or in this protocol will be 
considered as unexpected.  Any worsening of or new onset of symptoms related to 
hypercholesterolemia which occur during the screening period prior to study drug administration 
will be considered expected. 
In addition, the sponsor will report in an expedited manner all SAEs that are expected and at least 
reasonably related to the evinacumab to the health authorities, according to local regulations. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 65 of 97 
 
CONFIDENTIAL 
At the completion of the study, the sponsor will report all safety observations made during the 
conduct of the trial in the clinical study report to health authorities and IECs/IRB as appropriate. 
9.3. 
Definitions 
9.3.1. 
Adverse Event 
An AE is any untoward medical occurrence in a patient administered a study drug, which may or 
may not have a causal relationship with the study drug.  Therefore, an AE is any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease, which is 
temporally associated with the use of a study drug, whether or not considered related to the study 
drug. 
An AE also includes any worsening (ie, any clinically significant change in frequency and/or 
intensity) of a pre-existing condition that is temporally associated with the use of the study drug. 
9.3.2. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
 Results in death – includes all deaths, even those that appear to be completely unrelated 
to study drug (eg, a car accident in which a patient is a passenger). 
 Is life-threatening – in the view of the investigator, the patient is at immediate risk of 
death at the time of the event.  This does not include an AE that, had it occurred in a 
more severe form, might have caused death. 
 Requires in-patient hospitalization or prolongation of existing hospitalization.  
In-patient hospitalization is defined as admission to a hospital or an emergency room 
for longer than 24 hours.  Prolongation of existing hospitalization is defined as a 
hospital stay that is longer than was originally anticipated for the event, or is prolonged 
due to the development of a new AE as determined by the investigator or treating 
physician. 
 Results in persistent or significant disability/incapacity (substantial disruption of 
one’s ability to conduct normal life functions). 
 Is a congenital anomaly/birth defect 
 Is an important medical event - Important medical events may not be immediately 
life-threatening or result in death or hospitalization, but may jeopardize the patient or 
may require intervention to prevent one of the other serious outcomes listed above (eg, 
intensive treatment in an emergency room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospitalization; or development of drug 
dependency or drug abuse). 
9.3.3. 
Adverse Events of Special Interest 
An AE of special interest (AESI; serious or non-serious) is one of scientific and medical concern 
specific to the sponsor’s product or program, for which ongoing monitoring and rapid 
communication by the investigator to the sponsor can be appropriate.  Such an event might warrant 
further investigation in order to characterize and understand it.  Depending on the nature of the 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 66 of 97 
 
CONFIDENTIAL 
event, rapid communication by the study sponsor to other parties (eg, regulators) might also be 
warranted (Section 9.4.3). 
9.3.4. 
Infusion Reactions 
Infusion reactions are defined as any AE that occurs during the infusion or within 2 hours after the 
infusion is completed.  All infusion reactions must be reported as AEs (defined in Section 9.4.1) 
and graded using the grading scales as instructed in Section 9.5.1. 
9.4. 
Recording and Reporting Adverse Events  
9.4.1. 
Adverse Events 
The investigator (or designee) will record all AEs that occur from the time the informed consent 
is signed until the EOS.  Refer to the study reference manual for the procedures to be followed. 
Information on follow-up for AEs is provided in Section 9.4.6.  Laboratory, vital signs, or ECG 
abnormalities are to be recorded as AEs as outlined in Section 9.4.5. 
9.4.2. 
Serious Adverse Events 
All SAEs, regardless of assessment of causal relationship to study drug, must be reported to the 
sponsor (or designee) within 24 hours.  Refer to the study reference manual for the procedure to 
be followed. 
Information not available at the time of the initial report must be documented in a follow-up report.  
Substantiating data such as relevant hospital or medical records and diagnostic test reports may 
also be requested. 
In the event the investigator is informed of an SAE after the patient completes the study, the 
following will apply: 
 SAE with an onset within 30 days of the EOS/early termination visit- the SAE will be 
reported to the sponsor.  The investigator should make every effort to obtain follow-up 
information on the outcome until the event is considered chronic and/or stable. 
 SAE with an onset day greater than 30 days from the EOS/early termination visit - only 
fatal SAEs and those deemed by the investigator to be drug-related SAEs will be 
reported to the sponsor.  The investigator should make every effort to obtain follow-up 
information on the outcome of a drug-related SAE until the event is considered chronic 
and/or stable. 
9.4.3. 
Other Events that Require Accelerated Reporting to Sponsor 
The following events also require reporting to the sponsor (or designee) within 24 hours of learning 
of the event: 
Symptomatic Overdose of Study Drug: 
Accidental or intentional overdose of at least 2 times 
the intended dose of study drug within the intended therapeutic window, if 
associated with an AE 
Pregnancy: 
Although pregnancy is not considered an AE, it is the responsibility of the 
investigator to report to the sponsor (or designee), within 24 hours of identification, 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 67 of 97 
 
CONFIDENTIAL 
any pregnancy occurring in a female or female partner of a male, during the study 
or within 24 weeks of the last dose of study drug.  Any complication of pregnancy 
affecting a female study patient or female partner of a male study patient, and/or 
fetus and/or newborn that meets the SAE criteria must be reported as an SAE. 
Outcome for all pregnancies should be reported to the sponsor 
Adverse Events of Special Interest: All AESIs, serious and non-serious, must be reported within 
24 hours of identification using the same reporting process as for SAE reporting, 
per Section 9.4.2. 
Adverse events of special interest for evinacumab include the following: 
 Anaphylactic reactions 
 Allergic reactions and/or local injection site reactions that require medical treatment 
or consultation with another physician for further evaluation  
 Increase in ALT or AST: ≥3 x ULN (if baseline <ULN), or ≥2 x baseline value (if 
baseline ≥ ULN) 
 Pregnancy 
 Symptomatic overdose with IMP 
 Neurocognitive events 
 New onset of diabetes 
 Pancreatitis 
Adverse events of special interest for alirocumab include the following: 
 Increase in ALT: ALT ≥3 x ULN (if baseline ALT < ULN), or ALT ≥2 x baseline 
value (if baseline ALT ≥ ULN) 
 Allergic events and/or local injection site reactions that require consultation with 
another physician for further evaluation 
 Pregnancy 
 Symptomatic overdose with IMP 
 Neurologic events that require additional examinations/procedures and/or referral to a 
specialist 
 Neurocognitive events 
 Cataracts 
 New onset of diabetes:  
The definition of new onset of diabetes will be the following: 
 Type 1 or type 2 diabetes treatment-emergent adverse event (TEAE) (grouping of 
MedDRA terms will be specified in the SAP) 
and/or 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 68 of 97 
 
CONFIDENTIAL 
 at least 2 values of HbA1c ≥6.5% during the TEAE period 
NOTE: For patients with only a single measurement available during the TEAE 
period, a single value ≥6.5% will be considered and qualify the patient as new onset 
of diabetes by default. 
For patients with several HbA1c measurements but only with the last one ≥6.5%, 
this single value ≥6.5% will be considered and qualify the patient as new onset of 
diabetes by default 
and/or 
 At least 2 values of fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) 
NOTE:  For patients with only a single measurement available during the TEAE 
period, a single value ≥126 mg/dL (7.0 mmol/L) will NOT be considered and will 
NOT qualify the patient as new onset of diabetes 
For patients with several fasting plasma glucose measurements but only with the 
last one ≥126 mg/dL (7.0 mmol/L), this single value ≥ 126 mg/dL (7.0 mmol/L) 
will NOT be considered and will NOT qualify the patient as new onset of diabetes 
9.4.4. 
Reporting Adverse Events Leading to Withdrawal from the Study 
All AEs that lead to a patient’s withdrawal from the study must be reported to the sponsor’s 
medical monitor within 30 days. 
9.4.5. 
Abnormal Laboratory, Vital Signs, or Electrocardiogram Results 
The criteria for determining whether an abnormal objective test finding should be reported as an 
AE include: 
 the test result is associated with accompanying symptoms, and/or 
 the test result requires additional diagnostic testing or medical/surgical intervention, 
and/or 
 the test result leads to a change in dosing (outside of protocol-stipulated dose 
adjustments), discontinuation from the study, significant additional concomitant drug 
treatment, or other therapy 
Contact the medical monitor in the event the investigator feels that an abnormal test finding 
should be reported as an AE, although it does not meet any of the above criteria. 
Repeating an abnormal test, in the absence of any of the above conditions, does not constitute an 
AE.  Any abnormal test result that is determined to be an error does not require reporting as an 
AE. 
Evaluation of severity of laboratory abnormalities will be assessed according to the scale 
outlined in Section 9.5.1. 
9.4.6. 
Follow-up 
Adverse event information will be collected until the patient’s last study visit. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 69 of 97 
 
CONFIDENTIAL 
Serious adverse event information will be collected until the event is considered chronic and/or 
stable. 
9.5. 
Evaluation of Severity and Causality 
9.5.1. 
Evaluation of Severity 
The severity of AEs will be graded according to the following scale: 
 Mild:  Does not interfere in a significant manner with the patient normal functioning 
level.  It may be an annoyance.  Prescription drugs are not ordinarily needed for relief 
of symptoms, but may be given because of personality of the patient. 
 Moderate:  Produces some impairment of functioning but is not hazardous to health.  
It is uncomfortable or an embarrassment.  Treatment for symptom may be needed. 
 Severe:  Produces significant impairment of functioning or incapacitation and is a 
definite hazard to the patient’s health.  Treatment for symptom may be given and/or 
patient hospitalized. 
If a laboratory value is considered an AE, its severity should be based on the degree of 
physiological impairment the value indicates. 
Infusion Reactions 
The severity of infusion reactions will be graded according to the following scale (semi-colon 
indicates “or” within description of the grade): 
 Mild:  Mild transient reaction; infusion interruption not indicated; intervention not 
indicated. 
 Moderate:  Therapy or infusion interruption indicated but responds promptly to 
symptomatic treatment (eg, antihistamines, NSAIDs, narcotics, IV fluids); prophylactic 
medications indicated for ≤24 hours. 
 Severe:  Prolonged (eg, not rapidly responsive to symptomatic medication and/or brief 
interruption of infusion); recurrence of symptoms following initial improvement; 
hospitalization indicated for clinical sequelae; life-threatening consequences; urgent 
intervention indicated; death. 
Injection Site Reactions 
The severity of injection site reactions will be graded according to the following scale (semi-colon 
indicates “or” within description of grade: 
 Mild:  Pain that does not interfere with activity; mild discomfort to touch; < 5 cm of 
erythema or induration that does not interfere with activity 
 Moderate:  Pain that requires repeated use of non-narcotic pain reliever > 24 hours or 
interferes with activity; discomfort with movement; 5.1 cm to 10 cm erythema or 
induration or induration that interferes with activity 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 70 of 97 
 
CONFIDENTIAL 
 Severe:  Pain that requires any use of narcotic pain reliever or that prevents daily 
activity; significant discomfort at rest; > 10 cm erythema or induration; prevents daily 
activity; requires ER visit or hospitalization; necrosis or exfoliative dermatitis 
9.5.2. 
Evaluation of Causality 
Relationship of Adverse Events to Study Drug: 
The relationship of AEs to study drug will be assessed by the blinded investigator, and will be a 
clinical decision based on all available information.  The following question will be addressed: 
Is there a reasonable possibility that the AE may have been caused by the study drug? 
The possible answers are: 
Not Related: There is no reasonable possibility that the event may have been caused by the study 
drug 
Related: 
There is a reasonable possibility that the event may have been caused by the study 
drug 
A list of factors to consider when assessing the relationship of AEs to study drug is provided in 
Appendix 1. 
The investigator should justify the causality assessment of each SAE. 
Relationship of Adverse Events to Study Conduct: 
The relationship of AEs to study conduct will be assessed by the blinded investigator, and will be 
a clinical decision based on all available information.  The following question will be addressed: 
Is there a reasonable possibility that the AE may have been caused by study conduct? 
The possible answers are: 
Not Related: There is no reasonable possibility that the event may have been caused by study 
conduct 
Related: 
There is a reasonable possibility that the event may have been caused by study 
conduct 
A list of factors to consider when assessing the relationship of AEs to study conduct is provided 
in Appendix 1. 
The investigator should justify the causality assessment of each SAE. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 71 of 97 
 
CONFIDENTIAL 
Relationship of Adverse Events to Injection Procedure, Study Procedure 
The relationship of AEs to injection procedure, study procedure, or background treatment, etc. will 
be assessed by the blinded investigator, and will be a clinical decision based on all available 
information.  The following question will be addressed: 
Is there a reasonable possibility that the AE may have been caused by the injection procedure, 
study procedure, or background treatment, etc.? 
The possible answers are: 
Not Related: There is no reasonable possibility that the event may have been caused by the 
injection procedure, study procedure, or background treatment, etc. 
Related: 
There is a reasonable possibility that the event may have been caused by the 
injection procedure, study procedure, or background treatment, etc. 
A list of factors to consider in assessing the relationship of AEs to injection procedure, study 
procedure, or background treatment, etc. is provided in Appendix 1. 
The sponsor will request information to justify the causality assessment of SAEs, as needed. 
9.6. 
Safety Monitoring 
The investigator will monitor the safety of study patient at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP).  Any questions or 
concerns should be discussed with the sponsor in a timely fashion.  The sponsor will monitor the 
safety data from across all study sites.  The medical monitor will have primary responsibility for 
the emerging safety profile of the compound, but will be supported by other departments (eg, 
Pharmacovigilance and Risk Management; Biostatistics and Data Management).  Safety 
monitoring will be performed on an ongoing basis (eg, individual review of SAEs) and on a 
periodic cumulative aggregate basis. 
9.7. 
Investigator Alert Notification 
Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as 
in any other clinical trial using the same investigational drug, of any SAE that potentially meets 
the relevant requirements for expedited reporting (an AE that is serious, unexpected based on the 
Investigator’s Brochure or this protocol, and has a reasonable suspected causal relationship to the 
medicinal/study drug). 
10. 
STATISTICAL PLAN 
This section provides the basis for the SAP for the study.  The SAP may be revised during the 
study to accommodate amendments to the clinical study protocol and to make changes to adapt to 
unexpected issues in study execution and data that may affect the planned analyses.  The final SAP 
will be issued before the database is locked at the time of the Group B patients’ first step analysis. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 72 of 97 
 
CONFIDENTIAL 
10.1. 
Statistical Hypothesis 
Let μ0 and μ1 be the population means of the percent change from baseline in calculated LDL-C 
at week 16 under each of the 2 placebo control arms and the 4 evinacumab treatment arms, 
respectively.  For the primary efficacy variable, the following null hypothesis and alternative will 
be tested: 
H0 : μ0 = μ1 
versus 
H1 : μ0 ≠ μ1 
Study treatment route of administration (Group A or B), HeFH diagnosis (Yes/No), and 
high-intensity statin (Yes/No) (high-intensity statin defined as rosuvastatin 20 mg to 40 mg daily, 
atorvastatin 40 mg to 80 mg daily, or simvastatin 80 mg daily) will be the 3 stratification factors 
for patient randomization.  Stratification factors HeFH diagnosis and high-intensity statin will be 
accounted for in the statistical modeling for efficacy. 
10.2. 
Justification of Sample Size 
Four pairwise comparisons of evinacumab to a placebo control arm corresponding to the route of 
administration (Group A or Group B) are hypothesized for the primary efficacy analysis of this 
study.  A total of 216 patients are planned for assessing the primary measure at week 16.  
Specifically, a sample size of 36 patients per treatment arm will have 90% power to detect a 
treatment group difference in mean percent change LDL-C of 20% in any 1 pairwise comparison 
(ie, evinacumab mean = 27% and control mean = 7%), assuming that the common standard 
deviation (SD) is 25 using an independent group t-test.  This sample size has been adjusted for a 
5% dropout rate.  The alpha level for each of the 4 pairwise comparisons is 0.05 (2-sided), and 
assumes control of the overall type-1 error rate using a pre-specified hierarchical inferential 
approach. 
Further, the evinacumab 5 mg/kg IV Q4W regimen has been added to Group B, allowing for an 
assessment of dose-response in the IV route of administration.  The additional 36 patients for this 
second IV dose regimen culminate in a total of 252 patients planned for the study. 
With the intent to gain evinacumab experience across these dose regimens for future study 
planning in patients with HeFH, a subgroup analysis is planned for the stratified sub-population of 
patients diagnosed with HeFH.  To ensure an adequate number of patients are randomized into the 
HeFH strata level, a total of 175 patients are planned for assessing the percent change LDL-C from 
baseline at week 16.  Specifically, a sample size of 36 patients per treatment arm will have 90% 
power to detect a treatment group difference in mean percent change LDL-C of 20% in any 1 
pairwise comparison (ie, evinacumab mean = 27% and Control mean = 7%), assuming that the 
common SD is 20 using an independent group t-test.  This sample size has been adjusted for a 5% 
dropout rate. 
Blinded Sample Size Adjustment 
Referencing the ICH E9 regulatory guidance, the study sample size may be re-estimated after 
approximately 75% of the patients reach the week 8 visit in the double-blind period, to ensure 
adequate power in the case of a larger-than-expected variability in the data.  This sample size 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 73 of 97 
 
CONFIDENTIAL 
re-estimation process may be performed twice; once for Group A and again for Group B.  The 
sample size re estimation will be based on the actual blinded pooled SD (adjusted as described in 
Keiser 2003) for the primary efficacy measure.  Since the patients’ post-baseline LDL-C levels are 
masked to all study participants (patients, site personnel, and sponsor staff), the blinded pooled SD 
will be calculated by a designated statistician external to Regeneron who has access to the lipid 
data.  As mentioned in Kieser 2003, the blinded sample size re-estimation does not affect type-I 
error materially for continuous endpoints. 
This re-estimation procedure will assess the need for an increase or decrease in sample size 
(unrestricted recalculation).  The result of this procedure is non-binding, since the decision to 
increase the sample size will also take into account other study execution factors (for example, 
availability of patients).  In the case the re-estimated sample size is implemented, a protocol 
amendment will document the modification. 
10.3. 
Analysis Sets  
10.3.1. 
Efficacy Analysis Sets 
10.3.1.1. Intent-to-Treat  
The ITT population (also known as the full analysis set) is defined as all randomized patients who 
received at least 1 dose or part of a dose of double-blind study drug and have an evaluable primary 
endpoint.  The endpoint is evaluable when the following 2 conditions are met: 
 Availability of at least 1 measurement value for calculated LDL-C before first dose of 
study drug (ie, baseline). 
 Availability of at least 1 measurement value for calculated LDL-C within 1 of the 
analysis windows up to week 16. 
Patients in the ITT population will be analyzed according to the treatment group allocated by 
randomization (ie, as-randomized group). 
10.3.1.2. Modified Intent-to-Treat 
The modified intent-to-treat (mITT) population is defined as all randomized patients who took at 
least 1 dose or part of a dose of study drug and have an evaluable primary endpoint.  The primary 
endpoint is considered as evaluable when both of the following conditions are met: 
 Availability of at least 1 measurement value for calculated LDL-C value before first 
dose of study drug (ie, baseline). 
 Availability of at least 1 calculated LDL-C value during the efficacy treatment period 
and within 1 of the analysis windows up to week 16.  The group A (SC dose regimens) 
efficacy treatment period is defined as the time from the first study drug administration 
up to 14 days after the last double-blind study drug injection.  The Group B (IV dose 
regimens) efficacy treatment period is defined as the time from the first study drug 
administration up to 35 days after the last double-blind study drug infusion, or up to 
the first dose of the open-label study drug, whichever is earlier. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 74 of 97 
 
CONFIDENTIAL 
Patients in the mITT population will be analyzed according to the treatment group allocated by 
randomization. 
10.3.2. 
Safety Analysis Set 
10.3.2.1. Double-Blind Safety Analysis Set 
The double-blind safety analysis set (SAF) population considered for safety analyses will be the 
randomized patients who received at least 1 dose or part of a dose of study drug.  Patients will be 
analyzed according to the treatment received (as-treated placebo or evinacumab).  
In addition: 
 Randomized patients, for whom it is unclear whether they took the study drug, will be 
included in the SAF as randomized. 
 For patients receiving study drug from more than 1 treatment group during the trial, the 
treatment group allocation for as-treated analysis will be the one in which the patient 
was treated with the highest number of injections (Group A) or infusions (Group B). 
Treatment compliance/administration and all clinical safety variables will be analyzed using the 
SAF. 
10.3.2.2. Open-Label Safety Analysis Set 
For Group B, the open-label SAF considered for safety analyses will be the randomized population 
who received at least 1 dose or part of a dose of open-label study drug. 
10.3.3. 
Pharmacokinetic and Anti-drug Antibody Analysis Sets 
The PK population includes all treated patients who received any study drug (safety population) 
and had at least 1 non-missing drug concentration result following the first dose of study drug. 
The ADA population includes all treated patients who received any study drug (safety population) 
and had at least one non-missing ADA assay result following the first dose of study drug. 
10.3.4. 
Pharmacodynamic Analysis Set 
The PD population includes all treated patients who received any study drug (safety population) 
and had at least one non-missing ANGPTL3 value or other protocol defined PD marker 
(Section 8.2.5) following the first dose of study drug. 
10.4. 
Statistical Methods 
Unless otherwise noted, descriptive statistics for continuous variables will include the following 
information:  the number of patients reflected in the calculation (n), mean, median, SD, minimum, 
and maximum.  For categorical variables, frequencies and percentages will be displayed for each 
category. 
10.4.1. 
Patient Disposition 
The following data will be summarized: 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 75 of 97 
 
CONFIDENTIAL 
 The total number of screened patients, defined as having met the inclusion criteria and 
signed the ICF. 
 The total number of randomized patients, defined as all screened patients with a 
double-blind treatment kit number allocated and recorded in the IVRS database, 
regardless of whether the treatment kit was used. 
For any patient randomized more than once, safety data from the first randomization 
will be included in the SAF, with safety data associated with the later randomization 
reported separately.  Since this is expected to be a rare event, inclusion of efficacy data 
from the patient randomized more than once in the efficacy population will be decided 
on a case-by-case basis prior to the unblinding of treatment assignments and will be 
documented in the clinical study report. 
 The total number of patients randomized, but not receiving study treatment 
 The total number of patients randomized and receiving study treatment  
 The total number of patients who completed the double-blind treatment period, defined 
for Group A as at least 15 weeks of study treatment exposure and week 16 visit 
performed; and defined for Group B as at least 20 weeks of study treatment exposure 
and week 24 visit performed  
 The total number of Group B patients who completed week 16 visit, defined as at least 
12 weeks of study treatment exposure and week 16 visit performed 
 The total number of Group B patients who completed the open-label treatment period, 
defined as at least 44 weeks of open-label study treatment exposure and visit week 72 
performed. 
 The total number of patients who prematurely discontinued study treatment during the 
double-blind treatment period, and the reasons for discontinuation 
 The total number of patients who prematurely discontinued study treatment during 
the open-label treatment period, and the reasons for discontinuation 
 The total number of patients who did not complete the study follow-up period, defined 
as the last visit  performed less than 23 weeks after the last study treatment 
administration. Patients who died during the study are excluded 
 The total number of patients in each analysis set  
 A listing of patients treated but not randomized, patients randomized but not treated, 
and patients randomized but not treated as randomized 
 A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation 
10.4.2. 
Demography and Baseline Characteristics 
For the double-blind treatment period, demographic and baseline characteristics will be 
summarized descriptively by treatment group in the ITT population. For the Group B open-label 
treatment period, demographic and baseline characteristics will be summarized descriptively by 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 76 of 97 
 
CONFIDENTIAL 
treatment group assigned in the double-blind period, as well as for patient total, for patients in the 
open-label SAF. 
10.4.3. 
Efficacy Analyses 
10.4.3.1. Primary Efficacy Analysis 
For the double-blind primary efficacy analysis, the percent change from baseline in calculated 
LDL-C at week 16, as defined in Section 4.2, will be analyzed in the ITT population using a 
mixed-effect model with repeated measures (MMRM) approach.  All post-baseline data available 
within week 2 to week 16 analysis windows will be used and missing data are accounted for by 
the MMRM model.  Each model will include the fixed categorical effects of treatment group 
(placebo and evinacumab dose regimens), randomization strata, time point (weeks 4, 8, 12, 16 for 
the Group B treatment groups; weeks 2, 4, 6, 8, 12, 16 for the Group A treatment groups), 
strata-by-time point interaction, and treatment-by-time point interaction, as well as the continuous 
fixed covariates of baseline LDL-C value and baseline value-by-time point interaction.  Contrast 
and estimate statements will be used to assess the treatment effects (LS means with confidence 
intervals) and each dose regimen pairwise comparison to placebo (mean difference and p-values). 
This model will be run separately for each route of administration (Group A or Group B, with 
Group B consisting of 3 dose regimens for the variability estimate) using an unstructured 
correlation matrix to model the within-patient errors.  Parameters will be estimated using a 
restricted maximum likelihood method with the Newton-Raphson algorithm.  Denominator 
degrees of freedom will be estimated using Satterthwaite’s approximation.  
The 4 primary treatment group comparisons will evaluate at week 16 each evinacumab dose 
regimen to the placebo group corresponding to the route of administration (IV or SC).  
1. Evinacumab 15 mg/kg IV Q4W compared to Placebo IV 
2. Evinacumab 450 mg SC QW compared to Placebo SC 
3. Evinacumab 300 mg SC QW compared to Placebo SC 
4. Evinacumab 300 mg SC Q2W compared to Placebo SC 
The statistical testing of the 4 pairwise comparisons for the primary measure will be evaluated at 
a 2-sided significance level of 0.05 per pair wise comparison, adjusting for multiplicity through a 
hierarchical inferential approach. 
Robustness of this statistical method will be assessed through sensitivity analyses detailed in the 
SAP, including the effects of missing data on the primary efficacy endpoint (pattern mixture 
modeling which will take into account the differing missing value patterns based on calculated 
LDL-C collected in the presence or absence of study treatment administration), and an 
on-treatment analysis of the primary endpoint (mITT patient population). 
10.4.3.2. Secondary Efficacy Endpoint Analysis 
For secondary efficacy endpoints (defined in Section 4.2) collected in the double-blind treatment 
period, descriptive summaries and analyses will be performed in the ITT population for each of 
the 5 pairwise treatment group comparisons, including the comparison of evinacumab 5 mg/kg IV 
Q4W patient treated group to the Placebo IV group.  
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 77 of 97 
 
CONFIDENTIAL 
For descriptive summaries, percent change, and when appropriate absolute change from baseline, 
in calculated LDL-C, total-C, HDL-C, TG, non-HDL-C, ApoB, ApoA-1, and Lp(a) will be 
provided at each time point.  All measurements, scheduled or unscheduled, will be assigned to 
analysis windows defined in the SAP in order to provide an assessment for these time points.  
Laboratory assessments other than the ones provided by the central laboratory will be excluded.  
For TG, measurements on non-fasting patients will be excluded.  The time profile of each 
parameter will be plotted by treatment group with the corresponding standard errors.   
Multiple types of measurements are planned to be analyzed during differing time points in the trial, 
specifically continuous measurements expected to have a normal distribution (example:  percent 
change in calculated LDL-C), continuous measurements expected to have a non-normal 
distribution (example: TG), and binary measurements (example:  proportion of patients reaching 
LDL-C < 100mg/dL).  
I. Continuous endpoints anticipated to have a normal distribution 
Continuous secondary variables defined in Section 4.2 anticipated to have a normal distribution 
(ie, lipids other than TG and Lp[a]) will be analyzed separately for Group A and Group B using 
the same MMRM model as for the primary endpoint.  Specifically, the model will contain fixed 
categorical effects of treatment group, randomization strata, planned time points up to the time 
point of interest, strata-by-time point interaction and treatment-by-time point interaction, as well 
as the continuous fixed covariates of corresponding baseline value and baseline value-by-time 
point interaction.  
II. Continuous endpoints anticipated to have a non-normal distribution 
Continuous secondary efficacy endpoints defined in Section 4.2 anticipated to have a non-normal 
distribution (ie, TG and Lp(a)), will be analyzed using a robust regression model (ie, 
ROBUSTREG SAS procedure with M-estimation option) with treatment group and randomization 
stratum as main effect and corresponding baseline value(s) as covariate.  Missing values will be 
addressed using a multiple imputation approach, which will be described in the SAP.  The variables 
in the multiple imputation model will at least include the same variables as used in the robust 
regression model.  The treatment group combined means will be provided with respective standard 
error (SE) estimates.  The combined mean difference between the treatment groups will be 
provided with the SE, 95% confidence interval and p-value. 
III. Binary endpoints 
Binary secondary efficacy endpoints defined in Section 4.2 will be analyzed using stratified 
logistic regression (using the strata option of the SAS logistic procedure) with treatment group and 
randomization stratum as main effect and corresponding baseline value(s) as covariate.  Missing 
values will be addressed using a multiple imputation approach, which will be described in the SAP.  
The variables in the multiple imputation model will at least include the same variables as used in 
the logistic regression model.  Treatment effects will be compared and the combined odds ratio 
estimate between the treatment groups, with their corresponding 95% confidence intervals and p-
value will be provided. 
In the data dependent case that the logistic regression method is not applicable (eg, the response 
rate is zero in one treatment arm and thus the maximum likelihood estimate may not exist), the 
LOCF (last observation carried forward) approach would be used for handling of missing values 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 78 of 97 
 
CONFIDENTIAL 
and an exact conditional logistic regression would be performed to compare treatment effects.  The 
LOCF imputation method will consist of using the last value obtained up to the week 16 time 
window to impute the missing week 16 value. 
10.4.3.3. Dose-Response Analysis 
Within each route of administration (Group A or Group B), a dose-response descriptive analysis 
is planned for the evinacumab dose regimens, with the placebo group in the role of the null dose, 
for patients in the ITT population.  Summary tables will provide descriptive statistics (at least 
mean, median, SD, min/max) for percent change from baseline in LDL-C at each protocol planned 
visit in the double-blind period, by treatment group.  Graphs will provide mean and standard error 
bars for percent change from baseline in calculated LDL-C at each protocol planned visit, by 
treatment group.  
In addition to the analyses results for each evinacumab dose regimen comparison to placebo, the 
comparisons among the evinacumab dose regimens will be assessed in the ITT population for the 
percent change from baseline in calculated LDL-C at week 16.  This analysis will employ the same 
statistical methodology as described for the primary comparisons, specifically the MMRM 
approach, for evaluating effects among the evinacumab dose regimens.  P-values will be provided 
for descriptive purposes to aid in interpretation of the dose-response. 
10.4.3.4. Subgroup Analysis 
To assess the evinacumab treatment effect during the double-blind treatment period on the 
stratification variable HeFH (Yes/No), specifically the strata level containing patients diagnosed 
with HeFH (Yes), a subgroup analysis is planned for the change from baseline LDL-C in the ITT 
population for each route of administration (Group A or Group B).  Specifically, the primary 
MMRM model used to assess the treatment group pairwise comparisons will have the additional 
variables of treatment-by-HeFH strata and treatment-by time point-by HeFH strata interaction 
terms.  For each dose regimen versus placebo at week 16, the LS mean treatment group difference 
will be provided for the HeFH (Yes) strata level, along with the corresponding SE, 95% CI and 
p-value (p-value is provided for descriptive purposes only).  The HeFH (Yes/No) stratification 
factor to be used for this subgroup analysis will be as recorded in the electronic data capture 
system.  
In addition, evinacumab treatment effect will also be explored in patients with a baseline LDL-C 
≥100 mg/dL or ≥130 mg/dL during the double-blind treatment period.  
10.4.3.5. Multiplicity Considerations 
To control the 5% overall type-I error for the 4 pairwise comparisons in the primary analysis, the 
overall study α level will be controlled by the use of a hierarchical inferential approach.  Statistical 
significance of the first pairwise treatment comparison is required before drawing inferential 
conclusions about the second pairwise treatment comparison at the 0.05 alpha level.  Inferential 
conclusions about successive pairwise treatment comparisons require statistical significance of the 
prior treatment comparison.  The hierarchy testing sequence is the order of treatment comparisons 
as presented in Section 10.4.3.1.  This fixed hierarchical approach will ensure a strong control of 
the overall type-I error rate at the 0.05 level for each evinacumab dose regimen comparison. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 79 of 97 
 
CONFIDENTIAL 
No further adjustments will be made for secondary efficacy endpoints collected during the 
double-blind treatment period, nor for the comparison of the evinacumab 5 mg/kg IV Q4W patient 
treated group to the Placebo IV group on any efficacy endpoint collected during the double-blind 
treatment period.  P-values will be provided for descriptive purposes only. 
10.4.4. 
Safety Analysis 
In general, for the double-blind period, the summary of safety results for patients in the 
double-blind SAF population will be presented by route of administration (Group A or Group B), 
pooling the evinacumab dose regimens within each route of administration (Group A or Group B), 
with the intent to maximize efforts to identify potential safety signals.  The treatment group data 
(individual evinacumab dose regimens and placebo) will also be presented with the intent to 
support the pooled dose regimens.  No formal inferential testing will be performed.  Summaries 
will be descriptive in nature. 
For Group B, summaries of safety results for the open-label period will be presented for patients 
in the open-label SAF, by the total patients administered open-label study treatment (total), as well 
as by the patient subgroups of study treatment received in the double-blind treatment period (ie, 
evinacumab dose, placebo). 
All safety analyses will use the following common rule: 
 The baseline value is defined as the last available value before the first dose of study 
drug. 
10.4.4.1. Adverse Events 
Definitions 
For safety variables, the following observation periods are defined: 
 The pre-treatment period is defined as the day the ICF is signed to the day before the 
first dose of double-blind study drug. 
 The double-blind TEAE period is defined for each route of administration from the day 
of the first dose of double-blind study treatment to the day of the last dose of double-
blind study treatment + 168 days (24 weeks) (based on PK considerations, residual 
effect of study treatment might be observed until 24 weeks after the last dose of study 
drug) for those patients not proceeding into the open-label treatment period (ie, Group 
A patients and Group B patients who prematurely discontinue study treatment), or up 
to the day before the first dose of open-label study treatment administration for those 
patients proceeding into the open-label treatment period 
 The open-label TEAE observation period is defined from the day of the first open-label 
study treatment administration to the day of the last open-label study treatment 
administration + 168 days (24 weeks). 
 The post-treatment period is defined as the time from the day after the end of the 
respective TEAE periods to the last study visit. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 80 of 97 
 
CONFIDENTIAL 
Double-blind TEAEs are defined as those events that developed, worsened, or became serious 
during the double-blind TEAE period. Open-label TEAEs are defined as those events that 
developed, worsened, or became serious during the open-label TEAE period. 
Analysis 
All AEs reported in this study will be coded using the currently available version of the Medical 
Dictionary for Regulatory Activities (MedDRA®).  Adverse event incidence tables will present 
data by system organ class (SOC) sorted alphabetically and preferred term (PT) sorted by 
decreasing frequency, and summarize the number (n) and percentage (%) of patients experiencing 
an AE.  Multiple occurrences of the same event in the same patient will be counted only once in 
the tables.  Data conventions for missing or partial AE dates will be addressed in the SAP.  The 
denominator for computation of percentages is the respective SAF populations (ie, double-blind 
SAF or open-label SAF) within each treatment group. 
Summaries of TEAEs incidences will include: 
 All TEAEs (and patient listing) 
 All treatment-emergent SAEs, including patient deaths (and patient listing) 
 All TEAEs of interest, which will be defined by a PT or a prespecified grouping of 
terms 
 TEAEs by severity (according to the grading scale outlined in Section 9.5.1), depicting 
the worse TEAE severity for those patients with multiple occurrences of the same event  
 All TEAEs leading to permanent treatment discontinuation (and patient listing) 
An AE patient listing will be provided for all patient deaths occurring during the respective TEAE 
periods (ie, double-blind or open-label) and the post-treatment period. 
10.4.4.2. Other Safety 
Definitions 
The following definitions will be applied to laboratory parameters and vital signs: 
 The potentially clinically significant value (PCSV) criteria are defined as abnormal 
values considered medically important by the sponsor according to predefined 
criteria/thresholds based on literature review and defined by the sponsor for clinical 
laboratory tests and vital signs.  PCSV criteria will be provided in the SAP. 
 PCSV criteria will determine which patients had at least 1 PCSV during the respective 
TEAE periods (double-blind or open-label), taking into account all evaluations 
performed during the respective TEAE periods, including unscheduled or repeated 
evaluations.  The number of all such patients will be the numerator for the PCSV 
percentage.   
 Double-blind treatment period:  The treatment period used for quantitative analysis in 
the double-blind period is defined as the day after the first study drug administration to 
the day of the last double-blind study drug injection + 7 days for Group A. For Group 
B, the treatment period is defined from the day after the first administration of double-
blind study treatment to the day of the last administration of double-blind study 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 81 of 97 
 
CONFIDENTIAL 
treatment + 28 days for those patients not proceeding into the open-label treatment 
period, or up to the day of the first open-label study treatment administration for those 
patients proceeding into the open-label treatment period. 
 Open-label treatment period:  The treatment period used for quantitative analysis in the 
open-label study period is defined from the day after the first dose of open-label study 
treatment to the day of the last dose of open label study treatment + 28 days. 
Analysis 
Summary statistics of all laboratory variables (including lipid HDL-C) and all vital signs 
parameters (raw data and changes from baseline) will be calculated for each protocol scheduled 
visit assessed during the respective treatment periods.  For selected parameters, mean changes 
from baseline with the corresponding standard error will be plotted over time (at same time points) 
in each treatment group. 
The incidence of PCSVs at any time during the respective TEAE periods will be summarized 
regardless of the baseline level, and again according to the following baseline categories: 
 Normal/missing 
 Abnormal according to PCSA criterion or criteria 
For laboratory parameters for which PCSA criterion is not defined, similar table(s) using the 
normal range will be provided. 
Listings will be provided with flags indicating the laboratory values meeting PCSV criteria. 
10.4.4.3. Treatment Exposure 
The duration of treatment exposure for Group A patients will be calculated as: 
 Duration of study drug exposure in weeks defined as:  (last study drug dosing date +7 
– first study drug dosing date + 1 day)/7, regardless of unplanned intermittent 
discontinuations 
 The total number of injections by patient  
The duration of treatment exposure in the double-blind period for Group B patients will be 
calculated as: 
 Duration of study drug exposure in weeks defined as:  (last double-blind study drug 
administration date + 28 – first double-blind study drug administration date + 1 day)/7, 
regardless of unplanned intermittent discontinuations 
 The total number double-blind treatment of infusions by patient  
The duration of evinacumab exposure in the open-label period for Group B patients will be 
calculated as:  
 Duration of evinacumab exposure in weeks: (last open-label evinacumab 
administration date + 28 – first open-label evinacumab treatment administration 
date)/7, regardless of unplanned intermittent discontinuations. 
 The total number of open-label evinacumab infusions by patient. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 82 of 97 
 
CONFIDENTIAL 
The duration of evinacumab cumulative exposure in the double-blind and open-label periods for 
Group B patients will be calculated as: 
 Combined patient duration of evinacumab exposure in weeks: double-blind 
evinacumab treatment duration + open-label evinacumab treatment duration, 
regardless of unplanned intermittent discontinuations. 
 Combined total number of evinacumab treatment infusions by patient defined as: total 
number of double-blind evinacumab infusions + total number of open-label 
evinacumab infusions. 
The durations of study treatment exposure (double-blind, open-label, and cumulative across the 
study) measured in weeks, and the categorical data of maximum number of injections/infusions 
(double-blind, open-label, and cumulative across study) will be summarized for each treatment 
group and for the pooled evinacumab dose regimens within each group as applicable (A or B). 
10.4.4.4. Treatment Compliance 
Compliance during the double-blind period will be assessed by injection/infusion frequency, 
specifically: 
 For Group A, defined for each patient as the average number of days between 
2 injections, that is: (last dose date – first dose date)/(number of injections). 
 For Group B, defined for each patient as the average number of days between 
2 infusions, that is: (last dose date – first dose date)/(number of infusions). 
This parameter will be summarized descriptively by treatment group. 
10.4.5. 
Analysis of Drug Concentration Data and Total ANGPTL3 Data 
Descriptive statistics of evinacumab concentrations and ANGPTL3 concentration at each sampling 
time will be provided by treatment group.  Plots of mean concentrations (linear and log scales) 
versus time will be presented.  
No formal statistical analysis will be performed. 
10.4.6. 
Analysis of Anti-Drug Antibody Data 
Listings of ADA positivity and titers presented by patient, time point, and treatment group will be 
provided.  Prevalence of treatment-emergent and treatment-boosted ADA will be assessed as 
absolute occurrence (N) and percent of patients (%), grouped by study treatment groups. 
Plots of drug concentrations will be examined and the influence of ADAs on individual 
concentration-time profiles evaluated.  Assessment of impact of ADA on safety and efficacy may 
be provided. 
10.4.7. 
Analysis of Quality of Life Data 
Quality of life data is not collected in this study. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 83 of 97 
 
CONFIDENTIAL 
 
 
 
 
 
 
10.4.9. 
Timing of Statistical Analyses 
10.4.9.1. First Step: Group B Main Efficacy and Safety Analysis 
The first analysis will be conducted when all Group B patients have been randomized and all data 
through week 24 has been collected and validated for these patients.  This will consist of the final 
efficacy analysis of the primary and secondary endpoints for the Group B patients.  The safety 
analysis will be performed on all safety data (double-blind and open-label periods) collected and 
validated at the time of the first step analysis. 
The results of the first analysis will not be used to change the conduct of the ongoing study in any 
aspect.  Since the Group B primary efficacy measure data collection will have been concluded at 
the time of this first analysis, the significance level for the study remains at 0.05.  This first analysis 
may be used for submission to health authorities.  
Individuals involved in the first step analysis of the study will not be involved in the conduct of 
the study afterwards.  Individual patient identification will not be released to anyone who is directly 
involved in the conduct of the study.  The first step analysis process, the measures used to protect 
the blind and the integrity of the study, the communication plan, and the confidentiality agreement 
will be described in a separate document. 
10.4.9.2. Second Step: Group A Main Efficacy and Safety Analysis 
The second analysis will be conducted when all Group A patients have been randomized and all 
data through week 16 has been collected and validated for these patients.  This will consist of the 
final efficacy analysis of the primary and secondary endpoints for the Group A patients.  The 
Group A and Group B (open-label period) safety analyses will be performed on all safety data 
collected and validated at the time of the second step analysis. 
Results of the second analysis will not be used to change the conduct of the ongoing study in any 
aspect.  Since the Group A primary efficacy measure data collection will have been concluded at 
the time of this second analysis, the significance level for the study will remain at 0.05.  This 
second analysis may be used for submission to health authorities.  
Individuals involved in the second step analysis of the study will not be involved in the conduct of 
the study afterwards.  Individual patient identification will not be released to anyone who is directly 
involved in the conduct of the study.  The second step analysis process, the measures used to 
protect the blind and the integrity of the study, the communication plan, and the confidentiality 
agreement, will be described in a separate document. 
10.4.9.3. Third Step: Final Safety Analysis 
The third analysis will be conducted at EOS and will consist of the final safety analysis through 
the follow-up period (week 39 for Group A and week 92 for Group B). 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 84 of 97 
 
CONFIDENTIAL 
10.5. 
Additional Statistical Data Handling Conventions 
Additional analysis and data conventions will be provided in the SAP, including the definitions 
for the analysis windows around each visit. 
10.6. 
Statistical Considerations Surrounding the Premature Termination 
of a Study  
If the study is terminated prematurely, only those parameters required for the development 
program and/or reporting to regulatory authorities will be summarized.  Investigator and sponsor 
responsibilities surrounding the premature termination of a study are presented in Section 16.1. 
11. 
DATA MANAGEMENT AND ELECTRONIC SYSTEMS 
11.1. 
Data Management 
A data management plan specifying all relevant aspects of data processing for the study (including 
data validation, cleaning, correcting, releasing) will be maintained and stored at Regeneron. 
A medical coding plan will specify the processes and the dictionary used for coding.  All data 
coding (eg, AEs, baseline findings, medication, medical history/surgical) history will be done 
using internationally recognized and accepted dictionaries. 
The CRF data for this study will be collected with an electronic data capture (EDC) tool Medidata 
Rave. 
11.2. 
Electronic Systems 
Electronic systems that may be used to process and/or collect data in this study will include the 
following: 
 IVRS/IWRS system – randomization, study drug supply 
 EDC system – data capture 
 Statistical Analysis System (SAS) – statistical review and analysis 
 Pharmacovigilance safety database 
12. 
STUDY MONITORING  
12.1. 
Monitoring of Study Sites 
The study monitor and/or designee (eg, CRO monitor) will visit each site prior to enrollment of 
the first patient, and periodically during the study.  
12.2. 
Source Document Requirements 
Investigators are required to prepare and maintain adequate and accurate patient records (source 
documents). 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 85 of 97 
 
CONFIDENTIAL 
The investigator must keep all source documents on file with the CRF (throughout this protocol, 
CRF refers to either a paper CRF or an electronic CRF).  Case report forms and source documents 
must be available at all times for inspection by authorized representatives of the sponsor and 
regulatory authorities. 
12.3. 
Case Report Form Requirements 
Study data obtained in the course of the clinical study will be recorded on electronic CRFs within 
the EDC system by trained site personnel.  All required CRFs must be completed for each and 
every patient enrolled in the study.  After review of the clinical data for each patient, the 
investigator must provide an electronic signature.  A copy of each patient CRF casebook is to be 
retained by the investigator as part of the study record and must be available at all times for 
inspection by authorized representatives of the sponsor and regulatory authorities. 
Corrections to the CRF will be entered in the CRF by the investigator or an authorized designee.  
All changes, including date and person performing corrections, will be available via the audit trail, 
which is part of the EDC system.  For corrections made via data queries, a reason for any alteration 
must be provided. 
13. 
AUDITS AND INSPECTIONS  
This study may be subject to a quality assurance audit or inspection by the sponsor or regulatory 
authorities.  Should this occur, the investigator is responsible for: 
 Informing the sponsor of a planned inspection by the authorities as soon as notification 
is received, and authorizing the sponsor’s participation in the inspection 
 Providing access to all necessary facilities, study data, and documents for the inspection 
or audit 
 Communicating any information arising from inspection by the regulatory authorities 
to the sponsor immediately 
 Taking all appropriate measures requested by the sponsor to resolve the problems found 
during the audit or inspection 
Documents subject to audit or inspection include but are not limited to all source documents, CRFs, 
medical records, correspondence, ICFs, IRB/EC files, documentation of certification and quality 
control of supporting laboratories, and records relevant to the study maintained in any supporting 
pharmacy facilities.  Conditions of study material storage are also subject to inspection.  In 
addition, representatives of the sponsor may observe the conduct of any aspect of the clinical study 
or its supporting activities both within and outside of the investigator's institution. 
In all instances, the confidentiality of the data must be respected. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 86 of 97 
 
CONFIDENTIAL 
14. 
ETHICAL AND REGULATORY CONSIDERATIONS  
14.1. 
Good Clinical Practice Statement  
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory 
requirements. 
14.2. 
Informed Consent 
The principles of informed consent are described in ICH guidelines for GCP. 
The ICF used by the investigator must be reviewed and approved by the sponsor prior to 
submission to the appropriate IRB/EC.  A copy of the IRB/EC-approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to the study site. 
It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain 
written informed consent from each patient prior to his/her participation in the study and after the 
aims, methods, objectives, and potential hazards of the study have been explained to the patient in 
language that he/she can understand.  The ICF should be signed and dated by the patient and by 
the investigator or authorized designee who reviewed the ICF with the patient.   
 Patient who can write but cannot read will have the ICF read to them before signing 
and dating the ICF. 
 Patient who can understand, but who can neither write nor read, will have the ICF read 
to them in presence of an impartial witness, who will sign and date the ICF to confirm 
that informed consent was given. 
The original ICF must be retained by the investigator as part of the patient 's study record, and a 
copy of the signed ICF must be given to the patient. 
If new safety information results in significant changes in the risk/benefit assessment, the ICF must 
be reviewed and updated appropriately.  All study patients must be informed of the new 
information and provide their written consent if they wish to continue in the study.  The original 
signed revised ICF must be maintained in the patient’s study record and a copy must be given to 
the patient. 
The principles of informed consent are described in ICH guidelines for Good Clinical Practice. 
The ICF used by the investigator must be reviewed and approved by the sponsor prior to 
submission to the appropriate IRB/EC.  A copy of the IRB/EC-approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to the study site. 
It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain 
written informed consent from each patient and his/her parent(s) or legal guardian(s) prior to the 
patient’s participation in the study and after the aims, methods, objectives, and potential hazards 
of the study have been explained to the fullest possible extent in language that the patient and the 
parent(s) or legal guardian(s) can understand.  The ICF should be signed and dated by the patient’s 
parent(s) or legal guardian(s) and the same investigator or designee who explained the ICF. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 87 of 97 
 
CONFIDENTIAL 
The patient may also be required to sign and date the ICF, as determined by the IRB/EC and in 
accordance with the local regulations and requirements. 
 Patients who can write but cannot read will have the ICF form read to them before 
writing their name on the form. 
 Patients who can understand, but who can neither write nor read, will have the ICF read 
to them in presence of an impartial witness, who will sign and date the ICF to confirm 
that informed consent was given. 
The original ICF must be retained by the investigator as part of the patient's study record, and a 
copy of the signed ICF must be given to the patient’s parent(s) or legal guardian(s). 
If new safety information results in significant changes in the risk/benefit assessment, the ICF must 
be reviewed and updated appropriately.  All study patients and their parent(s) or legal guardian(s) 
must be informed of the new information and provide their written consent if they wish the patient 
to continue in the study.  The original signed revised ICF must be maintained in the patient’s study 
record and a copy must be given to the patient’s parent(s) or legal guardian(s). 
14.3. 
Patient Confidentiality and Data Protection 
The investigator must take all appropriate measures to ensure that the anonymity of each study 
patient will be maintained.  Patients should be identified by a patient identification number, only, 
on CRFs or other documents submitted to the sponsor.  Documents that will not be submitted to 
the sponsor (eg, signed ICF) must be kept in strict confidence. 
The patient's and investigator's personal data, which may be included in the sponsor database, will 
be treated in compliance with all applicable laws and regulations.  The sponsor shall take all 
appropriate measures to safeguard and prevent access to this data by any unauthorized third party. 
14.4. 
Institutional Review Board/Ethics Committee 
An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and 
approve: 
 The protocol, ICF, and any other materials to be provided to the patients 
(eg, advertising) before any patient may be enrolled in the study 
 Any amendment or modification to the study protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the patients, in 
which case the IRB/EC should be informed as soon as possible  
 Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the IRB/EC should be informed of any event likely to affect the safety of patients or 
the continued conduct of the clinical study. 
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their functions 
must be received by the sponsor prior to shipment of drug supplies to the investigator.  The 
approval letter should include the study number and title, the documents reviewed, and the date of 
the review. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 88 of 97 
 
CONFIDENTIAL 
Records of the IRB/EC review and approval of all study documents (including approval of ongoing 
studies) must be kept on file by the investigator. 
15. 
PROTOCOL AMENDMENTS 
The sponsor may not implement a change in the design of the protocol or ICF without an 
IRB/EC-approved amendment.  Regulatory authority approvals will also be sought where required 
by applicable regulations. 
16. 
PREMATURE TERMINATION OF THE STUDY OR 
CLOSE-OUT OF A SITE 
16.1. 
Premature Termination of the Study 
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the sponsor decide to terminate the study, the 
investigator(s) will be notified in writing. 
16.2. 
Close-out of a Site 
The sponsor and the investigator have the right to close-out a site prematurely. 
Investigator’s Decision 
The investigator must notify the sponsor of a desire to close-out a site in writing, providing at least 
30 days’ notice.  The final decision should be made through mutual agreement with the sponsor.  
Both parties will arrange the close-out procedures after review and consultation. 
Sponsor’s Decision 
The sponsor will notify the investigator(s) of a decision to close-out a study site in writing.  
Reasons may include the following, among others:  
 The investigator has received all items and information necessary to perform the study, 
but has not enrolled any patient within a reasonable period of time 
 The investigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelines  
 The total number of patients required for the study are enrolled earlier than expected 
In all cases, the appropriate IRB/EC and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be given to the protection of 
the patients’ interests. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 89 of 97 
 
CONFIDENTIAL 
17. 
STUDY DOCUMENTATION 
17.1. 
Certification of Accuracy of Data 
A declaration assuring the accuracy and content of the data recorded on the CRF/eCRF must be 
signed electronically by the investigator.  This signed declaration accompanies each set of patient 
final CRF/eCRF that will be provided to the sponsor. 
17.2. 
Retention of Records 
The investigator must retain all essential study documents, including ICFs, source documents, 
investigator copies of CRFs, and drug accountability records for at least 15 years following the 
completion or discontinuation of the study, or longer, if a longer period is required by relevant 
regulatory authorities.  The investigator must consult with the sponsor before discarding or 
destroying any essential study documents following study completion or discontinuation.  Records 
must be destroyed in a manner that ensures confidentiality. 
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the sponsor and the relevant records will be transferred to a mutually 
agreed-upon destination. 
18. 
CONFIDENTIALITY 
Confidentiality of information is provided as a separate agreement. 
19. 
FINANCING AND INSURANCE  
Financing and insurance information is provided as a separate agreement. 
20. 
PUBLICATION POLICY  
The publication policy is provided as a separate agreement. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 90 of 97 
 
CONFIDENTIAL 
21. 
REFERENCES  
Moriarty PM, Thompson PD, Cannon CP, et al.  Efficacy and safety of alirocumab vs ezetimibe 
in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE 
randomized trial.  J Clin Lipidol. 2015 Nov-Dec;9(6):758-769. doi: 10.1016/j.jacl.2015.08.006. 
Epub 2015 Aug 29. 
Nissen SE, Stroes E, Dent-Acosta RE, et al.  Efficacy and Tolerability of Evolocumab vs Ezetimibe 
in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.  
JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608 
Schwartz G, Szarek M, Bhatt DL, et al.  The ODYSSEY OUTCOMES Trial: Topline Results 
Alirocumab in Patients After Acute Coronary Syndrome.  American College of Cardiology – 67th 
Scientific Sessions.  March 10, 2018. 
Abul-Husn NS, Manickam K, Jones LK, Wright EA, Hartzel DN, Gonzaga-Jauregui C, et al., 
Genetic Identification of familial hypercholesterolemia within a single U>S. health care system. 
Science 2016; 354 (6319)  1550-1559. 
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL 
cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 
2010;376:1670–81. 
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: 
prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 
Lancet. 2005;366:1267–78. 
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive 
lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised 
trials. Lancet. 2010; 376(9753): 1670-81. 
Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of Statin Treatment on the Clinical Fate of 
Heterozygous Familial Hypercholesteremia. J Atheroscler Thromb. 2010;17:667-674. 
Huijgen R, Kindt I, Verhoeven SBJ, et al. Two Years after Molecular Diagnosis of Familial 
Hypercholesterolemia: Majority on Cholesterol-lowering Treatment but a Minority Reaches 
Treatment Goal. PLoS ONE. 2010;5:e9220. 
Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with 
alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart 
J. 2015 Nov 14;36(43):2996-3003. 
Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing 
Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll 
Cardiol. 2016 Jun 7;67(22):2578-89. 
Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect the 
type I error rate. Stat Med. 2003; 22(23): 3571-81.  
Neil A, Cooper H, Betteridge J, et al. Reduction in all-cause, cancer, and coronary mortality in 
statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry 
study. Eur Heart J. 2008;29:2625-2638. 
Praluent Product Insert. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 91 of 97 
 
CONFIDENTIAL 
Repatha Product Insert. 
Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol 
and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER 
trial. Lancet. 2009;373:1175–82. 
Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. 
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and 
management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious 
Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006; 
117(2): 391-7. 
Stone NJ,  Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, 
et al., American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 
2014 Jul 1;63(25 Pt B):2889-934. 
Vermissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial 
hypercholesterolaemia: a long term cohort study. BMJ. 2008; 337:a2423. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 92 of 97 
 
CONFIDENTIAL 
22. 
INVESTIGATOR’S AGREEMENT 
I have read the attached protocol:  A Randomized, Double-Blind, Placebo-Controlled Study of the 
Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with 
Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy, and 
agree to abide by all provisions set forth therein. 
I agree to comply with the current International Council for Harmonisation Guideline for Good 
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, state, 
or locality relating to the conduct of the clinical study. 
I also agree that persons debarred from conducting or working on clinical studies by any court or 
regulatory agency will not be allowed to conduct or work on studies for the sponsor or a partnership 
in which the sponsor is involved.  I will immediately disclose it in writing to the sponsor if any 
person who is involved in the study is debarred, or if any proceeding for debarment is pending, or, 
to the best of my knowledge, threatened. 
This document contains confidential information of the sponsor, which must not be disclosed to 
anyone other than the recipient study staff and members of the IRB/EC.  I agree to ensure that this 
information will not be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of the sponsor. 
 
 
 
 
 
 
(Signature of Investigator) 
 
(Date) 
 
 
 
(Printed Name) 
 
 
 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 93 of 97 
 
CONFIDENTIAL 
Appendix 1: Factors to Consider in Assessing the Relationship of Adverse Events to Study 
Drug and Study Conduct or Injection Procedure, Study Procedure, or 
Background Treatment, etc. 
Is there a reasonable possibility that the event may have been caused by the study drug or study 
conduct or injection procedure, study procedure, or background treatment, etc.? 
No: 
 due to external causes such as environmental factors or other treatment(s) being 
administered 
 due to the patient’s disease state or clinical condition 
 do not follow a reasonable temporal sequence following the time of administration of 
the dose of study drug or injection procedure, study procedure, or background 
treatment, etc. 
 do not reappear or worsen when dosing with study drug or injection procedure, study 
procedure, or background treatment, etc. is resumed 
 are not a suspected response to the study drug or injection procedure, study procedure, 
or background treatment, etc. based upon preclinical data or prior clinical data 
Yes: 
 could not be explained by environmental factors or other treatment(s) being 
administered 
 could not be explained by the patient’s disease state or clinical condition 
 follow a reasonable temporal sequence following the time of administration of the dose 
of study drug or injection procedure, study procedure, or background treatment, etc. 
 resolve or improve after discontinuation of study drug or injection procedure, study 
procedure, or background treatment, etc. 
 reappear or worsen when dosing with study drug or injection procedure, study 
procedure, or background treatment, etc. is resumed 
 are known or suspected to be a response to the study drug or injection procedure, study 
procedure, or background treatment, etc. based upon preclinical data or prior clinical 
data 
NOTE:  This list is not exhaustive. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 94 of 97 
 
CONFIDENTIAL 
Appendix 2: Simon Broome Register Diagnostic Criteria for Heterozygous Familial 
Hypercholesterolemia 
Definite familial hypercholesterolemia is defined as: 
 Total-C >6.7 mmol/l (260 mg/dL) or LDL cholesterol above 4.0 mmol/l (155 mg/dL) 
in a child <16 years or Total-C >7.5 mmol/l (290 mg/dL) or LDL cholesterol above 
4.9 mmol/l (190 mg/dL) in an adult. (Levels either pre-treatment or highest on 
treatment) 
PLUS 
 Tendon xanthomas in patient, or in 1st degree relative (parent, sibling, child), or in 2nd 
degree relative (grandparent, uncle, aunt) 
OR 
 DNA-based evidence of an LDL receptor mutation or familial defective ApoB-100 
Possible familial hypercholesterolemia is defined as: 
 Total-C >6.7 mmol/l (260 mg/dL) or LDL cholesterol above 4.0 mmol/l (155 mg/dL) 
in a child <16 years or Total-C >7.5 mmol/l (290 mg/dL) or LDL cholesterol above 
4.9 mmol/l (190 mg/dL) in an adult. (Levels either pre-treatment or highest on 
treatment) 
And at least one of the following: 
 Family history of myocardial infarction below 50 years of age in 2nd degree relative or 
below 60 years of age in 1st degree relative. 
 Family history of raised cholesterols >7.5 mmol/l (290 mg/dL) in adult 1st or 2nd 
degree relative or >6.7 mmol/l (260 mg/dL) in child or sibling under 16 years of age. 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 95 of 97 
 
CONFIDENTIAL 
Appendix 3: WHO Criteria (Dutch Lipid Network clinical criteria) for Diagnosis of 
Heterozygous Familial Hypercholesterolemia (HeFH) 
Diagnostic Scoring for Heterozygous Familial Hypercholesterolemia 
Family history 
a First degree relative with known premature (men <55 yrs, women <60 yrs) coronary 
and vascular disease. 
1 
b First degree relative with known LDL-cholesterol >95th percentile for age and sex. 
 
and/or 
a First degree relative with tendon xanthomata and/or arcus cornealis. 
2 
b Children below 18 yrs. with LDL-cholesterol >95th percentile for age and sex. 
 
 
 
 
Clinical history 
a Patient has premature (men <55 yrs, women <60 yrs) coronary artery disease 
2 
b Patient has premature (men <55 yrs, women <60 yrs) cerebral or peripheral vascular 
disease. 
1 
 
 
 
Physical examination 
a Tendon xanthomata 
6 
b Arcus cornealis below the age of 45 yrs. 
4 
 
 
 
Laboratory analysis 
 
 
mmol/L 
mg/dL 
 
a LDL-cholesterol 
>8.5 
>330 
8 
b LDL-cholesterol 
6.5-8.4 
250-329 
5 
c LDL-cholesterol 
5.0-6.4 
190-249 
3 
d LDL-cholesterol 
4.0-4.9 
155-189 
1 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 96 of 97 
 
CONFIDENTIAL 
Diagnostic Scoring for Heterozygous Familial Hypercholesterolemia 
 
(HDL-cholesterol and triglycerides are normal) 
 
 
 
 
DNA-analysis 
a Functional mutation low-density lipoprotein receptor gene present 
8 
 
 
 
Diagnosis of HeFH is: 
Certain When 
>8 points 
Probable When 
6-8 points 
Possible When 
3-5 points 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Clinical Study Protocol 
R1500-CL-1643 Amendment 5 
Regeneron Pharmaceuticals, Inc. 
 
Page 97 of 97 
 
CONFIDENTIAL 
SIGNATURE OF SPONSOR’S RESPONSIBLE OFFICERS 
(Scientific/Medical Monitor, Regulatory Representative, Clinical Study Team Lead, and 
Biostatistician) 
To the best of my knowledge, this protocol accurately describes the conduct of the study. 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and 
Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients 
with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid 
Modifying Therapy  
Protocol Number: 
R1500-CL-1643 
Protocol Version: 
R1500-CL-1643 Amendment 5 
See appended electronic signature page 
Sponsor’s Responsible Scientific/Medical Monitor 
 
 
See appended electronic signature page 
Sponsor’s Responsible Regulatory Representative 
 
 
See appended electronic signature page 
Sponsor’s Responsible Clinical Study Team Lead 
 
 
See appended electronic signature page 
Sponsor’s Responsible Biostatistician 
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00


Signature Page for VV-RIM-00089256 v1.0
Signature Page for VV-RIM-00089256 v1.0 Approved
ESig Approval
ESig Approval
ESig Approval
ESig Approval
                                        VV-RIM-00089256-1.0 Approved - 11 Oct 2019 GMT-5:00

SAP_001.pdf: 
Clinical Development and Regulatory Affairs 
 
 
Biostatistics and Data Management 
Document’s type 
Document Reference 
Effective Date 
Standard 
BDM-STD-STA4-2.2 
March 1, 2015 
 
STATISTICAL ANALYSIS PLAN 
VERSION: FINAL 
 
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and 
Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with 
Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid 
Modifying Therapy 
 
 
 
Compound: 
 
 
Evinacumab 
Protocol Number: 
 
R1500-CL-1643 Version 4 
Clinical Phase:  
 
Phase 2 
Sponsor: 
 
 
Regeneron Pharmaceuticals, Inc. 
Study Biostatistician:  
 
Clinical Trial Manager: 
 
Study Medical Director: 
 
Version/Date:  
 
Version 2 / Amended October 16, 2019 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Clinical Development and Regulatory Affairs 
 
 
Biostatistics and Data Management 
 
CONFIDENTIAL 
Page 2 of 80 
The approval signatures below indicate that these individuals have reviewed the Statistical 
Analysis Plan (SAP) and agreed on the planned analysis defined in this document for 
reporting. 
See appended electronic signature page 
Study Biostatistician  
 
 
 
See appended electronic signature page 
Study Clinical Pharmacologist 
 
 
 
See appended electronic signature page 
Study Bioanalytical Sciences (
 
 
 
See appended electronic signature page 
Head of Cardiovascular & Metabolism Therapeutics 
) 
 
 
See appended electronic signature page 
Study Director 
 
 
 
See appended electronic signature page 
Project Biostatistician (
) 
 
 
See appended electronic signature page 
Head of BDM or designee (
) 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 3 of 80 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ....................................................7 
1. 
OVERVIEW .................................................................................................................9 
1.1. 
Background/Rationale ..................................................................................................9 
1.2. 
Study Objectives ...........................................................................................................9 
1.2.1. 
Primary Objectives .......................................................................................................9 
1.2.2. 
Secondary Objectives .................................................................................................10 
1.2.3. 
Modifications from the Statistical Section in the Final Protocol ................................10 
1.2.4. 
Revision History for Statistical Analysis Plan Amendments .....................................11 
2. 
INVESTIGATION PLAN ..........................................................................................11 
2.1. 
Study Design and Randomization ..............................................................................11 
2.2. 
Sample Size and Power Considerations .....................................................................12 
2.3. 
Study Plan ...................................................................................................................13 
3. 
ANALYSIS POPULATIONS ....................................................................................14 
3.1. 
Efficacy Analysis Sets ................................................................................................14 
3.1.1. 
Intent-to-Treat (ITT) ...................................................................................................14 
3.1.2. 
Modified Intent-to-Treat (mITT) ................................................................................14 
3.2. 
Double-Blind Safety Analysis Set ..............................................................................15 
3.3. 
Open-Label Safety Analysis Set .................................................................................16 
3.4. 
Pharmacokinetic (PK) Analysis Set............................................................................16 
3.5. 
The Immunogenicity Analysis Set..............................................................................16 
3.6. 
Pharmacodynamic (PD) Analysis Set .........................................................................17 
4. 
ANALYSIS VARIABLES .........................................................................................17 
4.1. 
Demographic and Baseline Characteristics ................................................................17 
4.2. 
Medical History ..........................................................................................................18 
4.3. 
Prior and Concomitant Medications ...........................................................................19 
4.4. 
Prohibited Medications and Procedures During Study ...............................................20 
4.5. 
Patient Disposition ......................................................................................................20 
4.6. 
Study Treatment Exposure and Compliance Variables ..............................................22 
4.7. 
Efficacy Variable ........................................................................................................24 
4.7.1. 
Primary Efficacy Variable (s) .....................................................................................25 
4.7.2. 
Secondary Efficacy Variable(s) ..................................................................................25 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 4 of 80 
4.8. 
Safety Variables ..........................................................................................................26 
4.8.1. 
Adverse Events Variables ...........................................................................................26 
4.8.1.1. 
Adverse Events and Serious Adverse Events .............................................................26 
4.8.1.2. 
Adverse Events of Special Interest .............................................................................27 
4.8.1.3. 
Events Causing Death .................................................................................................27 
4.8.2. 
Laboratory Safety Variables .......................................................................................27 
4.8.3. 
Vital Signs ..................................................................................................................28 
4.8.4. 
12-Lead Electrocardiography (ECG) ..........................................................................28 
4.8.5. 
Physical Examination Variables .................................................................................29 
4.9. 
Other Variables ...........................................................................................................29 
4.10. 
Pharmacokinetic and Pharmacodynamic Variables ....................................................29 
4.11. 
Immunogenicity Variables (ADA and NAb) ..............................................................29 
5. 
STATISTICAL METHODS .......................................................................................29 
5.1. 
Demographics and Baseline Characteristics ...............................................................29 
5.2. 
Medical History ..........................................................................................................30 
5.3. 
Prior and Concomitant Medications ...........................................................................30 
5.4. 
Prohibited Medications ...............................................................................................31 
5.5. 
Patient Disposition ......................................................................................................31 
5.6. 
Extent of Study Treatment Exposure and Compliance ...............................................31 
5.6.1. 
Exposure to Investigational Product ...........................................................................32 
5.6.2. 
Study Treatment Compliance .....................................................................................32 
5.7. 
Analyses of Efficacy Variables ..................................................................................32 
5.7.1. 
Analysis of Primary Efficacy Variable .......................................................................32 
5.7.1.1. 
Sensitivity of the Primary Efficacy Analysis..............................................................33 
5.7.1.2. 
Dose-Response Analysis ............................................................................................36 
5.7.1.3. 
Sub-group Analyses ....................................................................................................37 
5.7.1.4. 
Multiplicity Considerations ........................................................................................37 
5.7.2. 
Analysis of Secondary Efficacy Variables .................................................................38 
5.7.2.1. 
Continuous Endpoints Anticipated to have a Normal Distribution ............................38 
5.7.2.2. 
Continuous Endpoints Anticipated to have a Non-Normal Distribution ....................38 
5.7.2.3. 
Binary Endpoint Variables .........................................................................................39 
5.7.2.4. 
Sensitivity Analysis of Secondary Endpoint Variables ..............................................39 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 5 of 80 
5.7.2.5. 
Summary of Results by Time Point ............................................................................39 
5.8. 
Analysis of Safety Data ..............................................................................................40 
5.8.1. 
Adverse Events ...........................................................................................................41 
5.8.2. 
Analysis of Adverse Events of Special Interest ..........................................................43 
5.8.3. 
Clinical Laboratory Measurements.............................................................................44 
5.8.4. 
Analysis of Vital Signs ...............................................................................................45 
5.8.5. 
Analysis of 12-Lead ECG ...........................................................................................46 
5.8.6. 
Physical Exams ...........................................................................................................47 
5.9. 
Analysis of Other Variables ........................................................................................47 
5.10. 
Analysis of Pharmacokinetic and Pharmacodynamic Variables ................................48 
5.11. 
Analysis of Anti-evinacumab Antibody Variables .....................................................48 
6. 
DATA CONVENTIONS ............................................................................................49 
6.1. 
Definition of Baseline for Efficacy/Safety Variables .................................................49 
6.2. 
Data Handling Convention for Efficacy Variables .....................................................49 
6.3. 
Data Handling Convention for Missing Data .............................................................49 
6.4. 
Visit Windows ............................................................................................................50 
6.5. 
Unscheduled Assessments ..........................................................................................50 
6.6. 
Pooling of Centers for Statistical Analyses ................................................................50 
6.7. 
Statistical Technical Issues .........................................................................................50 
7. 
TIMING OF STATISTICAL ANALYSES ................................................................51 
7.1. 
First Step: Group B Main Efficacy and Safety Analysis ............................................51 
7.2. 
Second Step: Group A Main Efficacy and Safety Analysis .......................................51 
7.3. 
Third Step: Final Safety Analysis ...............................................................................51 
7.4. 
Additional Rules .........................................................................................................51 
8. 
SOFTWARE ...............................................................................................................53 
9. 
REFERENCES ...........................................................................................................54 
10. 
APPENDIX.................................................................................................................55 
10.1. 
Summary of Statistical Analyses ................................................................................55 
10.2. 
Windows for Analysis Time Points ............................................................................56 
10.3. 
List of AESIs with Data Sources and Definitions of SMQ/CMQ ..............................60 
10.4. 
Criteria for Potentially Clinically Significant Values (PCSV) ...................................65 
10.5. 
Detailed Description of the Multiple Imputation Procedure ......................................68 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 6 of 80 
10.6. 
Detailed Description of Pattern Mixture Model .........................................................68 
10.7. 
Schedule of Time and Events .....................................................................................71 
 
LIST OF TABLES 
Table 1: 
Screening Schedule of Events – Patients Requiring Medication Change or 
Daily Statin Stabilization at Study Entry ....................................................................71 
Table 2: 
Screening Schedule of Events – Patients on Stable Statin, PCSK9 Inhibitor 
Antibody and Lipid Modifying Therapy Regimen at Study Entry .............................72 
Table 3: 
Schedule of Events for SC Treatment Group A .........................................................73 
Table 4: 
Schedule of Events for IV Treatment Group B ..........................................................75 
Table 5: 
Schedule of Events for IV Treatment Group B (Continued for Open-Label) ............77 
Table 6: 
Follow-up Schedule of Events for SC Treatment Group A ........................................78 
Table 7: 
Follow-up Schedule of Events for IV Treatment Group B .........................................79 
 
LIST OF FIGURES 
Figure 1: 
Study Flow Diagram ...................................................................................................13 
 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 7 of 80 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
ADA 
Anti-drug antibody 
AE 
Adverse event 
AESI 
Adverse event of special interest 
ALT 
Alanine aminotransferase 
ANGPTL3 
Angiopoietin-like 3 
Apo A-1 
Apolipoprotein A-1 
Apo B 
Apolipoprotein B 
Apo CIII 
Apolipoprotein CIII 
ASCVD 
Atherosclerotic cardiovascular disease 
AST 
Aspartate aminotransferase 
BUN 
Blood urea nitrogen 
CEC 
Clinical Events Committee 
CI 
Confidence interval 
CPK 
Creatine phosphokinase 
CRF 
Case report form (electronic or paper) 
CV 
Cardiovascular 
CVD 
Cardiovascular disease 
DBTP 
Double-blind treatment period 
ECG 
Electrocardiogram 
EOT 
End of treatment 
FH 
Familial hypercholesterolemia 
FSH 
Follicle stimulating hormone 
HbA1c 
Hemoglobin A1c 
HDL 
High-density lipoprotein 
HDL-C 
High-density lipoprotein cholesterol 
HoFH 
Homozygous familial hypercholesterolemia 
ICH 
International Council for Harmonisation 
IDMC 
Independent Data Monitoring Committee 
ITT 
Intent-to-treat 
IV 
Intravenously 
IVRS 
Interactive voice response system 
LDH 
Lactate dehydrogenase 
LDL-C 
Low-density lipoprotein cholesterol 
LDLR 
Low-density lipoprotein receptor 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 8 of 80 
LMT 
Lipid modifying therapy 
Lp(a) 
Lipoprotein a 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
Myocardial infarction 
MMRM 
Mixed-effect model with repeated measures 
OLTP 
Open-label treatment period 
PCSV 
Potentially clinically significant value 
PD 
Pharmacodynamic 
PK 
Pharmacokinetic 
PMM 
Pattern Mixture Model 
PT 
Preferred term 
Q4W 
Every 4 weeks 
RBC 
Red blood cell 
Regeneron 
Regeneron Pharmaceuticals, Inc. 
SAE 
Serious adverse event 
SAF 
Safety analysis set 
SAP 
Statistical analysis plan 
SAS 
Statistical Analysis System 
SC 
Subcutaneous 
SD 
Standard deviation 
SE 
Standard error 
SMT 
Safety Monitoring Team 
SOC 
System organ class 
TC 
Total cholesterol 
TEAE 
Treatment-emergent adverse event 
TG 
Triglyceride 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
WBC 
White blood cell 
 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 9 of 80 
1. 
OVERVIEW 
The purpose of the statistical analysis plan (SAP) is to ensure the credibility of the study results 
by pre-specifying prior to the database lock the statistical approaches for the analysis of study 
data. The SAP is intended to be a comprehensive and detailed description of the strategy and 
statistical methods to be used in the analysis of data collected in the R1500-CL-1643 study. The 
content of this SAP is inclusive of the first, second, and third step analyses as described in the 
protocol. 
This plan may be revised during the study to accommodate protocol amendments and adapt to 
unexpected issues in study execution that may affect planned analyses. These revisions will be 
based on blinded data review, and a final plan will be issued prior to the first step database lock 
(i.e. before treatment assignments become known for Group B). For the purposes of this 
document, REGN1500 will be referred to as “evinacumab”. 
1.1. 
Background/Rationale 
Angiopoietin-like 3 (ANGPTL3) has recently emerged as an attractive target for the treatment of 
elevated levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs), both 
factors for the development of cardiovascular disease (CVD).  Importantly, population genetic 
studies indicate that patients heterozygous for Angiopoietin-like 3 (ANGPTL3) protein loss-of-
function (LOF) mutations have reduced cardiovascular (CV) risk.  These data suggest that 
inhibiting ANGPTL3 may be a meaningful strategy for lowering serum lipids in patients whose 
elevated LDL-C levels place them at significant residual CV risk, despite otherwise optimized 
lipid-lowering therapy. 
Evinacumab (REGN1500) is a fully human monoclonal antibody, created with Regeneron’s 
VelocImmune technology platform, which specifically binds to ANGPTL3. Additional 
background information on the study drug and development program can be found in the 
Investigator’s Brochure. 
1.2. 
Study Objectives  
1.2.1. 
Primary Objectives 
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in 
comparison to placebo after 16 weeks in patients with primary hypercholesterolemia 
(heterozygous familial hypercholesterolemia [HeFH], or non-HeFH with a history of clinical 
atherosclerotic cardiovascular disease [ASCVD]) with persistent hypercholesterolemia despite 
receiving maximally-tolerated LMT.  Persistent hypercholesterolemia is defined as LDL-C 
≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL 
(2.59 mmol/L) for those patients without clinical ASCVD. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 10 of 80 
1.2.2. 
Secondary Objectives 
The secondary objectives of the study are: 
 To evaluate the dose-response effect of evinacumab on other lipid parameters (ie, 
Apolipoprotein B [ApoB], non-high-density lipoprotein cholesterol [non-HDL-C], 
total cholesterol [TC], Lipoprotein(a) [Lp (a)], triglycerides [TGs], ApoCIII), and 
total ANGPTL3 in patients with primary hypercholesterolemia 
 To evaluate the safety and tolerability of subcutaneous (SC) and intravenous (IV) 
doses of evinacumab in patients with primary hypercholesterolemia 
 To assess systemic concentrations of evinacumab in serum in patients with primary 
hypercholesterolemia  
 To evaluate the potential development of anti-evinacumab antibodies  
1.2.3. 
Modifications from the Statistical Section in the Final Protocol 
The summary of modifications is listed in the following table. 
Item 
Protocol Section 
Description 
1 
10.3.1.1 Intent-to-Treat (ITT) 
SAP Section 3.1.1 
Evaluable primary endpoint requirement for 
the 
primary 
analysis 
population 
was 
removed per FDA request. 
2 
10.3.2.1 Double-Blind Safety Analysis 
Set/second item 
“For patients receiving study drug from 
more than 1 treatment group during the 
trial, the treatment group allocation for 
as-treated analysis will be the one in 
which the patient was treated with the 
highest number of injections (Group A) 
or infusions (Group B).” 
 
SAP Section 3.2: 
The second item for determining the as-
treated 
treatment 
group 
will 
be 
conservatively changed to: 
“For randomized patients receiving both 
evinacumab and placebo study treatment 
during the trial, the treatment group 
allocation for as-treated analysis will be 
evinacumab. 
3 
10.4.3.1 Primary Efficacy Analysis  
“Each model will include the fixed 
categorical effects of treatment group 
(placebo and evinacumab dose 
regimens), randomization strata, time 
point (weeks 4, 8, 12, 16 for the Group 
B treatment groups; weeks 2, 4, 6, 8, 12, 
16 for the Group A treatment groups)” 
SAP Section 5.7.1 
Timepoints in the MMRM model are 
updated:  
“Each model will include the fixed 
categorical effects of treatment group 
(evinacumab 
dose 
regimens 
versus 
placebo), 
randomization 
strata 
(high-
intensity statin [Yes/No] and HeFH status 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 11 of 80 
Item 
Protocol Section 
Description 
 
[Yes/No]), time point (weeks 2, 4, 6, 8, 12, 
16 for the Group B treatment groups; weeks 
2, 4, 6, 8, 10, 12, 14, 16 for the Group A 
treatment groups)” 
4 
4.2.2. Secondary Efficacy Analysis 
 Proportion 
of 
patients 
with 
calculated LDL-C < 100 mg/dL 
(2.59 mmol/L) at week 16 
 Proportion 
of 
patients 
with 
calculated LDL-C < 70 mg/dL (1.81 
mmol/L) at week 16 
SAP Section 4.7.2 
These two secondary endpoints were 
removed due to the protocol amendment for 
changes 
to 
the 
inclusion 
criteria. 
Specifically, the LDL-C threshold was 
lowered 
to 
aid 
patient 
enrollment, 
potentially allowing patients to achieve one 
or both of the secondary endpoints at 
baseline. 
1.2.4. 
Revision History for Statistical Analysis Plan Amendments 
The following modification has been made in this SAP version 2, as compared to version 1. 
Item 
SAP Section 
Description 
1 
Appendix 10.2 
The upper bound for Week 16 in Table 1 
and 2 (analysis windows for Group B) was 
increased by 2 days (from study day 126 to 
128). These extra 2 days in the week 16 
analysis window will reduce the missing 
data rate for the primary efficacy endpoint. 
 
2. 
INVESTIGATION PLAN 
2.1. 
Study Design and Randomization 
This is a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to assess 
varying doses of SC and IV regimens of evinacumab in patients diagnosed with primary 
hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) who have an 
LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C 
≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD, despite receiving a stable 
maximally-tolerated LMT.  The LMT should include a stable, maximally-tolerated statin and 
stable PCSK9 inhibitor antibody for patients who are HeFH, or non-HeFH with a history of 
clinical ASCVD.  Patients with HeFH not on a statin are eligible if there is documentation of 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 12 of 80 
inability to tolerate at least 2 statins (see Protocol Section 7.3) Background Treatments for 
further information). 
Patients who meet all inclusion criteria and who meet none of the exclusion criteria will be 
randomized within either Group A (1:1:1:1) or Group B (1:1:1) to receive: 
Group A 
 Evinacumab 300 mg SC QW for 16 weeks, or  
 Evinacumab 300 mg SC Q2W, for 16 weeks (alternating with placebo on opposite 
weeks), or 
 Evinacumab 450 mg SC QW, for 16 weeks, or  
 Placebo SC QW, for 16 weeks 
Group B 
 Evinacumab 5 mg/kg IV Q4W, for 24 weeks, or  
 Evinacumab 15 mg/kg IV Q4W, for 24 weeks, or 
 Placebo IV Q4W, for 24 weeks 
Enrollment of IV cohorts will occur before enrollment of SC cohorts, accordingly, enrollment of 
Group A will not begin until Group B enrollment is completed. 
Patients enrolled to the SC (Group A) and IV (Group B) treatment groups will have different 
visit schedules because of the differences in dosing frequency.   
Randomization will be stratified by high-intensity statin (Yes/No) and HeFH (Yes/No) at 
baseline.  High-intensity statin is defined as rosuvastatin 20 mg or 40 mg daily, atorvastatin 
40 mg or 80 mg daily, or simvastatin 80 mg daily (if already on this dose for >1 year).  To ensure 
an adequate number of patients with HeFH are included in this study and exposed to each dose, 
randomization will be stratified 2:1 (HeFH:non-HeFH; 24:12) within each treatment group.  
2.2. 
Sample Size and Power Considerations 
Four pairwise comparisons of evinacumab to a placebo control arm corresponding to the route of 
administration (Group A or Group B) are hypothesized for the primary efficacy analysis of this 
study.  A total of 216 patients are planned for assessing the primary measure at week 16.  
Specifically, a sample size of 36 patients per treatment arm will have 90% power to detect a 
treatment group difference in mean percent change LDL-C of 20% in any 1 pairwise comparison 
(ie, evinacumab mean = 27% and control mean = 7%), assuming that the common standard 
deviation (SD) is 25 using an independent group t-test.  This sample size has been adjusted for a 
5% dropout rate.  The alpha level for each of the 4 pairwise comparisons is 0.05 (2-sided), and 
assumes control of the overall type-1 error rate using a pre-specified hierarchical inferential 
approach. 
Further, the evinacumab 5 mg/kg IV Q4W regimen has been added to Group B, allowing for an 
assessment of dose-response in the IV route of administration.  The additional 36 patients for this 
second IV dose regimen culminate in a total of 252 patients planned for the study. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 13 of 80 
With the intent to gain evinacumab experience across these dose regimens for future study 
planning in patients with HeFH, a subgroup analysis is planned for the stratified sub-population 
of patients diagnosed with HeFH.  To ensure an adequate number of patients are randomized into 
the HeFH strata level, a total of 175 patients are planned for assessing the percent change LDL-C 
from baseline at week 16.  Specifically, a sample size of 36 patients per treatment arm will have 
90% power to detect a treatment group difference in mean percent change LDL-C of 20% in any 
1 pairwise comparison (ie, evinacumab mean = 27% and Control mean = 7%), assuming that the 
common SD is 20 using an independent group t-test.  This sample size has been adjusted for a 
5% dropout rate. 
Blinded Sample Size Adjustment 
Referencing the ICH E9 regulatory guidance, the study sample size may be re-estimated after 
approximately 75% of the patients reach the week 8 visit in the double-blind period, to ensure 
adequate power in the case of a larger-than-expected variability in the data.  This sample size 
re-estimation process may be performed twice; once for Group A and again for Group B.  The 
sample size re-estimation will be based on the actual blinded pooled SD (adjusted as described in 
Keiser 2003) for the primary efficacy measure.  Since the patients’ post-baseline LDL-C levels 
are masked to all study participants (patients, site personnel, and sponsor staff), the blinded 
pooled SD will be calculated by a designated statistician external to Regeneron who has access 
to the lipid data.  As mentioned in Keiser 2003, the blinded sample size re-estimation does not 
affect type-I error materially for continuous endpoints. 
This re-estimation procedure will assess the need for an increase or decrease in sample size 
(unrestricted recalculation).  The result of this procedure is non-binding, since the decision to 
increase the sample size will also take into account other study execution factors (for example, 
availability of patients).  In the case the re-estimated sample size is implemented, a protocol 
amendment will document the modification. 
2.3. 
Study Plan 
The study consists of 4 (for Group A [SC treatment groups]) or 5 (for Group B [IV treatment 
groups]) periods: a run-in period (for patients whose background LMT has not been stable prior 
to screening, who are not already receiving a PCSK9 inhibitor antibody, or whose background 
LMT is not optimized), a 2-week screening period, a 16-week double-blind treatment period for 
the SC dose groups or 24-week double-blind treatment period for the IV dose groups, an 
approximately 48-week open-label treatment period for the IV dose groups, and a follow-up 
period lasting 24 weeks after the last dose of study drug (Figure 1). 
The Study event table is presented in Appendix 10.7 . 
Figure 1: 
Study Flow Diagram 
 
Run-in 
Screening 
Double-Blind 
Treatment 
Open-Label 
Treatment  
Follow-Up Period 
 
 
 
 
Group A: SC x 16 weeks  
Group B: IV x 24 weeks 
Group B: IV x 
48 weeks 
Group A: 23 weeks 
Group B: 20 weeks 
 
 
 
 
Baseline 
 
End of Double-Blind  
End of Open-Label 
End of Study  
Variable 
(Day –14) 
 
(Day 1) 
(Day 113/ Day 169) 
(Approx Day 505) 
(Day 274/ Day 
645) 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 14 of 80 
3. 
ANALYSIS POPULATIONS 
In accordance with guidance from the International Conference of Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline ICH E9 
Statistical Principles for Clinical Trials (ICH, 1998), below are the patient populations defined 
for statistical analysis. Two efficacy populations are planned for this study, specifically the 
Intent-to-Treat (ITT) population and the Modified Intent-to-Treat population (mITT).  The 
primary efficacy analysis population is the ITT population.  Additional patient populations are 
defined for safety, anti-drug (evinacumab) anti-body (ADA), pharmacokinetic (PK), 
pharmacodynamic (PD), and open-label analyses. For the purposes of the definitions below, a 
patient is considered randomized to study treatment when they have been screened and received 
a double-blind treatment kit number allocated and recorded in the IVRS/IWRS database, 
regardless of whether the treatment kit was used or not.      
As with all trials, odd cases (usually rare) occur for patient eligibility in the analysis populations.  
The following are three cases with the planned resolution of each type of case should they occur. 
 Patients administered study treatment without randomization or before randomization 
will not be considered as “randomized” and therefore will not be included in any 
analysis population. The safety experience from these patients will be reported 
separately. 
 For patients found to be randomized and treated more than once in this trial, safety 
data from the first randomization and treatment will be included in the safety 
population, with safety data associated with the later randomization and treatment 
reported separately.  Inclusion of efficacy data from the patient randomized and 
treated more than once in the two efficacy populations will be decided on a case-by-
case basis prior to the unblinding of treatment assignments and documented in the 
study report. 
 Patients successfully randomized and administered study treatment, but later found to 
violate inclusion/exclusion criteria, will be included in all analyses with appropriate 
documentation for the protocol deviation.  
3.1. 
Efficacy Analysis Sets 
3.1.1. 
Intent-to-Treat (ITT) 
The ITT population (also known as the full analysis set) is defined as all randomized patients 
who received at least 1 dose or part of a dose of double-blind study drug. Patients in the ITT 
population will be analyzed according to the treatment group allocated by randomization (ie, as-
randomized group). 
3.1.2. 
Modified Intent-to-Treat (mITT) 
The modified ITT (mITT) population is defined as the all randomized population who took at 
least 1 dose or part of a dose of study drug and have an evaluable primary endpoint. The 
endpoint is considered evaluable when both of the following conditions are met: 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 15 of 80 
 Availability of at least 1 measurement value for calculated LDL-C before first dose of 
study drug (i.e., baseline). 
 Availability of at least 1 calculated LDL-C value during the efficacy treatment period 
and within one of the efficacy analysis windows in the DBTP up to week 16. The 
group A (SC dose regimens) efficacy treatment period is defined as the time from the 
first study drug administration up to 14 days after the last double-blind study drug 
injection.  The Group B (IV dose regimens) efficacy treatment period is defined as 
the time from the first study drug administration up to 35 days after the last 
double-blind study drug infusion, or up to the first dose of the open-label study drug, 
whichever is earlier. 
Patients in the mITT population will be analyzed according to the treatment group allocated by 
randomization. 
3.2. 
Double-Blind Safety Analysis Set 
The double-blind safety analysis set (SAF) considered for safety analyses will be the randomized 
population who received at least 1 dose or part of a dose of double-blind study drug. Patients will 
be analyzed according to the treatment received (placebo IV, evinacumab 5 mg/kg or 15 mg/kg 
IV Q4W, placebo SC, evinacumab 300 mg SC QW or Q2W, evinacumab 450 mg SC QW). 
Actual treatment received is defined as follows: 
 For Group A, each study drug administration visit is assigned 3 kits with 150 mg IP 
concentration in each kit, and each kit contains either evinacumab or placebo. 
Different combinations of evinacumab or placebo kits determine the actual dosage as 
follows: 
 For the evinacumab 450 mg SC QW treatment group, the 3 kits at all weekly 
visits contain evinacumab as recorded in eCRF “Study Drug Administration- 
Evinacumab/Placebo SC” 
 For the 300 evinacumab mg SC QW treatment group, 2 kits contain evinacumab 
and 1 kit contains placebo at all weekly visits as recorded in eCRF “Study Drug 
Administration- Evinacumab/Placebo SC” 
 For the 300 evinacumab mg SC Q2W treatment group, 2 kits contain evinacumab 
and 1 kit contains placebo at all even-numbered weekly visits (Day 1, Week 2, 
Week 4, etc.) as recorded in eCRF “Study Drug Administration- 
Evinacumab/Placebo SC.” All odd-numbered weekly visits (Week 1, Week 3, 
etc.) contain 3 kits of placebo as recorded in eCRF “Study Drug Administration- 
Evinacumab/Placebo SC” 
 For the placebo SC QW treatment group, the 3 kits at all weekly visits contain 
placebo as recorded in eCRF “Study Drug Administration- Evinacumab/Placebo 
SC” 
 For Group B, each study drug administration visit is assigned 1 kit, and it contains 
either evinacumab or placebo (regardless of evinacumab dose). The actual study 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 16 of 80 
treatment received (placebo, evinacumab 5mg/kg IV, or evinacumab 15 mg/kg IV) is 
defined as follows:  
 Active study treatment (evinacumab or placebo) is defined from the kit number in 
eCRF “Study Drug Administration- IV” 
 Evinacumab study treatment dose (5 mg/kg or 15 mg/kg) is defined as “active 
study treatment = evinacumab” and the dose is defined in the “Total IP Dose 
Administration – IV Double-blind (Unblinded)” eCRF page.  
In addition:   
 Randomized patients for whom it is unclear whether they took the study drug will be 
included in the safety population as randomized. 
 For randomized patients receiving both evinacumab and placebo study treatment 
during the trial, the treatment group allocation for as-treated analysis will be 
evinacumab. 
 If a randomized patient receives both evinacumab doses (300 mg SC and 450 mg SC 
for Group A; 5 mg/kg IV and 15 mg/kg IV for Group B), the treatment group 
allocation for as-treated analysis will be the most frequently administered evinacumab 
dose. 
3.3. 
Open-Label Safety Analysis Set 
For Group B, the open-label SAF considered for safety analyses will be the randomized 
population who received at least 1 dose or part of a dose of open-label study drug.  
3.4. 
Pharmacokinetic (PK) Analysis Set 
The PK analysis set is defined as all randomized patients who received any study drug and have 
at least 1 non-missing post-baseline measurement of evinacumab concentration.  Treatment 
assignments for the DBTP are based on the treatment received (placebo or evinacumab). 
The total target analysis set is defined as all randomized patients who received any study drug 
and have at least 1 non-missing measurement of total ANGPTL3 concentration following the 
first dose of study drug.  
3.5. 
The Immunogenicity Analysis Set 
The anti-evinacumab antibody (ADA) analysis set is defined as all randomized patients who 
received any study treatment, and have at least 1 non-missing ADA result following the first 
dose of study treatment. Patients will be analyzed according to a treatment actually received. 
The neutralizing antibody (NAb) analysis set includes all subjects/patients who received any 
study drug and who are negative in the REGN1500 ADA assay or with at least one non-missing 
result in the REGN1500 NAb assay after first dose of the study drug. Patients who are ADA 
negative are set to negative in the NAb analysis set. Patients will be analyzed according to the 
treatment actually received. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 17 of 80 
3.6. 
Pharmacodynamic (PD) Analysis Set 
The PD population includes all treated patients who received any study drug (safety population) 
and had at least one non-missing protocol defined PD marker (as defined in Protocol/Section 
8.2.5) following the first dose of study drug. 
4. 
ANALYSIS VARIABLES 
4.1. 
Demographic and Baseline Characteristics 
For each patient, demographic and baseline characteristics will be obtained from the last 
available value up to the date of the first study treatment administration (i.e. baseline definition).  
For patients randomized and not treated in R1500-CL-1643, the baseline value is defined as the 
last available measurement prior to the date of randomization.  
All baseline safety and efficacy parameters (apart from those listed below) will be presented 
along with the summary statistics in the safety and efficacy sections. 
The following variables will be summarized:  
Demographic Characteristics 
 Sex (Male, Female) 
 Race (White, Black or African American, Asian, American Indian or Alaska Native, 
Native Hawaiian or other Pacific Islander, Not Reported, Other) 
 Age in years (quantitative and qualitative variable: ≥18 to <45, ≥45 to <65, ≥65 to 
<75, and ≥75 years; and <65, and ≥65 years) 
 Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Not reported, Unknown) 
Baseline Characteristics 
 Baseline Weight (kg) 
 Baseline Height (cm) 
 Baseline Body mass index (BMI) in kg/m² (quantitative and qualitative variable 
defined as <30, ≥30) 
 Smoking Status (never, former, and current smoker) 
 Current alcohol consumption (yes/no) 
 Randomization strata as reported in the IVRS  
 High intensity statin (Yes/No) 
 HeFH status (Yes/ No) 
 Randomization strata as reported from the e-CRF 
Baseline Disease Characteristics 
 Lipid parameters - quantitative variables for all efficacy parameters  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 18 of 80 
 HbA1c both quantitative variable and qualitative variable defined as: <5.7%, ≥5.7% 
to <6.5%, ≥6.5% 
 hs-CRP 
 Calculated LDL-C categories: <70, ≥ 70 to <100, ≥100 to <130, ≥130 to <160, ≥160 
to <190, ≥190 mg/dL (<1.81, ≥1.81, <2.59, ≥2.59 to <3.37, ≥3.37 to <4.14, ≥4.14 to 
<4.91, ≥4.91 mmol/L) 
 Fasting TG categories: <150, ≥150 to <200, ≥200 mg/dL, and category ≥150 mg/dL 
for mixed dyslipidemia (<1.7, ≥1.7 to <2.3, ≥2.3 mmol/L, and category ≥ 1.7 
mmol/L), 
 Lp(a) categories: <30, ≥30 to <50, ≥50 mg/dL, and category ≥30 mg/dL (<75, ≥75 to 
<125, and ≥125 nmol/L, and category ≥ 75 nmol/L) 
4.2. 
Medical History 
As applicable, patient medical history, pre-listed or not in the e-CRF will be dictionary coded by 
primary system organ class and preferred term using the Medical Dictionary for Regulatory 
Activities (MedDRA), specifically the MedDRA version in effect at the time of the first database 
lock. The medical history of interest collected on dedicated and pre-listed e-CRFs is: 
cardiovascular history and risk factors, Primary and secondary CVD prevention, CV risk factors 
categorized by high and very high risk, hypercholesterolemia disease history (including LMT 
therapies) are also defined below from pre-defined risk factors collected on e-CRF. 
Medical history of interest is defined as the occurrence of these diseases: 
1. Coronary heart disease (CHD)  
2. CHD risk equivalents  
3. Cardiovascular (CV) risk factors other than hypercholesterolemia (hypertension, type 2 
diabetes, type 1 diabetes, family history of premature CHD).  
4. Family history of type 2 diabetes 
CHD and CHD risk equivalents will be derived from the respective e-CRF as follows: 
1. Coronary heart disease (CHD) (regardless if it is ongoing or not) is defined as the 
occurrence of at least one of the following events: 
 Acute myocardial infarction 
 Silent myocardial infarction 
 Angina (chronic stable or unstable) 
 Coronary revascularization procedure (e.g. PCI, CABG) 
2. CHD risk equivalent (regardless if it is ongoing or not) is defined as the occurrence of at 
least one of the following events: 
 Peripheral arterial disease (PAD)  
 Ischemic stroke 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 19 of 80 
 Chronic kidney disease (CKD) 
 Known history of diabetes mellitus (type 1 or 2) AND 2 or more additional risk 
factors among: 
 History of ankle-brachial index ≤ 0.90 
 History of hypertension 
 History of microalbuminuria or macroalbuminuria  
 History of proliferative diabetic retinopathy  
 Known family history of premature CHD  
Secondary CVD prevention is defined as patients with any of the following history of CVD 
(other patients will be classified as primary CVD prevention): 
 History of CHD (as defined above) 
 History of ischemic stroke 
 History of PAD with severity criteria defined as one of the following events: 
 PAD and ankle brachial index ≤ 0.90 
 Peripheral revascularization procedure (angioplasty, stenting) for PAD 
 Thrombolysis for PAD 
 Peripheral revascularization surgery (arterial bypass) for PAD 
CV Risk Factors are defined for this study as high risk and very high risk below. 
 Very high CV risk patients are defined as patients with CHD or CHD risk 
equivalents. 
 High CV risk patients are defined as all other patients. 
Hypercholesterolemia disease history will be assessed through diagnosis of HeFH, time from 
diagnosis to study randomization (years), method of diagnosis of HeFH (genotyping, clinical 
diagnosis), lipid modifying therapies history reported in the “History of Hypercholesterolemia 
/Statin Use” e-CRF page.  
4.3. 
Prior and Concomitant Medications 
All medications (including statin, non-statin LMT, and CV) taken from the time of informed 
consent to the final study visit, including medications that were started before the study and are 
ongoing during the study, will be reported in Concomitant Medications CRF.  
All medications will be dictionary coded using the World Health Organization-Drug Dictionary 
(WHO-DD) to both an anatomic category and a therapeutic category, with the version in effect at 
the time of the first database lock.  Drug names will be matched to respective Anatomical-
Therapeutic-Chemical (ATC) classification, although a drug can be matched to more than one 
ATC classification (i.e. patients can be counted in several categories for the same medication).   
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 20 of 80 
Prior medications, concomitant medications, and post-treatment medications are defined below 
and will be applied in the respective treatment periods (DBTP and OLTP for Group B only). 
 Prior medications are defined as medications for which the stop date is before the date 
of the first DBTP study treatment administration. 
 Concomitant medications are defined as medications that are administered to the 
patients during the respective study treatment periods. Specifically: 
 Start date of the concomitant medication is on or after the first study treatment 
administration in respective study treatment periods (≥ DBTP Day 1 or ≥ OLTP 
Week 24 for Group B only); or 
 Start date of the concomitant medication is before the first study treatment 
administration in respective study treatment periods and is “Ongoing” during the 
treatment emergent period; or  
 Start date of the concomitant medication is before the first study treatment 
administration in respective study treatment periods, and the end date is on or 
after the first study treatment administration in respective study treatment periods 
(≥ DBTP Day 1 or ≥ OLTP Week 24 for Group B only). 
The concomitant medication treatment emergent periods are defined as:  
 For concomitant medications in the DBTP, the treatment emergent period is defined 
from the first day of double-blind study treatment administration to the last day of 
double-blind study treatment +168 days (for Group A patients or Group B patients 
who do not continue into the OLTP) or to the day before the first open-label study 
treatment administration (for Group B patients who enter the OLTP). 
 For concomitant medications in the OLTP (Group B only), the treatment emergent 
period is defined from the first day of open-label study treatment administration to the 
last day of open-label study treatment +168 days. 
Note: In the case the start date is before first study treatment administration and both ongoing 
status and stop date are missing, the medication will be assumed to be concomitant. 
 Post-treatment medications are defined as medications for which the start date is after 
last date of study treatment administration +169 days (≥ last study treatment +169 
days).  
4.4. 
Prohibited Medications and Procedures During Study 
The definitions of prohibited medications and procedures are described in the section 7.8.1 of the 
protocol. They will be reviewed and identified by the study clinician and reported in protocol 
deviations.   
4.5. 
Patient Disposition 
Patient disposition will include the description of patient status at major milestone decisions in 
the study, as well as the patient analysis populations.   
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 21 of 80 
For patient study status, patient milestone categories for the DBTP are defined below.  As 
applicable, percentages will be calculated using the number of randomized patients in the 
denominator, with two exceptions.  Specifically, the two exceptions will be for the screened and 
non-randomized categories, which will not have associated percentages shown.  
 The total number of screened patients, defined as originally having met the inclusion 
criteria and signed the ICF.  
 The total number of screen failure (SF) patients: 
 if a SF patient’s first informed consent date is before randomization date of the 
last IV patient, this patient will be included in Group B; otherwise this patient will 
be included in Group A 
 The total number of randomized patients, defined as all screened patients with a 
double-blind treatment kit number allocated and recorded in the IVRS database, 
regardless of whether the treatment kit was used. 
 The total number of patients randomized but not receiving study treatment. 
 The total number of patients randomized and receiving study treatment. 
 The total number of patients who completed the DBTP as collected on the end of 
double-blind treatment e-CRF. 
 The total number of patients who completed the DBTP, defined for Group A as at 
least 15 weeks of study treatment administration and week 16 visit performed; and 
defined for Group B as at least 20 weeks of study treatment administration and week 
24 visit performed 
 The total number of Group B patients who completed week 16 visit, defined as at 
least 12 weeks of study treatment administration and week 16 visit performed 
 The total number of patients who prematurely discontinued study treatment during 
the double-blind period, and the reasons for discontinuation collected on the End of 
Double-blind Treatment e-CRF 
 The total number of patients in Group B who do not proceed into OLTP and complete 
the last study follow-up visit (i.e. Follow-up week 20). 
 The total number of patients in Group A who complete the last study follow-up visit 
(i.e. Follow-up week 20). 
 The total number of patients who did not complete the study follow-up period, 
defined as the last visit performed less than 23 weeks after the last study treatment 
administration. Patients who died during the study are excluded. (For Group B this 
applies only to patients who did not proceed to OLTP). 
Patient milestone categories for the OLTP (Group B only) are defined below.  As applicable, 
percentages will be calculated using a denominator of the number of patients administer open-
label study treatment.  
 The total number of patients receiving open-label study treatment. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 22 of 80 
 The total number of patients ongoing in OLTP (applicable for the first step analysis) 
 The total number of patients who completed the OLTP as collected on the end of 
open-label treatment e-CRF. 
 The total number of patients who completed the open-label treatment period, defined 
as at least 44 weeks of open-label study treatment administration and visit week 72 
performed. 
 The total number of patients who prematurely discontinued study treatment during 
the OLTP, and the reasons for discontinuation collected on the End of Open-label 
Treatment e-CRF. 
 The total number of patients from OLTP who complete the last study follow-up visit 
(i.e. Follow-up week 20). 
 The total number of patients who did not complete the study follow-up period, 
defined as the last visit performed less than 23 weeks after the last study treatment 
administration. Patients who died during the study are excluded 
The following patient populations for analyses are defined below: 
 Randomized population 
 Efficacy populations: ITT and mITT populations 
 Double-blind safety analysis set  
 Open-label safety analysis set 
 Anti-evinacumab antibody (ADA) analysis set 
 Pharmacokinetic (PK) analysis set 
 Pharmacodynamic (PD) analysis set 
The following patient listings will provide the details from the patient disposition table. 
 A listing of patients treated but not randomized, patients randomized but not treated, 
and patients randomized but not treated as randomized. 
 A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation. 
4.6. 
Study Treatment Exposure and Compliance Variables 
Study treatment exposure variables for injections administered during the DBTP for Group A 
patients are listed below with associated definitions: 
 Patient duration of double-blind study treatment exposure in weeks defined as: (last 
study drug dosing date +7 – first study drug dosing date + 1 day)/7. Unplanned 
intermittent discontinuations in study treatment will be addressed on a case-by-case 
basis, since this is expected to be a rare occurrence. 
 The total number of injections by patient  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 23 of 80 
 The following categories will be used for treatment exposure at 1 week intervals: ≥1 
day and <1 week, ≥1 weeks and <2 weeks, ≥2 weeks and <3 weeks, ≥3 weeks and <4 
weeks, ≥4 weeks and <5 weeks, ≥5 weeks and <6 weeks, ≥6 weeks and <7 weeks, 
≥7 weeks and <8 weeks, ≥8 weeks and <9 weeks, ≥9 weeks and <10 weeks, 
≥10 weeks and <11 weeks, ≥11 weeks and <12 weeks, ≥12 weeks and <13 weeks, 
≥13 weeks and <14 weeks, ≥14 weeks and <15 weeks,  ≥15 weeks and <16 weeks, 
≥16 weeks. 
Study treatment exposure variables for infusions administered during the DBTP for Group B 
patients are listed below with associated definitions: 
 Patient duration of double-blind study treatment exposure in weeks defined as: (last 
double-blind study treatment administration date +28 – first double-blind study 
treatment administration date + 1)/7.  Unplanned intermittent discontinuations in 
study treatment will be addressed on a case-by-case basis, since this is expected to be 
a rare occurrence. Values will be rounded to one decimal place. 
 The total number of double-blind study treatment infusions by patient.  
 The following categories will be used for treatment exposure at 4 week intervals: ≥1 
day and <4 weeks, ≥4 weeks and <8 weeks, ≥8 weeks and <12 weeks, ≥12 weeks and 
<16 weeks, ≥16 weeks and <20 weeks, ≥20 weeks and <24 weeks, ≥24 weeks.  
Study treatment exposure variables for infusions administered during the OLTP for Group B 
patients are listed below with associated definitions: 
 Patient duration of open-label study treatment exposure in weeks defined as: (last 
open-label evinacumab treatment administration date +28 – first open-label 
evinacumab treatment administration date)/7. Unplanned intermittent 
discontinuations in study treatment will be addressed on a case-by-case basis, since 
this is expected to be a rare occurrence. Values will be rounded to one decimal place. 
 Patient duration of open-label study treatment exposure in patient-years defined as: 
(last open-label evinacumab treatment administration date +28 – first open-label 
evinacumab treatment administration date)/365, regardless of unplanned intermittent 
discontinuations. 
 The total number of open-label evinacumab treatment infusions by patient.  
 The following categories will be used for treatment exposure at 4 week intervals: ≥1 
day and <4 weeks, ≥4 weeks and <8 weeks, ≥8 weeks and <12 weeks, ≥12 weeks and 
<16 weeks, ≥16 weeks and <20 weeks, ≥20 weeks and <24 weeks, ≥24 weeks and 
<28 weeks, ≥28 weeks and <32 weeks, ≥32 weeks and <36 weeks, ≥36 weeks and 
<40 weeks, ≥40 weeks and <44 weeks, ≥44 weeks and <48 weeks, ≥48 weeks 
Study treatment exposure variables combining DBTP and OLTP are listed below for all Group B 
patients who received evinacumab in the DBTP: 
 Cumulative patient duration of evinacumab exposure in weeks defined as: double-
blind treatment exposure plus open-label treatment exposure, regardless of unplanned 
intermittent discontinuations. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 24 of 80 
 Cumulative patient duration of evinacumab exposure in patient-years defined as: 
double-blind treatment exposure in patient-years plus open-label treatment exposure 
in patient-years, regardless of unplanned intermittent discontinuations. 
 Cumulative total number of evinacumab treatment infusions by patient defined as: 
total number of double-blind infusions plus total number of open-label infusions.  
 The following categories will be used for cumulative patient treatment exposure at 4 
week intervals: ≥1 day and <4 weeks, ≥4 weeks and <8 weeks, ≥8 weeks and <12 
weeks, ≥12 weeks and <16 weeks, ≥16 weeks and <20 weeks, ≥20 weeks and <24 
weeks, ≥24 weeks and <28 weeks, ≥28 weeks and <32 weeks, ≥32 weeks and <36 
weeks, ≥36 weeks and <40 weeks, ≥40 weeks and <44 weeks, ≥44 weeks and <48 
weeks, ≥48 weeks and <52 weeks, ≥52 weeks and <56 weeks, ≥56 weeks and <60 
weeks, ≥60 weeks and <64 weeks, ≥64 weeks and <68 weeks, ≥68 weeks and <72 
weeks, ≥72 weeks, etc.  
With respect to patient treatment administration compliance, the study treatment is administered 
during the investigative site visits and therefore study compliance will be accessed by 
infusion/injection frequency for respective treatment periods, specifically: 
 DBTP: The mean infusion/injection frequency for study treatment will be defined for 
each patient as the average number of days between 2 consecutive 
infusions/injections: (last double-blind dose date – first double-blind dose date) / 
(number of infusions/injections in DBTP -1), for patients receiving at least 2 
infusions/injections. 
 OLTP (Group B only): for each patient as the average number of days between 2 
infusions: (last open-label dose date – first open-label dose date) / (number of 
infusions in OLTP -1), for patients receiving at least 2 infusions. 
All important and minor protocol deviations potentially impacting efficacy analyses, 
randomization and drug-dispensing irregularities, as well as other deviations, will be collected 
and reviewed on an ongoing basis throughout the study as described in the Protocol Deviation 
Plan (PDP).  Both monitoring collected and programmatically derived deviations are listed and 
defined in the PDP.  
4.7. 
Efficacy Variable 
Efficacy will be assessed through the following lipid parameters: calculated LDL-C (using the 
Friedewald formula), total-C, TG, non-HDL-C (calculated by subtracting HDL-C from Total-C), 
Apo B, and Lp(a). All lipid parameters will be collected over the course of the study and sent to 
a central laboratory for evaluation, including scheduled and unscheduled blood draws.  
All lipid values obtained during the study (scheduled or unscheduled), regardless of fasting status 
(fasting or not fasting), can be used to provide a value for the primary and secondary efficacy 
endpoints, with the following exceptions:  
 Only fasting TG measurements will be included in the analysis. TG measurements 
with missing fasting status will be excluded from the analyses.  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 25 of 80 
All efficacy measurements will be assigned to efficacy analysis windows defined in 
Appendix 10.2 of this SAP, with the intent to provide an assessment for week 2 to week 16 
timepoints for Group A and 2 to week 24 timepoints for Group B. For all time points post-
baseline, the value used for the analyses at a given time point (e.g. at week 24) is the value 
obtained within the corresponding efficacy analysis window. The baseline value is defined as the 
last available measurement prior to the date of the first double-blind study treatment 
administration (applicable to measurement derivations during both DBTP and OLTP). For 
patients randomized and not treated, the baseline value is defined as the last available value prior 
to the date of randomization. 
4.7.1. 
Primary Efficacy Variable (s) 
The primary efficacy endpoint is the percent change in calculated LDL-C from baseline to week 
16 in the intent-to-treat (ITT) population, using the intent-to-treat [ITT] estimand (defined as all 
LDL-C values regardless of adherence to treatment and subsequent therapies). 
The primary endpoint is defined as:  100 x (calculated LDL-C value at week 16 - calculated 
LDL-C value at baseline)/calculated LDL-C value at baseline.  The baseline calculated LDL-C 
value will be the last LDL-C level obtained before the first dose of study drug.  The calculated 
LDL-C at week 16 will be the LDL-C level obtained within the week 16 analysis window. 
All calculated LDL-C values (scheduled or unscheduled, fasting or not fasting) may be used to 
provide a value for the primary efficacy endpoint, if appropriate, according to the above 
definition. 
4.7.2. 
Secondary Efficacy Variable(s) 
The secondary efficacy variables include: 
 The percent change in Apo B from baseline to week 16 (ITT estimand) 
 The percent change in non-HDL-C from baseline to week 16 (ITT estimand) 
 
The percent change in TC from baseline to week 16 (ITT estimand) 
 The proportion of patients with ≥ 30% reduction in calculated LDL-C at week 16 
(ITT estimand) 
 
The proportion of patients with ≥ 50% reduction in calculated LDL-C at week 16 
(ITT estimand) 
 Percent change in TGs from baseline to week 16 (ITT estimand) 
 Percent change in Lp(a) from baseline to week 16 (ITT estimand) 
 Proportion of patients with calculated LDL-C < 50 mg/dL (1.30 mmol/L) at week 16 
(ITT estimand) 
 Percent change in calculated LDL-C, Apo B, non-HDL-C, TC, TG, and Lp(a) from 
baseline to week 24 (only applicable to those patients receiving IV route of study 
treatment administration) (ITT estimand) 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 26 of 80 
4.8. 
Safety Variables 
Patient safety will be assessed through the collection of reported adverse events (AEs), clinical 
laboratory data, vital signs, and ECG. Unless otherwise noted, the baseline value is defined as 
the last available value before the first dose of double-blind study treatment. 
4.8.1. 
Adverse Events Variables 
The period of safety observation starts from the time when the patient gives informed consent 
and continues into the following periods: 
 The PRE-TREATMENT period is defined from the day the ICF is signed to the day 
before the first dose of double-blind study treatment administration. 
 The double-blind treatment-emergent adverse event (TEAE) period is defined from 
the day of the first dose of double-blind study treatment administration to the day of 
the last dose of double-blind study treatment administration + 168 days (24 weeks) 
(based on PK considerations, residual effect of study treatment might be observed 
until 24 weeks after the last dose of study drug) for those patients not proceeding into 
the OLTP (ie, Group A patients and Group B patients who prematurely discontinue 
study treatment), or up to the day before the first dose of open-label study treatment 
administration for those patients proceeding into the OLTP 
 The open-label treatment-emergent adverse event (TEAE) period (Group B only) is 
defined from the day of the first open-label study treatment administration to the day 
of the last open-label study treatment administration + 168 days (24 weeks).  
 The POST-TREATMENT period is defined from the day after the end of the 
respective TEAE periods to the last study visit.  
4.8.1.1. 
Adverse Events and Serious Adverse Events 
Adverse events (including serious adverse events (SAE), AEs causing permanent treatment 
discontinuation, deaths, and AEs of special interest) are recorded from the time of signed 
informed consent until the end of study. All AEs diagnosed by the Investigator will be reported 
and described. 
All AEs will be dictionary coded by “lowest level term (LLT)”, “preferred term (PT)”, “high 
level term (HLT)”, “high level group term (HLGT)” and associated primary “system organ class 
(SOC)” using the version of MedDRA in effect at the time of the first database lock. 
Adverse Event Observation Period  
 Pre-treatment AEs are AEs that developed or worsened or became serious during the 
pre-treatment period. 
 Double-blind and open-label TEAEs are AEs that developed or worsened or became 
serious during the respective TEAE period.  
 Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 27 of 80 
4.8.1.2. 
Adverse Events of Special Interest 
Adverse events of special interest (AESI) are AEs (serious or non-serious) required to be 
monitored, documented, and managed in a pre-specified manner. AESIs will be recorded on the 
adverse event e-CRF using dedicated tick boxes, and/or identified using standard MedDRA 
queries (SMQ), company MedDRA queries (CMQ), MedDRA terms, and/or applicable 
laboratory assessments. Appendix 10.3 contains the definitions used to identify AESIs: 
 The AESIs include: 
 Anaphylactic reactions (e-CRF) 
 General allergic events (SMQ) 
 Infusion reactions (e-CRF) 
 Hepatic Disorder (SMQ, lab data) 
 Pregnancy (e-CRF) 
 Symptomatic overdose with investigational medicinal product (e-CRF) 
 Neurocognitive events (CMQ) 
 Neurologic events (e-CRF) 
 New onset of diabetes (NOD) (lab data, HLT, and concomitant medications) 
 Diabetes mellitus or diabetic complication (CMQ, concomitant medications) 
 Pancreatitis (e-CRF) 
 Cataracts (MedDRA HLT) 
 Immune complex diseases SMQ  
 Muscle events/CK elevation (MedDRA SOC, MedDRA SMQ, lab data) 
4.8.1.3. 
Events Causing Death 
The observation periods for patient deaths are per the observation periods defined above.  
 Death on-treatment:  deaths occurring during the respective TEAE period (double-
blind or open-label), 
 Death post-treatment:  deaths occurring during the post-treatment period. 
4.8.2. 
Laboratory Safety Variables 
Clinical laboratory tests will consist of blood analyses (including hematology, clinical chemistry 
and other) and urinalysis. Clinical laboratory values will be converted and analyzed in both 
international units and US conventional units, with associated normal ranges provided by the 
central laboratory. Both actual test values and “change from baseline” values (defined as the 
post-baseline value minus the baseline value) will be used in the result summaries.  Potentially 
clinically significant values (PCSV) ranges will be applied to the laboratory test values as 
applicable (see Appendix 10.4 for PCSV definitions). For those laboratory tests that do not have 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 28 of 80 
PCSV ranges, central laboratory normal ranges will be applied to identify out-of-range values.  
All laboratory test samples will be collected before study treatment administration during the 
protocol scheduled visits. 
Unless otherwise specified below, blood samples for clinical laboratories will be collected at the 
protocol scheduled visits, and visits will be assigned to the Global Analysis Windows (See 
Appendix 10.2). The laboratory parameters (excluding those considered as efficacy parameters) 
will be classified as follows: 
Hematology: 
 Red blood cells and platelets:  hemoglobin, hematocrit, erythrocytes count, red blood 
cells, platelets count, reticulocyte count, red blood indices 
 White blood cells: white blood cells, neutrophils, lymphocytes, monocytes, basophils, 
eosinophils 
Clinical chemistry: 
 Metabolism:  glucose, total protein, albumin, creatine phosphokinase 
 Electrolytes:  sodium, potassium, chloride, calcium, bicarbonate 
 Renal function:  creatinine, blood urea nitrogen (BUN), uric acid 
 Liver function:  ALT, aspartate aminotransferases (AST), alkaline phosphatase 
(ALP), total bilirubin, LDH 
Non-Efficacy Lipid Panel 
Apo A-1, Apo CIII, and ratio Apo B/Apo A-1. 
Urinalysis 
Urinalysis will include the following parameters: color, clarity, pH, specific gravity, ketones, 
protein, glucose, blood, bilirubin, leukocyte esterase, nitrite, WBC, RBC, hyaline and other casts, 
bacteria, epithelial cells, crystals, and yeast. 
4.8.3. 
Vital Signs 
Vital signs parameters will include weight (kg), heart rate (bpm), respiration (rpm), temperature 
(C or F), systolic and diastolic blood pressure (mmHg) after resting at least five minutes. Both 
actual test values and “change from baseline” values (defined as the post-baseline value minus 
the baseline value) will be provided for protocol specified visits and visits will be assigned to the 
Global Analysis Windows (See Appendix 10.2). Potentially clinically significant values (PCSV) 
ranges will be applied to the vital sign parameter values as applicable (see Appendix 10.4 for 
PCSV definitions).  
4.8.4. 
12-Lead Electrocardiography (ECG) 
Electrocardiograms will be recorded in the supine position after the patient has rested for at least 
10 min. A standard 12-lead ECG will be performed at specified time points according to 
Appendix 10.2.  The ventricular rate, PR, QRS, RR, QTcF, QTcB, and QT intervals will be 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 29 of 80 
recorded.   Electrocardiogram assessments will be described as normal or abnormal, and visits 
will be assigned to the Global Analysis Windows (See Appendix 10.2). 
4.8.5. 
Physical Examination Variables 
Physical examination will be conducted at the protocol scheduled visits (See Appendix 10.7 for 
schedule of event). The result is an outcome of clinically significant (Yes/No, not examined) and 
visits will be assigned to the Global Analysis Windows (See Appendix 10.2). 
4.9. 
Other Variables 
Other assessment endpoints are listed and defined below. Protocol schedule visits will be 
assigned to the Global Analysis Windows (See Appendix 10.2).   
 The change in hemoglobin A1c (HbA1c [%]) from baseline to post-baseline visits. 
 The percent change in hs-CRP from baseline over time.  
 The percent change in HDL-C from baseline over time 
4.10. 
Pharmacokinetic and Pharmacodynamic Variables 
Pharmacokinetic (PK) and pharmacodynamic (PD) variables include total evinacumab 
concentrations and total ANGPTL3 concentrations at each time point. 
Pharmacodynamic variables include lipid profile and total PCSK9.  
4.11. 
Immunogenicity Variables (ADA and NAb) 
Anti-drug antibody variables will include ADA status, titer and neutralizing antibody (NAb) 
status for analyzed samples collected at each time point.  
5. 
STATISTICAL METHODS 
5.1. 
Demographics and Baseline Characteristics 
Demographic and baseline characteristics will be descriptively summarized by treatment group 
and overall for the study within each route of administration (Group A or B). In addition, the 
same descriptive statistics will be provided by treatment group and overall for each stratification 
factor level (IVRS/IWRS defined high intensity statin [yes/no] and HeFH [yes/no]), within each 
route of administration.  Parameters described in Section 4.1 will be summarized for those 
patients in the ITT population. 
Continuous data will be summarized using the number of patients with data, mean, SD, median, 
minimum and maximum for each treatment group and for each of the strata. First quartile (Q1) 
and third quartile (Q3) will be also provided for baseline lipid parameters, HbA1c, and hs-CRP. 
Categorical and ordinal data will be summarized using the number and percentage of patients in 
each treatment group. 
Treatment group comparisons within each route of administration for demographic 
characteristics and disease characteristics will be provided for descriptive purposes (i.e., 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 30 of 80 
confirmation of the randomization process to equally distribute relevant patient background 
profiles  among the treatment groups) using the Fisher exact test for categorical data and the 
asymptotic one-way ANOVA test for Wilcoxon scores (Kruskal-Wallis test) for continuous data. 
As applicable, other safety baseline data not listed in Section 4.1 will be presented collectively in 
the descriptive statistics summary tables containing respective post-baseline data. 
For the Group B open-label safety population, demographic and baseline characteristics will be 
summarized for all patients and by treatment group of the DBTP (i.e., 5 mg/kg IV evinacumab, 
15 mg/kg IV evinacumab, placebo). Parameters listed in Section 4.1 will be summarized as 
described for the DBTP, except for treatment group comparison testing. 
5.2. 
Medical History  
Medical history will be descriptively summarized by treatment group and overall for the study 
within each route of administration (Group A or Group B) for patients in the ITT population.  All 
reported patient’s medical history will be presented by primary SOC and HLT.  The tables will 
be presented by SOC sorted alphabetically and decreasing patient frequency of HLT based on the 
overall incidence in the study.  
All medical history of specific interest, primary and secondary CVD prevention including 
corresponding criteria, as described in Section 4.2, will be summarized by patient incidence and 
percentage. 
The number (%) of patients will be summarized by CVD prevention status (i.e. primary and 
secondary CVD prevention status). In addition, smoking status will be summarized in patients 
with primary CVD prevention status. 
For patient disease characteristics, as described in Section 4.2, continuous data will be 
summarized using the number of patients with data, mean, SD, median, minimum and maximum 
for the study and for each of the strata. Categorical and ordinal data will be summarized using 
the number and percentage of patients in the study and for each stratum.   
5.3. 
Prior and Concomitant Medications  
All prior medications, dictionary coded by WHO-DD, will be descriptively summarized by 
treatment group and overall for the study within each route of administration (Group A or 
Group B) for patients in the double-blind safety population. Summaries will present patient 
counts (and percentages) for all prior medications, by decreasing frequency of the overall 
incidence of ATC followed by therapeutic class.  In case of equal frequency across anatomic or 
therapeutic categories, alphabetical order will be used. Patients will be counted once in each 
ATC category (anatomic or therapeutic) linked to the medication, but may be counted several 
times for the same medication. Prior LMT (statins and non-statin) and CV medication use will 
also be summarized.  
For patients in the double-blind safety population, all concomitant medications during the DBTP, 
dictionary coded by WHO-DD, will be descriptively summarized by treatment group. 
Summaries will present patient counts (and percentages) for the concomitant medication groups 
described in  Section 4.3 for all concomitant medications (including statin, LMT, CV), by 
decreasing frequency of the evinacumab highest dose group incidence of ATC followed by 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 31 of 80 
therapeutic class.  In case of equal frequency across anatomic or therapeutic categories, 
alphabetical order will be used. Patients will be counted once in each ATC category (anatomic or 
therapeutic) linked to the medication, hence may be counted several times for the same 
medication.  Additionally, concomitant medications pre-specified from e-CRF as statin, LMT, 
and CV will be summarized by patient counts (and percentages) for the standardized medication 
names.  
For the OLTP, concomitant and post-treatment medications will be dictionary coded by WHO-
DD and will be descriptively summarized as described for the DBTP. For patient in the open-
label safety population, medications will be summarized for all patients and by treatment group 
of the DBTP (i.e., 5 mg/kg IV evinacumab, 15 mg/kg IV evinacumab, placebo). Summaries will 
present patient counts (and percentages). 
5.4. 
Prohibited Medications  
Listing of prohibited medications will be provided for the patients in the safety analysis set for 
the DBTP and OLTP. 
5.5. 
Patient Disposition 
Patient disposition includes the description of patient status at major milestone decisions in the 
study, as well as the patient analysis populations. 
Patient study status for the DBTP will be summarized by treatment group and overall for the 
study (screened patients, screen failures, and non-randomized but treated patients only) within 
each route of administration (Group A or Group B).  Summaries will provide the frequency (and 
percentage as applicable) of patients that met the criteria for the variables described in 
Section 4.5.  Exception listings will be generated for any patient treated but not randomized, 
randomized but not treated, and treated differently than randomized. 
DBTP patient analysis populations will be summarized by treatment group, depicting frequencies 
(and percentages) of patients that met the criteria for each population described in Section 3.  
For the OLTP, the patient study status and patient analysis populations will be summarized by all 
patients and by treatment group of the DBTP (i.e., 5 mg/kg IV evinacumab, 15 mg/kg IV 
evinacumab, placebo) on the open-label safety population for the variables described in 
Section 4.5.  
For both the DBTP and OLTP, the incidence of premature study treatment discontinuation 
(irrespective of the reason) and premature treatment discontinuation due to AEs will be presented 
graphically by treatment group in the respective safety analysis set using the Kaplan-Meier 
method. 
5.6. 
Extent of Study Treatment Exposure and Compliance 
The extent of study treatment exposure for the DBTP described in Section 4.6 will be assessed 
and summarized by treatment group, for patients in the double-blind safety analysis set. The 
extent of study treatment exposure for the OLTP described in Section 4.6 will be assessed and 
summarized for all patients and by treatment group of the DBTP (i.e., 5 mg/kg IV evinacumab, 
15 mg/kg IV evinacumab, placebo) for patients in the open-label safety analysis set. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 32 of 80 
5.6.1. 
Exposure to Investigational Product 
Study treatment exposure in the DBTP and OLTP will be descriptively summarized for treatment 
duration and total number of infusions/injections as described in Section 4.6. Treatment duration 
and total number of infusions will be summarized using the number of patients with data, 
mean, SD, median, minimum and maximum.  
Additionally, evinacumab dosing exposure for Group B will be summarized cumulatively across 
the study, combining DBTP and OLTP for patients who received evinacumab in the DBTP. 
5.6.2. 
Study Treatment Compliance 
Both monitored and derived protocol deviations will be summarized for important deviation 
categories by count (percentage), and again by type of important deviation (patient count and 
percentage). A patient listing of all important and minor protocol deviations will be provided. 
Descriptive statistics of the infusion or injection frequency of study treatment will be 
summarized. Further, study treatment infusion interruptions and incomplete infusions with 
reason will be summarized by patient count (percentage) and a patient listing will be provided 
for those patients with incomplete infusions. Cases of study treatment overdose will be reported 
in the AE e-CRF page and will be described in the adverse event analysis.  
5.7. 
Analyses of Efficacy Variables 
For statistics where international and conventional units do not impact the results (e.g. means and 
least square (LS) means for percent changes from baseline, statistical testing for both percent and 
absolute changes from baseline, rates of patients below a threshold), derivations will be 
calculated and statistical models will be run using conventional units. For other statistics (e.g. 
descriptive statistics at baseline and over time, absolute changes from baseline), derivations will 
be presented in both international and conventional units. 
Statistical analyses for the primary efficacy endpoints and secondary endpoints will be conducted 
in the DBTP as described below, and will be completed during the step 1 and 2 efficacy analyses 
(Section 7). Remaining descriptive efficacy analyses will be completed during step 3. The 
definition for baseline is applicable to derived variables (e.g., percent change from baseline) in 
both DBTP and OLTP. 
Within each study treatment route of administration (Group A or B), HeFH diagnosis (Yes/No), 
and high-intensity statin (Yes/No) (high-intensity statin defined as rosuvastatin 20 mg to 40 mg 
daily, atorvastatin 40 mg to 80 mg daily, or simvastatin 80 mg daily) will be the 2 stratification 
factors for patient randomization.  Stratification factors HeFH diagnosis and high-intensity statin 
will be accounted for in the statistical modeling for efficacy. 
5.7.1. 
Analysis of Primary Efficacy Variable 
For the double-blind primary comparison of the evinacumab group to the placebo group, the 
percent change from baseline in calculated LDL-C at week 16 will be analyzed in the ITT 
population using a mixed-effect model with repeated measures (MMRM) approach. All post-
baseline data available within week 2 to week 16 efficacy analysis windows will be used and 
missing data are accounted for by the MMRM model. Each model will include the fixed 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 33 of 80 
categorical effects of treatment group (evinacumab dose regimens versus placebo), 
randomization strata (high-intensity statin [Yes/No] and HeFH status [Yes/No]), time point 
(weeks 2, 4, 6, 8, 12, 16 for the Group B treatment groups; weeks 2, 4, 6, 8, 10, 12, 14, 16 for the 
Group A treatment groups), treatment-by-time point interaction, and strata-by-time point 
interaction, as well as the continuous fixed covariates of baseline calculated LDL-C value and 
baseline value-by-time point interaction. Contrast and estimate statements will be used to assess 
the treatment effects (LS means with confidence intervals) and each dose regimen pairwise 
comparison to placebo (mean difference and p-values). 
This model will be run separately for each route of administration (Group A or Group B, with 
Group B consisting of 3 dose regimens for the variability estimate) with an unstructured 
correlation matrix to model the within-patient errors.  Parameters will be estimated using 
restricted maximum likelihood method with the Newton-Raphson algorithm.  Denominator 
degrees of freedom will be estimated using Satterthwaite’s approximation.   
Let µ0 and µ1 be the population means of the percent change from baseline in calculated LDL-C 
at week 16 under each of 2 placebo control arms and the 4 evinacumab treatment arms, 
respectively. The hypothesis that will be tested is “H0: µ0 =µ1” versus “H1: µ0≠µ1”.  
The 4 primary treatment group comparisons will evaluate at week 16 each evinacumab dose 
regimen to the placebo group corresponding to the route of administration (IV or SC).  
1. Evinacumab 15 mg/kg IV Q4W compared to Placebo IV 
2. Evinacumab 450 mg SC QW compared to Placebo SC 
3. Evinacumab 300 mg SC QW compared to Placebo SC 
4. Evinacumab 300 mg SC Q2W compared to Placebo SC 
The statistical testing of the 4 pairwise comparisons for the primary measure will be evaluated at 
a 2-sided significance level of 0.05 per pair wise comparison, with corresponding least square 
estimate of mean difference, SE and 95% confidence interval. The overall study α level will be 
controlled by the use of a hierarchical inferential approach for the testing of the 4 pairwise 
comparisons, thereby adjusting for multiplicity. 
Within treatment group least-square means and standard errors will be adjusted using weights 
equal to the observed proportion of patients in strata variable levels (i.e. “population weight”), 
rather than equal weights.  Population weights are considered more appropriate than equal 
coefficients due to potential imbalances observed in the study population between levels of the 
randomization stratification factors.  
Prior to performing the primary efficacy analysis, statistical analysis method assumptions will be 
checked for baseline homogeneity of calculated LDL-C levels between treatment groups, 
normality of the percent change calculated LDL-C distribution for each treatment group, and 
homogeneity of variances between treatment groups using residual plot.  
5.7.1.1. 
Sensitivity of the Primary Efficacy Analysis 
Robustness of the primary analysis statistical methods will be assessed through sensitivity 
analyses, including a different methodology for missing data (e.g., pattern mixture model to 
assess the potential violation of the missing at random assumption) and on-treatment analysis for 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 34 of 80 
more clinically relevant treatment comparisons of the percent change in calculated LDL-C from 
baseline to week 16 (i.e., mITT patient population using calculated LDL-C values collected 
during the efficacy treatment period [on-treatment estimand]). 
Sensitivity to Stratification at Randomization 
To assess the robustness of the primary analysis to stratification mistakes made at the time of 
randomization (i.e. the stratum recorded in IVRS/IWRS differs from the actual stratum recorded 
in the e-CRF), the MMRM model will be re-run replacing the IVRS/IWRS strata with the e-CRF 
actual strata. 
Sensitivity to On-treatment Calculated LDL-C Values 
To assess the robustness of more clinically relevant between group comparisons for the analysis 
of the primary efficacy endpoint, the same statistical analysis method approach as described 
above in Section 5.7.1 will be applied in the mITT population. The intent-to-treat estimand will 
be replaced by the on-treatment estimand, which is defined as all LDL-C values collected during 
the efficacy treatment period (Section 3.1.2). 
Sensitivity to Non-Good Clinical Practice (GCP) Compliant Sites 
To assess the impact of non-GCP compliance sites on the primary efficacy endpoint, the primary 
efficacy analysis will be performed excluding non-GCP compliant sites.  Sites known to be non-
GCP compliant at the time of database lock will be identified for this analysis before database 
lock.  Any additional sites determined to be non-GCP compliant post-database lock will be 
separately identified. 
Sensitivity to the Handling of Missing Data 
Sensitivity analyses will be conducted to assess the robustness of primary efficacy analysis with 
regards to the handling of missing data (Little RJ 2012).  
Visual examination 
 In order to explore the missing data pattern, post-baseline calculated LDL-C 
observations (in the ITT population) will be described according to the following 
groups:  
 Group A 
1. 
Calculated LDL-C available at week 16 (i.e. primary efficacy endpoint 
available), 
2. 
Calculated LDL-C available at week 14 but missing at week 16, 
3. 
Calculated LDL-C available at week 12 but missing at week 14, 
4. 
Calculated LDL-C available at week 10 but missing at week 12, 
5. 
Calculated LDL-C available at week 8 but missing at week 10, 
6. 
Calculated LDL-C available at week 6 but missing at week 8, 
7. 
Calculated LDL-C available at week 4 but missing at week 6, 
8. 
Calculated LDL-C available at week 2 but missing at week 4 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 35 of 80 
9. 
Calculated LDL-C missing at week 2. 
 Group B 
10. 
Calculated LDL-C available at week 16 (i.e. primary efficacy endpoint 
available), 
11. 
Calculated LDL-C available at week 12 but missing at week 16, 
12. 
Calculated LDL-C available at week 8 but missing at week 12, 
13. 
Calculated LDL-C available at week 6 but missing at week 8 
14. 
Calculated LDL-C available at week 4 but missing at week 6 
15. 
Calculated LDL-C available at week 2 but missing at week 4 
16. 
Calculated LDL-C missing at week 2. 
A graph of mean percent change from baseline calculated LDL-C levels ± SE at baseline, and 
at time points (weeks 4, 8, 12, 16 for the Group B treatment groups; weeks 2, 4, 6, 8, 12, 16 
for the Group A treatment groups) will be provided by missing data pattern, for each 
treatment group. 
 In the ITT population, demographic and baseline lipids will be described within the 
missing data pattern number 1 above versus the remaining missing data patterns 
above. P-values from Fisher exact test for categorical data and from asymptotic one-
way ANOVA test for Wilcoxon scores (Kruskal-Wallis test) for continuous data, will 
be also provided, for descriptive purposes.  
Tipping point analysis 
Robustness of the primary analysis results to departure from the MAR assumption will be 
explored in the ITT population using the tipping point approach. For the tipping point approach, 
missing calculated LDL-C will be imputed using the multiple imputation method described in 
Appendix 10.5. All observed LDL-C values up to and including week 16 will be used, regardless 
of adherence to treatment and subsequent therapies (ITT estimand).   
For missing calculated LDL-C values at visits subsequent to permanent treatment 
discontinuation (Appendix 10.5, Step 2), a sequence of shift parameters, δ, will adjust the 
imputed calculated LDL-C values in the evinacumab treatment group. Each of the 100 imputed 
datasets will be analyzed using the MMRM model described for the primary efficacy analysis. 
For each δ, the SAS MIANALYZE procedure will be used to generate valid statistical inferences 
by combining results from the 100 analyses using Rubin’s formula.  By progressively increasing 
δ, this sensitivity analysis will explore the tipping point, e.g., δ value when the p-value for a 
treatment comparison is above 0.05. Results will be summarized in a table and graph.  
Pattern mixture model (PMM) 
The MMRM model relies on the “missing-at-random” (MAR) assumption.  Because the 
possibility for a not-missing-at-random (NMAR) missingness mechanism can never be excluded, 
sensitivity analysis to explore the impact of non-ignorable missingness on the primary efficacy 
analysis will be conducted using the PMM approach as described below (see Appendix 10.6 for 
more details). 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 36 of 80 
In the PMM approach, different imputation strategies will be applied to calculated LDL-C values 
missing during the double-blind on-treatment period (i.e. within the time period from the first 
double-blind study treatment administration up to the day of last double-blind administration +35 
days for Group B or +14 days for Group A) versus calculated LDL C values missing due to 
treatment discontinuation after the on-treatment period (i.e. after the day of last double-blind 
administration +35 days for Group B or +14 days for Group A) based on the following 
assumptions: 
 Patients within 35 days for Group B (14 days for Group A) of their last double-blind 
study treatment administration would continue to show benefit from treatment similar 
to that observed at the scheduled time point.  Therefore, LDL-C values missing 
during the on-treatment period (e.g., samples obtained out-side the specified window, 
no blood sample available although visit was performed, etc.) should be considered 
“Missing at Random” and imputed based on other observed measurements in the on-
treatment period. 
 Patients who stopped taking their study treatment no longer benefited from it after 
discontinuation, and thus tended to have LDL-C values returning to baseline.  
Therefore, LDL-C values missing after the on-treatment period should be imputed 
based on patient’s own baseline value. 
Missing data from the randomized population will be imputed 100 times to generate 100 
complete data sets, using the SAS MI procedure (using Markov Chain Monte Carlo).  The 100 
completed datasets of observed and imputed LDL-C data will be used for the sensitivity analysis 
of the primary efficacy analysis method. 
For the percent change from baseline calculated LDL-C endpoint, the 100 complete datasets of 
observed and imputed LDL-C data at week 16 will be analyzed using an ANCOVA model with 
treatment group and randomization strata as fixed effect, and the baseline LDL-C value as 
continuous covariate.  The SAS MIANALYZE procedure will be used to generate valid 
statistical inferences by combining results from the 100 analyses using Rubin’s formulae. 
5.7.1.2. 
Dose-Response Analysis 
Within each route of administration (Group A or Group B), a dose-response descriptive analysis 
is planned for the evinacumab dose regimens, with the placebo group in the role of the null dose, 
for patients in the ITT population.  Summary tables will provide descriptive statistics (at least 
mean, median, SD, min/max) for percent change from baseline in LDL-C at each protocol 
planned visit in the double-blind period, by treatment group.  A graph will provide mean and 
standard error bars for percent change from baseline in calculated LDL-C at each protocol 
planned visit, by treatment group.  
In addition to the analyses results for each evinacumab dose regimen comparison to placebo, the 
comparisons among the evinacumab dose regimens will be assessed in the ITT population for the 
percent change from baseline in calculated LDL-C at week 16.  This analysis will employ the 
same statistical methodology as described for the primary comparisons, specifically the MMRM 
approach, for evaluating effects among the evinacumab dose regimens.  P-values will be 
provided for descriptive purposes to aid in interpretation of the dose-response. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 37 of 80 
5.7.1.3. 
Sub-group Analyses 
To assess the homogeneity of the treatment effect across various subgroups, treatment-by-
subgroup factor, time point-by-subgroup factor and treatment-by time point-by subgroup factor 
interaction terms and a subgroup factor term will be added in the primary MMRM model for 
each route of administration (Group A or Group B). LS mean difference versus placebo at week 
16 will be provided, as well as the corresponding SE and 95% CI, within each subgroup. The 
significance level of the treatment-by-subgroup factor interaction term at week 16 will be also 
provided for each factor for descriptive purpose. Forest plots will be provided. In order to handle 
imbalances between randomization stratification factors levels, population weights will be used 
as for the primary analysis model.  
The following subgroups of interest will be evaluated, assuming there are enough patients in 
each subgroup level to perform the evaluation.  For the subgroup factors that are also 
randomization stratification factors, the IVRS strata will be used. 
 The baseline high-intensity statin (Yes, No) per IVRS, 
 The baseline HeFH status (Yes, No) per IVRS, 
 Gender (Female, Male),  
 Age (<65, ≥65), 
 Race 
 Ethnicity 
 Baseline LDL-C (<100, ≥100 mg/dL), 
 Baseline LDL-C (<130, ≥130 mg/dL). 
Subgroup analysis for HeFH patients 
To assess the evinacumab treatment effect during the double-blind treatment period on the 
stratification variable HeFH (Yes/No), specifically the strata level containing patients diagnosed 
with HeFH (Yes), a subgroup analysis is planned for the percent change from baseline LDL-C in 
the ITT population for each route of administration (Group A or Group B).  Specifically, the 
primary MMRM model used to assess the treatment group pairwise comparisons will have the 
additional variables of treatment-by-HeFH strata, time point-by-HeFH strata, treatment-by time 
point-by HeFH strata interaction terms, and a HeFH factor term. For each dose regimen versus 
placebo at week 16, the LS mean treatment group difference will be provided for the HeFH 
(Yes) strata level, along with the corresponding SE, 95% CI and p-value (p-value is provided for 
descriptive purposes only).  The HeFH (Yes/No) stratification factor to be used for this subgroup 
analysis will be as recorded in the electronic data capture system. 
5.7.1.4. 
Multiplicity Considerations  
To control the 5% overall type-I error for the 4 pairwise comparisons in the primary analysis, the 
overall study α level will be controlled by the use of a hierarchical inferential approach.  
Statistical significance of the first pairwise treatment comparison is required before drawing 
inferential conclusions about the second pairwise treatment comparison at the 0.05 alpha level.  
Inferential conclusions about successive pairwise treatment comparisons require statistical 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 38 of 80 
significance of the prior treatment comparison.  The hierarchy testing sequence is the order of 
treatment comparisons as presented in Section 5.7.1.  This fixed hierarchical approach will 
ensure a strong control of the overall type-I error rate at the 0.05 level for each evinacumab dose 
regimen comparison. 
No further adjustments will be made for secondary efficacy endpoints collected during the 
double-blind treatment period, nor for the comparison of the evinacumab 5 mg/kg IV Q4W 
patient treated group to the Placebo IV group on any efficacy endpoint collected during the 
double-blind treatment period.  P-values will be provided for descriptive purposes only. 
5.7.2. 
Analysis of Secondary Efficacy Variables 
Statistical analyses for the secondary efficacy endpoints (defined in Section 4.7.2) collected in 
the double-blind treatment period will be performed in the ITT population using the ITT 
estimand for each of the 5 pairwise treatment group comparisons, including the comparison of 
evinacumab 5 mg/kg IV Q4W patient treated group to the Placebo IV group. P-values will be 
provided for descriptive purposes only. 
Multiple types of measurements are planned to be analyzed during differing time points in the 
trial, specifically continuous measurements expected to have a normal distribution (example:  
percent change in LDL-C), continuous measurements expected to have a non-normal distribution 
(example: TG), and binary measurements (example: proportion of patients with at least 30% 
reduction in LDL-C). 
5.7.2.1. 
Continuous Endpoints Anticipated to have a Normal Distribution 
Continuous secondary variables defined in Section 4.7.2 anticipated to have a normal distribution 
(i.e. lipids other than TG and Lp(a)) will be analyzed using the same MMRM model as described 
for the primary endpoint.  Specifically, the model will contain the fixed categorical effects of 
treatment group, randomization strata (as per IVRS/IWRS), planned time points up to week 16 or 
week 24 (depending on the time point of interest), strata-by-time point, and treatment-by-time 
point interaction, as well as, the continuous fixed covariates of corresponding baseline value and 
baseline value-by-time point interaction. 
5.7.2.2. 
Continuous Endpoints Anticipated to have a Non-Normal Distribution 
Continuous secondary efficacy variables defined  in Section 4.7.2 anticipated to have a non-
normal distribution (i.e. TG and Lp(a)) will be analyzed using the multiple imputation approach 
for handling of missing values as described  in Appendix 10.5, with data log-transformed before 
imputation process and then back transformed to create the imputed data sets using the 
TRANSFORM statement of SAS MI procedure. 
The percent change from baseline at time point of interest will be derived from observed and 
imputed lipid values at this time point. Multiple imputation will be followed by robust regression 
model (Mehrotra, 2012) to compare treatment group differences, with the endpoint of interest as 
the response variable using M-estimation (using SAS ROBUSTREG procedure) with treatment 
group, randomization strata (as per IVRS/IWRS) and corresponding baseline value(s).  
Combined means estimates for both treatment groups, as well as the differences of these 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 39 of 80 
estimates, with their corresponding SEs, 95% CIs and p-value will be provided through the SAS 
MIANALYZE procedure. 
5.7.2.3. 
Binary Endpoint Variables 
Binary secondary efficacy endpoints defined in Section 4.7.2 will be analyzed using the multiple 
imputation approach for handling of missing values as described in Appendix 10.5. 
The binary endpoint at time point of interest will be derived from observed and imputed lipid 
values at this time point. Multiple imputation will be followed by stratified logistic regression, 
(with strata defined as randomized in the IVRS/IWRS) using the strata option of the SAS logistic 
procedure. The logistic regression procedure will be used to compare treatment group 
differences, with the model containing treatment group and corresponding baseline value(s) as 
covariate, stratified by randomization strata defined as per IVRS/IWRS. Combined estimates of 
odds ratio versus placebo, 95% CI, and p-value will be obtained through the SAS MIANALYZE 
procedure. 
In the data dependent case such logistic regression is not applicable (e.g. the response rate is zero 
in one treatment arm and thus the maximum likelihood estimate may not exist), the last 
observation carried forward (LOCF) approach would be used for handling of missing values. 
Treatment effects would be compared using the stratified exact conditional logistic regression 
method, specifically using the strata option of the SAS logistic procedure (with strata defined as 
randomized in the IVRS/IWRS). In case the model would not converge with stratification 
variables, an unstratified exact logistic regression will be performed. The LOCF imputation 
method will consist of using the last value obtained up to the week 16 efficacy analysis window 
to impute the missing week 16 value. 
In case of computing issues with exact logistic regression, the baseline level(s) will be entered in 
the model as a categorical variable(s) using quartiles. Exact odds ratio versus placebo, 95% CI, 
and p-value will be provided. 
5.7.2.4. 
Sensitivity Analysis of Secondary Endpoint Variables 
In order to assess the robustness of more clinically relevant between group comparisons for the 
analysis of the secondary efficacy endpoints, the same statistical analysis method approach as 
described above in Sec 5.7.2 will be applied in the mITT population. The intent-to-treat estimand 
will be replaced by the on-treatment estimand, which is defined as all secondary efficacy 
endpoints values collected during the efficacy treatment period (Section 3.1.2). 
5.7.2.5. 
Summary of Results by Time Point 
Central laboratory values (in conventional (US) and international units), percent change from 
baseline, and/or when appropriate absolute change from baseline (in conventional and 
international units) will be summarized at protocol scheduled visits by treatment group for 
calculated LDL-C, Total-C, fasting TG, non-HDL-C, Apo B, and Lp(a). Summaries will include 
both the ITT and mITT populations. The time profile of each parameter will be plotted by 
treatment group with the corresponding standard errors. Further details are described below:  
 For lipids other than TG and Lp(a): LS mean and SE for each treatment group, 
obtained from the same MMRM models as used for endpoints above and including 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 40 of 80 
planned time points (see Section 5.7.2.1) and with raw values, changes from baseline, 
and percent change from baseline as response variable in the model as appropriate.  
 For lipids other than TG and Lp(a):  Observed data raw values, change from baseline 
(as applicable), and percent change from baseline response variables will be 
summarized by patient counts, mean and SD for each treatment group at all planned 
time points. 
 For TG and Lp(a): mean and SE for each treatment group obtained from multiple 
imputation approach followed by the robust regression models as used for endpoints 
above and including planned time points (see Section 5.7.2.2) and with raw values or 
percent changes from baseline as response variable in the model as appropriate. 
 For TG and Lp(a): Observed data raw values and percent change from baseline 
response variables will be summarized by patient counts, mean, SD, median, Q1, and 
Q3 for each treatment group at all planned time points.  
During the OLTP, efficacy variables for Group B will be explored through descriptive statistics 
at each protocol scheduled visit for the total patients administered open-label study treatment 
(total), as well as by the patient subgroups of study treatment received in the double-blind 
treatment period (i.e., 5 mg/kg IV evinacumab, 15 mg/kg IV evinacumab, placebo).  Formal 
statistical testing is not planned.  Descriptive statistics will include the observed values of the 
same parameters as described for each variable in the DBTP, for patients in the open-label safety 
analysis set.  
For Group B patients receiving evinacumab in the DBTP, a combined summary including both 
the DBTP and OLTP assessments may be considered, referencing the double-blind baseline for 
variable calculations.  Prolonged time between last dose of double-blind treatment and first dose 
of open-label treatment will need to be taken into consideration when combining longitudinal 
efficacy data.  Formal statistical testing is not planned.  Descriptive statistics will include the 
observed values of the same parameters as described for each variable in the DBTP, for patients 
in the double-blind safety analysis set.  
5.8. 
Analysis of Safety Data 
In general, for the double-blind period, the summary of safety results for patients in the 
double-blind SAF population will be presented by route of administration (Group A or Group B) 
and pooling the evinacumab dose regimens within each route of administration (Group A or 
Group B), with the intent to maximize efforts to identify potential safety signals. The treatment 
group data (individual evinacumab dose regimens and placebo) will also be presented with the 
intent to support the pooled dose regimens. No formal inferential testing will be performed. 
Summaries will be descriptive in nature. 
For Group B, summaries of safety results for the open-label period will be presented for patients 
in the open-label SAF, by the total number of patients administered open-label study treatment 
(i.e.,15 mg/kg IV), as well as by the patient subgroups of study treatment received in the DBTP 
(i.e., 5 mg/kg IV, 15 mg/kg IV, or placebo). Summaries will be descriptive in nature. 
General common rules 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 41 of 80 
All safety analyses will be performed, unless otherwise specified, using the following common 
rules: 
 For DBTP, safety data in patients who do not belong to the double-blind safety 
analysis set (i.e., exposed but not randomized) will be listed separately. 
 PCSV values are defined as abnormal values considered medically important by the 
Sponsor according to predefined criteria/thresholds based on literature review and 
defined by the Sponsor for clinical laboratory tests and vital signs (PCSV version 
dated January 2009 [Appendix 10.4]). Considering that the threshold defined in the 
PCSV list for monocytes and basophils can be below the ULN, the following PCSV 
criterion will be used for the PCSV analysis of monocytes and basophils:  
 PCSV criterion for monocytes: >0.7 Giga/L or >ULN (if ULN ≥0.7 Giga/L). 
 PCSV criterion for basophils: >0.1 Giga/L or >ULN (if ULN ≥0.1 Giga/L). 
 PCSV criteria will determine which patients had at least 1 PCSV during the 
respective TEAE periods, taking into account all evaluations including unscheduled 
or repeated evaluations. 
 The treatment-emergent PCSV denominator by treatment group for a given parameter 
will be based on the number of patients assessed for that given parameter at least once 
during the respective TEAE periods. 
 All measurements, scheduled or unscheduled, fasting or not fasting, will be assigned 
to Global Analysis Windows defined in Appendix 10.2 in order to provide an 
assessment for the screening visit through follow-up visit time points. 
 For quantitative safety parameters including central laboratory measurements and 
vital sign scores, descriptive statistics will be used to summarize observed values and 
change from baseline values by visit.  
5.8.1. 
Adverse Events  
In general, the primary focus of AE reporting will be on TEAEs summarized in respective TEAE 
periods, specifically the DBTP and OLTP.   
If an AE onset date (occurrence, worsening, or becoming serious) is incomplete, an imputation 
algorithm will be used to classify the AE as pre-treatment, treatment-emergent, or post-
treatment.  The algorithm for imputing date of onset will be conservative and will classify an AE 
as treatment-emergent unless there is definitive information to determine pre-treatment or post-
treatment status.  Details on classification of AEs with missing or partial onset dates are provided 
in Section 6.3. 
Adverse event incidence tables will present the number (n) and percentage (%) of patients 
experiencing an AE by SOC and PT. In addition, incidence tables by SOC, HLGT, HLT, and PT 
will be provided for all TEAEs, serious TEAEs, and TEAE leading to permanent treatment 
discontinuation. Multiple occurrences of the same event in the same patient will be counted only 
once in a table. For tables presenting severity of events, the worst severity will be chosen for 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 42 of 80 
patients with multiple instances of the same event. The denominator for computation of 
percentages is the respective safety analysis set within each treatment group. 
AE incidence tables will present data by SOC sorted alphabetically and PT sorted by decreasing 
frequency of the pooled evinacumab treated group, and summarize the number (n) and 
percentage (%) of patients experiencing an AE. 
Analysis of all treatment-emergent adverse events 
The following TEAE summaries will be generated: 
 Overview of TEAEs, summarizing number (%) of patients with any 
 TEAE; 
 Serious TEAE; 
 TEAE leading to death; 
 TEAE leading to permanent treatment discontinuation. 
 All TEAEs by primary SOC, HLGT, HLT, and PT 
 All TEAEs by primary SOC and PT 
 Number (%) of patients experiencing common TEAE(s) presented by primary SOC 
and PT (PT incidence ≥ 5 % in any treatment group) 
 All TEAEs relationship (related/not related) to evinacumab 
 All TEAEs by maximum severity (i.e., mild, moderate or severe) 
 For the OLTP only, the event rate per patient-year (the number of patients with an 
event in question divided by total patient-years) will be provided for all TEAEs by 
SOC and PT. For a patient with an event, patient-year is censored at time of first 
event. For a patient without an event, patient-year corresponds to the length of the 
TEAE period. 
 A common TEAE related to any clinically significant signal will be further 
characterized as appropriate. The characterization of the clinically significant signal 
can include Kaplan-Meier curves for time from first dose to first occurrence of 
selected TEAE, time to resolution, and event duration. Patients without any event will 
be censored at the end of the respective TEAE period.  
Analysis of all treatment emergent serious adverse event(s) 
 All Serious TEAEs by primary SOC, HLGT, HLT, and PT 
 All Serious TEAEs by primary SOC and PT 
 Patient listings of serious TEAEs will be provided in the report appendix. 
 All Serious TEAEs relationship (related/not related) to evinacumab 
 A serious TEAE related to any clinically significant signal will be further 
characterized as appropriate. The characterization of the clinically significant signal 
can include Kaplan-Meier curves for time from first dose to first occurrence of 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 43 of 80 
selected TEAE, time to resolution, and event duration. Patients without any event will 
be censored at the end of the respective TEAE period. 
Analysis of all treatment-emergent adverse event(s) leading to treatment discontinuation 
 All TEAEs leading to permanent treatment discontinuation, by primary SOC, HLGT, 
HLT, and PT 
 All TEAEs leading to permanent treatment discontinuation, by primary SOC and PT 
 Patient listings of TEAEs leading to permanent treatment discontinuation will be 
provided in the report appendix.  
 A TEAE leading to permanent treatment discontinuation and related to any clinically 
significant signal will be further characterized as appropriate. The characterization of 
the clinically significant signal can include Kaplan-Meier curves for time from first 
dose to first occurrence of selected TEAE, time to resolution, and event duration. 
Patients without any event will be censored at the end of the respective TEAE period. 
Analysis of Cardiovascular events 
 TEAEs suspected of being CV events by primary SOC and PT 
 TEAEs suspected of being CV events categorized by adjudicated outcome of positive, 
negative, or in-process (as applicable) 
 Number of patients with adjudication positive by outcome categories, specifically 
CHD death, non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina 
requiring hospitalization, congestive heart failure requiring hospitalization, ischemia 
driven coronary revascularization procedure   
 Patient listing of positively adjudicated TEAE CV events 
Patient Deaths 
The following summaries of deaths will be generated. 
 Number (%) of patients who died by study period (TEAE and post-treatment) and 
reason for death;  
 TEAEs leading to death (death as an outcome on the AE CRF page, as reported by 
the Investigator) by SOC and PT. 
5.8.2. 
Analysis of Adverse Events of Special Interest  
Treatment-emergent adverse events of special interest (AESI), as listed in Section 4.8.1.2, will be 
presented by SOC and PT as applicable.  AESI are defined by SMQ, CMQ, lab data, and/or 
dedicated e-CRF as described in Appendix 10.3.   
For Group B, the following variables will also be tabulated for infusion reactions TEAEs: 
 Intensity of the event (mild, moderate, or severe); 
 Number of events divided by the number of study treatment administrations received 
in respective treatment periods; 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 44 of 80 
 Time from first study treatment administration (DBTP or OLTP depending on the 
analysis) to first infusion reaction; 
For Group A, the following variables will also be tabulated for injection reactions TEAEs: 
 Intensity of the event (mild, moderate, or severe); 
 Number of events divided by the number of study treatment administrations received 
in DBTP treatment period; 
 Time from first study treatment administration to first injection reaction; 
 Description of the highest intensity of each symptom recorded in the specific e-CRF 
page with table and bar chart.  
5.8.3. 
Clinical Laboratory Measurements  
The following definitions will be applied to laboratory parameters: 
 Double-blind treatment period:  The treatment period used for quantitative analysis in 
the double-blind period is defined as the day after the first study drug administration 
to the day of the last double-blind study drug injection + 7 days for Group A. For 
Group B, the treatment period is defined from the day after the first administration of 
double-blind study treatment to the day of the last administration of double-blind 
study treatment + 28 days for those patients not proceeding into the open-label 
treatment period, or up to the day of the first open-label study treatment 
administration for those patients proceeding into the open-label treatment period. 
 Open-label treatment period:  The treatment period used for quantitative analysis in 
the open-label study period is defined from the day after the first dose of open-label 
study treatment to the day of the last dose of open label study treatment + 28 days. 
For respective treatment period (DBTP and OLTP), clinical laboratory parameter actual values 
(quantitative) and change from baseline values will be descriptively summarized at baseline and 
each post-baseline visit by at least patient number, mean, median, Q1, Q3, SD, minimum and 
maximum. Clinical laboratory parameters mean changes from baseline, with the corresponding 
SE, can be plotted at each visit in the case results warrant further investigation.  These 
parameters will be presented by the biological functions defined in Section 4.8.2. For glucose, 
only fasting samples will be included in the summaries. 
Individual patient laboratory parameter measurements will be additionally evaluated by PCSV 
criteria (See Appendix 10.4), specifically identifying patients with at least one post-baseline 
measurement that meets the PCSV criteria within the respective TEAE periods. These laboratory 
parameters will be presented by the biological functions defined in Section 4.8.2. The incidence 
of PCSVs at any time during the respective TEAE periods will be summarized regardless of the 
baseline level, and again according to the following baseline categories: 
 Normal (according to PCSV criterion/criteria)/missing 
 Abnormal according to PCSV criterion or criteria 
Patient listings of laboratory measurements that meet PCSV criteria will be provided for the 
report appendix.  For those laboratory parameters that don’t have an associated PCSV criteria, 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 45 of 80 
similar summary tables can be provided based on measurements outside the central laboratory 
normal ranges, if applicable. 
Drug-induced liver injury 
For respective treatment period (DBTP and OLTP), an evaluation of drug-induced serious 
hepatotoxicity (eDISH) with the graph of distribution of peak values of ALT versus peak values 
of total bilirubin will also be presented using post-baseline values during respective TEAE 
periods. Note that the ALT and total bilirubin values are presented on a logarithmic scale. The 
graph will be divided into 4 quadrants with a vertical line corresponding to 3 x ULN for ALT 
and a horizontal line corresponding to 2 x ULN for total bilirubin. 
Patient listing of possible Hy’s law cases identified by treatment group (i.e., patients with any 
elevated ALT>3 x ULN, and associated with an increase in bilirubin >2 x ULN, concomitantly 
or not) with ALT, AST, ALP, total bilirubin, and if available direct and indirect bilirubin will be 
provided. 
5.8.4. 
Analysis of Vital Signs 
The following definitions will be applied to vital signs parameters: 
 Double-blind treatment period:  The treatment period used for quantitative analysis in 
the double-blind period is defined as the day after the first study drug administration 
to the day of the last double-blind study drug injection + 7 days for Group A. For 
Group B, the treatment period is defined from the day after the first administration of 
double-blind study treatment to the day of the last administration of double-blind 
study treatment + 28 days for those patients not proceeding into the open-label 
treatment period, or up to the day of the first open-label study treatment 
administration for those patients proceeding into the open-label treatment period. 
 Open-label treatment period:  The treatment period used for quantitative analysis in 
the open-label study period is defined from the day after the first dose of open-label 
study treatment to the day of the last dose of open label study treatment + 28 days. 
For respective treatment period (DBTP and OLTP), the vital sign actual values and change from 
baseline values obtained while sitting will be descriptively summarized at baseline and each 
post-baseline visit by at least patient number, mean, median, Q1, Q3, SD, minimum and 
maximum. Vital sign mean changes from baseline, with the corresponding SE, can be plotted at 
each visit in the case results warrant further investigation. 
Individual patient vital sign measurements (regardless of sitting position) will be additionally 
evaluated by PCSV criteria, specifically identifying patients with at least one post-baseline 
measurement that meets the PCSV criteria within the TEAE period.  The incidence of PCSVs at 
any time during the respective TEAE periods will be summarized regardless of the baseline 
level, and again according to the following baseline categories: 
 Normal (according to PCSV criterion/criteria)/missing 
 Abnormal according to PCSV criterion or criteria 
Patient listings of vital sign measurements that meet PCSV criteria will be provided for the 
report appendix.   
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 46 of 80 
5.8.5. 
Analysis of 12-Lead ECG 
The following definitions will be applied to ECG parameters: 
 Double-blind treatment period:  The treatment period used for quantitative analysis in 
the double-blind period is defined as the day after the first study drug administration 
to the day of the last double-blind study drug injection + 7 days for Group A. For 
Group B, the treatment period is defined from the day after the first administration of 
double-blind study treatment to the day of the last administration of double-blind 
study treatment + 28 days for those patients not proceeding into the open-label 
treatment period, or up to the day of the first open-label study treatment 
administration for those patients proceeding into the open-label treatment period. 
 Open-label treatment period:  The treatment period used for quantitative analysis in 
the open-label study period is defined from the day after the first dose of open-label 
study treatment to the day of the last dose of open label study treatment + 28 days. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 47 of 80 
For respective treatment period (DBTP and OLTP), ECG parameters will be described through 
an overall interpretation of ECG status (e.g. normal, abnormal [clinically significant (Yes/No)]). 
The count and percentage of patients with at least 1 abnormal post-baseline ECG during the 
respective TEAE period will be summarized according to the following baseline status 
categories: 
 Normal/missing; 
 Abnormal 
Individual patient ECG measurements will be additionally evaluated by PCSV criteria, 
specifically identifying patients with at least one post-baseline measurement that meets the 
PCSV criteria within the TEAE period.  The incidence of PCSVs at any time during the 
respective TEAE periods will be summarized regardless of the baseline level, and again 
according to the following baseline categories: 
 Normal (according to PCSV criterion/criteria)/missing 
 Abnormal according to PCSV criterion or criteria 
Patient listings of ECG measurements that meet PCSV criteria will be provided for the report 
appendix.   
5.8.6. 
Physical Exams 
A list of patients with any clinically significant abnormality results will be generated. 
5.9. 
Analysis of Other Variables 
In general, for the double-blind period, the summary of results for other variables for patients in 
the double-blind SAF population will be presented by route of administration (Group A or Group 
B) and pooling the evinacumab dose regimens within each route of administration (Group A or 
Group B), with the intent to maximize efforts to identify potential safety signals. The treatment 
group data (individual evinacumab dose regimens and placebo) will also be presented with the 
intent to support the pooled dose regimens. No formal inferential testing will be performed. 
Summaries will be descriptive in nature. 
For Group B, summaries of safety results for the open-label period will be presented for patients 
in the open-label SAF, by the total number of patients administered open-label study treatment 
(ie.,15 mg/kg IV), as well as by the patient subgroups of study treatment received in the DBTP 
(ie., 5 mg/kg IV, 15 mg/kg IV, or placebo). No formal inferential testing will be performed for 
either period. Summaries will be descriptive in nature.  
All measurements, scheduled or unscheduled, fasting or not fasting, will be assigned to Global 
Analysis Windows (Appendix 10.2) in order to provide an assessment for all post-baseline visit.   
Hs-CRP, HbA1c, and HDL-C parameters will be summarized for the number of patients with 
data, mean, SD, median, minimum, maximum, Q1 and Q3 by analysis visit during the treatment 
period. The medians (with Q1-Q3) will be plotted for hs-CRP. The means (+/-SE) will be plotted 
for HbA1c and HDL-C. In addition, HbA1C will be summarized at each visit by diabetic status 
as recorded in the medical history e-CRF page (regardless of the ongoing status). Applying the 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 48 of 80 
PCSV criteria to HbA1c at any time during the TEAE period, the number of patients (and 
percentages) meeting the criteria will be summarized.  
5.10. 
Analysis of Pharmacokinetic and Pharmacodynamic Variables 
Descriptive statistics of concentrations of total evinacumab and total ANGPTL3 will be 
presented. For the determination of arithmetic means and descriptive statistics, individual 
concentration values below the LLOQ, will be set to zero. If geometric means are determined, 
individual concentrations values below the LLOQ will be imputed as LLOQ/2. 
Plots of the mean concentrations (linear and log scales) will be presented by nominal sampling 
time. Plots of the individual concentrations (linear and log scales) will be presented by actual 
sampling time. In the linear-scaled plots, concentrations below the LLOQ will be set to zero; in 
the log-scaled plots, concentrations below the LLOQ will be imputed as LLOQ/2. 
When appropriate, relationship between concentrations of evinacumab and LDL-C or other 
biomarkers may be evaluated descriptively. 
5.11. 
Analysis of Anti-evinacumab Antibody Variables 
The ADA variables described in Section 4.11 will be summarized by dose/cohort group in the 
ADA analysis set. Listings of ADA results and titers values presented by patient, time point, and 
study treatment received will be provided. Prevalence of treatment-emergent ADA will be 
assessed as absolute occurrence (N) and percent of patients (%), grouped by study treatment 
received. 
The influence of ADA on drug concentrations will be evaluated. Assessment of impact of ADA 
on safety and efficacy may be provided.  
Anti-drug antibody status and titer over the study duration may be classified as follows:  
 Pre-existing immunoreactivity, defined as a positive ADA assay response at baseline, 
with all post-dose ADA results negative, or a positive assay response at baseline, with 
all post-dose ADA assay responses less than 9-fold over baseline titer levels. 
 Treatment emergent - defined as any post-dose ADA positive response when baseline 
results are negative or missing. 
 Persistent - A positive result in the ADA assay detected in at least 2 consecutive 
post baseline samples separated by at least a 16-week post baseline period [based 
on nominal sampling time], with no ADA-negative results in-between, regardless 
of any missing samples 
 Indeterminate - A positive result in the ADA assay at the last collection time point 
analyzed only, regardless of any missing samples 
 Transient - Not persistent or indeterminate regardless of any missing samples 
 Treatment boosted - defined as any post-dose ADA response that is at least 9-fold 
over baseline titer levels when baseline results are positive 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 49 of 80 
 Titer category for subjects, by maximum ADA titer value: 
 Low (titer <1,000) 
 Moderate (1,000≤ titer ≤10,000) 
 High (titer >10,000) 
 NAb status (positive or negative) 
6. 
DATA CONVENTIONS 
The following analysis conventions will be used in the statistical analysis.  
6.1. 
Definition of Baseline for Efficacy/Safety Variables 
Unless otherwise specified, the baseline assessment is programmatically as the last available 
measurement prior to the date of the first double-blind study treatment administration. For 
patients randomized and not treated, the baseline value is defined as the last available value prior 
to the date of randomization. 
6.2. 
Data Handling Convention for Efficacy Variables  
Rules for handling missing data for primary and secondary efficacy variables are described in 
Section 5.7.1 and Section 5.7.1.4. 
6.3. 
Data Handling Convention for Missing Data 
Missing data will not be imputed in listings.  This section includes the methods for missing data 
imputation for some summary analyses, if necessary. 
Date and Time of First/Last Study Treatment 
Since the study drug is administered at the site, the date and time of study drug administration 
are filled in e-CRF. No missing data is expected. Date of first/last administration is the first/last 
start date of study drug filled in e-CRF. 
Adverse Event 
If the intensity of a TEAE is missing, it will be classified as “severe” in the frequency tables by 
intensity of TEAEs. If the assessment of relationship of a TEAE to the investigational product is 
missing, it will be classified as related to the investigational product. 
When the partial AE date/time information does not indicate that the AE started prior to study 
treatment or after the TEAE period, the AE will be classified as treatment-emergent. 
Medication/Procedure 
No imputation of medication/procedure start/end dates or times will be performed.  If a 
medication date or time is missing or partially missing and it cannot be determined whether it 
was taken prior or concomitantly or stopped prior to the first study treatment administration, it 
will be considered as concomitant medication/procedure. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 50 of 80 
Potentially Clinically Significant Value (PCSV) 
If a patient has a missing baseline value, this patient will be grouped in the category 
“normal/missing at baseline.” 
For PCSVs with 2 conditions, one based on a change from baseline value and the other on a 
threshold value or a normal range, with the first condition being missing, the PCSV will be based 
only on the second condition. 
For a PCSV defined on a threshold and/or a normal range, this PCSV will be derived using this 
threshold if the normal range is missing; e.g., for eosinophils the PCSV is >0.5 giga/L or >ULN 
if ULN ≥0.5 giga/L.  When ULN is missing, the value 0.5 should be used. 
Measurements flagged as invalid by the laboratory will not be summarized or taken into account 
in the computation of PCSVs. 
6.4. 
Visit Windows 
Visit windows will be programmatically imposed on those efficacy and safety measures 
repeatedly collected over the course of the study. These visit windows are derived from the 
number of days in study, specifically assigning day ranges to represent the study assessment 
schedule provided in the protocol.  Data analyzed by time point (including efficacy, laboratory 
safety data, vital signs, and ECG) will be summarized using the analysis windows given in 
Appendix 10.2 (i.e. efficacy analysis windows for efficacy and global analysis windows for 
safety). These analysis windows will be applicable for all analyses, and they are defined to 
provide more homogeneous data for time point-specific analyses. If multiple valid values of a 
variable exist within an analysis window, the nearest from the targeted study day will be selected 
for analysis, unless otherwise specified. If the difference is a tie, the value after the targeted 
study day will be used. If multiple valid values of a variable exist within a same day, then the 
first value of the day will be selected when time is available, else the scheduled visit will be 
selected. 
6.5. 
Unscheduled Assessments 
For efficacy, safety laboratory data, vital signs, and ECG unscheduled visit measurements may 
be used to provide a measurement for a time point, including baseline, if appropriate according 
to their definitions. The measurements may also be used to determine abnormal values, AESIs, 
and PCSVs. 
6.6. 
Pooling of Centers for Statistical Analyses 
The randomization scheme was not stratified by center because the primary efficacy variable is 
centrally assessed and expected not to be influenced by the center when other factors such as diet 
are already controlled. Therefore, the center will not be added as factor in the primary analysis 
model. 
6.7. 
Statistical Technical Issues 
Not Applicable.  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 51 of 80 
7. 
TIMING OF STATISTICAL ANALYSES 
7.1. 
First Step: Group B Main Efficacy and Safety Analysis 
The first analysis will be conducted when all Group B patients have been randomized and all 
data through week 24 has been collected and validated for these patients.  This will consist of the 
final efficacy analysis of the primary and secondary endpoints for the Group B patients.  The 
Group B safety analysis will be performed on all double-blind safety data and any open-label 
safety data collected and validated at the time of the first step analysis. 
The results of the first analysis will not be used to change the conduct of the ongoing study in 
any aspect. This first analysis may be used for submission to health authorities.  
Individuals involved in the first step analysis of the study will not be involved in the conduct of 
the study afterwards.  Individual patient identification will not be released to anyone who is 
directly involved in the conduct of the study.  The first step analysis process, the measures used 
to protect the blind and the integrity of the study, the communication plan, and the 
confidentiality agreement will be described in a separate document. 
7.2. 
Second Step: Group A Main Efficacy and Safety Analysis 
The second analysis will be conducted when all Group A patients have been randomized and all 
data through week 16 has been collected and validated for these patients.  This will consist of the 
final efficacy analysis of the primary and secondary endpoints for the Group A patients.  The 
Group A and Group B (open-label period) safety analyses will be performed on all safety data 
collected and validated at the time of the second step analysis. 
Results of the second analysis will not be used to change the conduct of the ongoing study in any 
aspect.  This second analysis may be used for submission to health authorities.  
Individuals involved in the second step analysis of the study will not be involved in the conduct 
of the study afterwards.  Individual patient identification will not be released to anyone who is 
directly involved in the conduct of the study.  The second step analysis process, the measures 
used to protect the blind and the integrity of the study, the communication plan, and the 
confidentiality agreement, will be described in a separate document. 
7.3. 
Third Step: Final Safety Analysis 
The third analysis will be conducted at EOS and will consist of the final safety analysis through 
the follow-up period (week 39 for Group A and week 92 for Group B). 
7.4. 
Additional Rules 
Analyses methods and conventions described in the other sections of this SAP will be applied for 
all analyses as applicable. The following additional rules will apply for analyses performed at 
first and second step analyses: 
 Any lipid assessments within efficacy analysis windows up to the week 24 visit for 
Group B and week 16 visit for Group A will be taken into account (may include few 
unscheduled lipid data soon after the cut-off date).  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 52 of 80 
 Patients without end of treatment visit performed at the time of the cut-off date will 
be considered as ongoing and exposed up to the cut-off date. Therefore: 
 Patients who did not complete the respective treatment period nor prematurely 
discontinued the study treatment at cut-off date will be analyzed as “ongoing” in 
the disposition summary. 
 Their TEAE period and treatment period will end at the respective data cut-off 
date. 
 Their treatment duration will be derived by considering date of cut-off as last 
administration date.  
 Analyses of number of administrations, and mean administration frequency will be 
performed up to the last administration reported in the e-CRF up to the cut-off date.  
 AEs occurring, worsening or becoming serious after the cut-off date will not be 
included in the analyses. However, any available outcome before database lock, 
regardless of timing in relation to the cut-off date, of an adverse event starting prior to 
the cut-off date will be taken into account. Medications, treatment 
discontinuations/completions and deaths occurring after the cut-off date will not be 
included in the analyses.  
 Post-treatment period, and post-study period are not applicable for ongoing patients. 
Analyses of post-study deaths and post-treatment medications will be performed for 
patients who either completed or prematurely discontinued the treatment before or at 
the data cut-off date. 
 Analysis of status at last study contact and proportion of patients with insufficient 
follow-up will be provided for patients who either completed or prematurely 
discontinued the treatment before or at the data cut-off date. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 53 of 80 
8. 
SOFTWARE 
All analyses will be done using SAS Version 9.4 or higher. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 54 of 80 
9. 
REFERENCES 
1. ICH. (1998, February 5). ICH Harmonized tripartite guideline: Statistical principles for 
clinical trials (E9). International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use. 
2. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The 
prevention and treatment of missing data in clinical trials. N Engl J Med. 2012 Oct 
4;367(14):1355-60. doi: 10.1056/NEJMsr1203730. 
3. Mehrotra DV, Li X, Liu J, Lu K. Analysis of longitudinal clinical trials with missing data 
using multiple imputation in conjunction with robust regression. Biometrics. 2012 
Dec;68(4):1250-9. doi: 10.1111/j.1541-0420.2012.01780.x. 
4. Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not 
affect the type I error rate. Stat Med. 2003; 22(23): 3571-81.
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 55 of 80 
10. 
APPENDIX 
10.1. 
Summary of Statistical Analyses 
Primary Efficacy Analysis: 
Endpoint 
Analysis 
Populations 
Estimand 
Statistical 
Method 
Supportive 
Analysis 
Subgroup 
Analysis 
Other 
Analyses 
Primary Endpoint 
Percent 
change 
from 
baseline in 
calculated 
LDL-C at 
week 16 
ITT 
ITT estimand: 
The calculated 
LDL-C at 
week 16 will 
be the LDL-C 
value obtained 
within the 
week 16 
efficacy 
analysis 
window, 
regardless of 
adherence to 
treatment and 
subsequent 
therapies. 
MMRM 
Yes 
Yes 
 
1. mITT 
2. PMM (randomized 
population) 
3. MMRM using strata 
based on observed 
data 
 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 56 of 80 
10.2. 
Windows for Analysis Time Points 
Below are the definitions for the visit windows programmatically imposed on measures 
repeatedly collected over the course of the study.  These visit windows reflect the study schedule 
of assessments as described in the protocol.  
The visit windows are constructed using ranges applied to the number of days in study (study 
days) when the measure is collected. Below are the relevant definitions for the analysis visit 
windows:  
1. Study day is defined as the number of days since the first study treatment administration 
+1. The first study treatment occurs on Study Day 1. 
2. Open-label study day is defined as the number of days since the first open-label study 
treatment administration+1 
3. Since the protocol specifies that measurements be collected before study treatment is 
administered on a given day, it is appropriate that baseline include Day 1. 
4. For randomized but not treated patients, Day 1 is the day of randomization.   
Table 1 Global Analysis Windows for Group B (IV)  
Visit label 
Targeted Study Day 
Targeted Open-Label Study 
Day 
Analysis Window in Study 
Day 
Screening 
< Day 1 
N/A 
Measurement obtained prior 
to first study treatment, and 
not defined as baseline visit 
Baseline  
1 
N/A 
Measurement obtained 
closest to first study 
treatment, while remaining 
prior to first study treatment 
Week 2 
15 
N/A 
2 to 21 
Week 4 
29 
N/A 
22 to 35 
Week 6 
43 
N/A 
36 to 49 
Week 8 
57 
N/A 
50 to 70 
Week 12 
85 
N/A 
71 to 98 
Week 16 
113 
N/A 
99 to 128 
Week 20 
141 
N/A 
129 to 154 
Week 24 
169 
Day 1 
155 to 182 
Week 28 
197 
29 
183 to 210 
Week 32 
225 
57 
211 to 238 
Week 36 
253 
85 
239 to 266 
Week 40 
281 
113 
267 to 294 
Week 44 
309 
141 
295 to 322 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 57 of 80 
Visit label 
Targeted Study Day 
Targeted Open-Label Study 
Day 
Analysis Window in Study 
Day 
Week 48 
337 
169 
323 to 350 
Week 52 
365 
197 
351 to 378 
Week 56 
393 
225 
379 to 406 
Week 60 
421 
253 
407 to 434 
Week 64 
449 
281 
435 to 462 
Week 68 
477 
309 
463 to 490 
Week 72 
505 
337 
491 to 518 
FU – W4   
For patients prematurely 
discontinued trt: last 
study trt + 28 days  
For patients completed 
OLTP: 533 
 
For patients prematurely 
discontinued trt: last study trt + 
28 days  
For patients completed OLTP: 
365 
 
For patients prematurely 
discontinued trt: last study trt 
to 56 days after last study trt 
For patients completed 
OLTP: 519 to 560 
 
 FU – W12 
For patients prematurely 
discontinued trt: last 
study trt + 84 days  
For patients completed 
OLTP: 589 
 
For patients prematurely 
discontinued trt: last study trt + 
84 days  
For patients completed OLTP: 
421 
 
For patients prematurely 
discontinued trt: 57 days 
after to 112 days after last 
study trt 
For patients completed 
OLTP: 561 to 616 
 
FU – W20 
For patients prematurely 
discontinued trt: last 
study trt + 140 days  
For patients completed 
OLTP: 645 
 
For patients prematurely 
discontinued trt: last study trt + 
140 days  
For patients completed OLTP: 
477 
 
For patients prematurely 
discontinued trt: 113 days 
after to 168 days after last 
study trt 
For patients completed 
OLTP: 617 to 672 
 
FU > W20 
N/A 
N/A 
 For patients prematurely 
discontinued trt: >168 days 
after last study trt  
For patients completed 
OLTP:  
> 672 
 
Study days are calculated from the day of first double-blind IMP infusion, the day of first double-blind IMP 
infusion being Day 1. For randomized but not treated patients, Day 1 is the day of randomization.  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 58 of 80 
Table 2 Efficacy Analysis Windows – Statistical Testing for Group B (IV) 
Visit Label 
Targeted study day 
Analysis window in study days 
Screening 
< Day 1 
Measurement obtained prior to first study 
treatment, and not defined as baseline visit 
Baseline  
1 
Measurement obtained closest to first study 
treatment, while remaining prior to first study 
treatment 
Week 2 
15 
2 to 21 
Week 4 
29 
22 to 35 
Week 6 
43 
36 to 49 
Week 8 
57 
50to 70 
Week 12 
85 
71 to 98 
Week 16 
113 
99 to 128 
Week 20 
141 
129 to 154 
Week 24 
169 
155 to 182  
Table 3 Global Analysis Windows for Group A (SC)  
Visit label 
Targeted Study Day 
Analysis Window in Study Day 
Screening 
< Day 1 
Measurement obtained prior to first study 
treatment, and not defined as baseline visit 
Baseline  
1 
Measurement obtained closest to first study 
treatment, while remaining prior to first study 
treatment 
Week 1 
8 
2 to 11 
Week 2 
15 
12 to 18 
Week 3 
22 
19 to 25 
Week 4 
29 
26 to 32 
Week 5 
36 
33 to 39 
Week 6 
43 
40 to 46 
Week 7 
50 
47 to 53 
Week 8 
57 
54 to 60 
Week 9 
64 
61 to 67 
Week 10 
71 
68 to 74 
Week 11 
78 
75 to 81 
Week 12 
85 
82 to 88 
Week 13 
92 
89 to 95 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 59 of 80 
Visit label 
Targeted Study Day 
Analysis Window in Study Day 
Week 14 
99 
96 to 102 
Week 15 
106 
103 to 109 
Week 16 
113 
110 to 140 
FU – W8   
For patients prematurely discontinued 
trt: last study trt + 56 days  
For patients completed DBTP: 169 
 
For patients prematurely discontinued trt: last 
study trt to 84 days after last study trt 
For patients completed DBTP: 141 to 196 
 
 FU – W16 
For patients prematurely discontinued 
trt: last study trt + 112 days  
For patients completed DBTP: 225 
 
For patients prematurely discontinued trt: 85 days 
after last study trt to 137 days after last study trt 
For patients completed DBTP: 197 to 249 
 
FU – W23 
For patients prematurely discontinued 
trt: last study trt + 161 days  
For patients completed DBTP: 274 
 
For patients prematurely discontinued trt: 138 
days after last study trt to 186 days after last study 
trt 
For patients completed DBTP: 250 to 298 
 
FU > W23 
N/A 
For patients prematurely discontinued trt: >186 
days after last study trt  
For patients completed DBTP:  
> 298 
 
Table 4 Efficacy Analysis Windows – Statistical Testing for Group A (SC)  
Visit label 
Targeted Study Day 
Analysis Window in Study Day 
Screening 
< Day 1 
Measurement obtained prior to first study 
treatment, and not defined as baseline visit 
Baseline  
1 
Measurement obtained closest to first study 
treatment, while remaining prior to first study 
treatment 
Week 2 
15 
12 to 21 
Week 4 
29 
22 to 35 
Week 6 
43 
36 to 49 
Week 8 
57 
50 to 63 
Week 10 
71 
64 to 77 
Week 12 
85 
78 to 91 
Week 14 
99 
92 to 106 
Week 16 
113 
107 to 126 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 60 of 80 
10.3. 
List of AESIs with Data Sources and Definitions of SMQ/CMQ  
Table 3 Summary of AESIs and the Methods of Data Collections and Derivations 
AESI 
Using an e-CRF specific 
tick box on AE page 
Using Standard MedDRA 
Query (SMQ)/company 
MedDRA Query (CMQ) or lab 
data 
Anaphylactic reactions   
 
Yes 
No 
General allergic events  
No 
SMQ “hypersensitivity” (broad 
and narrow) excluding the 
following preferred terms linked 
to local injection site reactions 
(“infusion site dermatitis”, 
“infusion site hypersensitivity”, 
“infusion site rash”, “infusion 
site urticaria”, “injection site 
dermatitis”, “injection site 
hypersensitivity”, “injection site 
rash”, “injection site urticaria”, 
“injection site vasculitis”) plus 
“idiopathic angioedema” 
Infusion reactions  
Yes 
No 
Hepatic Disorders 
 
No 
 SMQ Drug-related hepatic 
disorder 
 Potentially clinically 
significant value (PCSV) in 
Appendix 10.4,  
 Hy’s law eDISH plot, 
Pregnancy 
Yes 
No 
Symptomatic overdose with 
investigational medicinal 
product 
Yes 
No 
Neurocognitive events 
No 
CMQ for neurocognitive events 
as define based on Regulatory 
Agency request for another lipid 
lowering program (See Table 4 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 61 of 80 
AESI 
Using an e-CRF specific 
tick box on AE page 
Using Standard MedDRA 
Query (SMQ)/company 
MedDRA Query (CMQ) or lab 
data 
in Appendix 10.3 for the list of 
terms) 
Neurologic events  
Yes 
No 
New onset of diabetes (NOD) 
No 
No medical history of diabetes as 
specified in “Cardiovascular 
History and Cardiovascular Risk 
Factors” CRF page  
AND 
one of the following criteria: 
  
Lab criteria: At least 2 values 
of HbA1c ≥6.5% during the 
TEAE period. NOTE: For 
patients with only a single 
measurement available 
during the TEAE period, a 
single value ≥6.5% will be 
considered and qualify the 
patient as NOD by default. 
For patients with several 
HbA1c measurements but 
only with the last one ≥6.5%, 
this single value ≥6.5% will 
be considered and qualify the 
patient as NOD by default. 
OR 
  
Lab criteria: At least 2 values 
of fasting glucose ≥126 
mg/dL (7.0 mmol/L). NOTE: 
For patients with only a 
single measurement available 
during the TEAE period, a 
single value ≥126 mg/dL (7.0 
mmol/L) will NOT be 
considered and will NOT 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 62 of 80 
AESI 
Using an e-CRF specific 
tick box on AE page 
Using Standard MedDRA 
Query (SMQ)/company 
MedDRA Query (CMQ) or lab 
data 
qualify the patient as NOD. 
For patients with several 
fasting glucose 
measurements but only with 
the last one ≥126 mg/dL (7.0 
mmol/L), this single value ≥ 
126 mg/dL (7.0 mmol/L) will 
NOT be considered and will 
NOT qualify the patient as 
NOD. 
OR 
 HLT Diabetes mellitus (incl 
subtypes) 
OR 
 Initiation of any new 
concomitant medication for 
hyperglycemia during the 
treatment period 
Diabetes mellitus or diabetic 
complications 
No 
 HLGT “diabetes 
complications” (including 
PTs pertaining to the 
secondary SOC included in 
the HLGT), HLT “diabetes 
mellitus”, and HLT 
“carbohydrate tolerance 
analyses (incl diabetes)” 
excluding PTs “blood 
glucose decreased” and 
“Glycosylated haemoglobin 
decreased” and including the 
PTs “hyperglycaemia”, 
“Hyperglycaemic 
unconsciousness” and 
“Hyperglycaemic seizure” 
from the HLT 
"Hyperglyceamic conditions 
NEC"  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 63 of 80 
AESI 
Using an e-CRF specific 
tick box on AE page 
Using Standard MedDRA 
Query (SMQ)/company 
MedDRA Query (CMQ) or lab 
data 
 Changes in diabetic 
medication dosage 
(specifically increases in 
dosage) or initiation of 
additional diabetic 
medication 
Pancreatitis 
Yes 
No 
Cataracts 
No 
HLT Cataract conditions 
Immune complex diseases 
No 
SMQ (Narrow) Systemic lupus 
erythematous  
SMQ (Narrow) Vasculitis 
SMQ (Narrow) Guillain-Barre 
syndrome 
Muscle events/CK elevation 
No 
 Lab data analyses (e.g. 
PCSV) 
 All preferred terms under 
system organ class (SOC): 
Musculoskeletal and 
connective tissue disorders  
 Rhabdomyolysis/myopathy 
(Narrow SMQ) 
Table 4 CMQ “Neurocognitive disorders – FDA’s recommendation” 
MedDRA level 
MedDRA Term Label 
PTCD 
Amnesia 
PTCD 
Amnestic disorder 
PTCD 
Anterograde Amnesia 
PTCD 
Behavioural and Psychiatric Symptoms of Dementia 
PTCD 
Change in sustained attention 
LLTCD 
Cognitive Deterioration 
PTCD 
Cognitive Disorder 
LLTCD 
Confusion 
LLTCD 
Confusion Aggravated 
PTCD 
Confusional State 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 64 of 80 
MedDRA level 
MedDRA Term Label 
PTCD 
Delirium 
PTCD 
Dementia 
PTCD 
Dementia Alzheimer's type 
LLTCD 
Dementia Nos 
LLTCD 
Dementia Nos Aggravated 
LLTCD 
Dementia of the Alzheimer's type NOS 
PTCD 
Dementia with Lewy Bodies 
PTCD 
Disorientation 
PTCD 
Disturbance in attention 
PTCD 
Executive dysfunction 
PTCD 
Frontotemporal Dementia 
LLTCD 
Global Amnesia 
PTCD 
Illogical Thinking 
PTCD 
Impaired reasoning 
PTCD 
Incoherent 
PTCD 
Judgement impaired 
PTCD 
Memory Impairment 
PTCD 
Mental Impairment 
LLTCD 
Mental Impairment Nos 
LLTCD 
Mental State Abnormal Aggravated 
PTCD 
Mental Status Changes 
PTCD 
Mini Mental Status Examination Abnormal 
PTCD 
Presenile Dementia 
PTCD 
Retrograde Amnesia 
PTCD 
Senile Dementia 
LLTCD 
Senile Dementia Nos 
LLTCD 
Short-term Memory Loss 
PTCD 
Thinking Abnormal 
LLTCD 
Thinking Slowed 
PTCD 
Transient Global Amnesia 
PTCD 
Vascular Dementia 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 65 of 80 
10.4. 
Criteria for Potentially Clinically Significant Values (PCSV) 
Parameter 
PCSV 
Clinical chemistry 
ALT 
By distribution analysis: 
 
>2 ULN and baseline ≤ 2 ULN 
>3 ULN and baseline ≤ 3 ULN 
>5 ULN and baseline ≤ 5 ULN 
>10 ULN and baseline ≤ 10 ULN 
>20 ULN and baseline ≤ 20 ULN 
 
AST 
By distribution analysis: 
 
>2 ULN and baseline ≤ 2 ULN 
>3 ULN and baseline ≤ 3 ULN 
>5 ULN and baseline ≤ 5 ULN 
>10 ULN and baseline ≤ 10 ULN 
>20 ULN and baseline ≤ 20 ULN  
Alkaline Phosphatase 
> 1.5 ULN and baseline ≤ 1.5 ULN 
Total Bilirubin 
> 1.5 ULN and baseline ≤ 1.5 ULN 
> 2 ULN and baseline ≤ 2 ULN 
Conjugated bilirubin 
> 35% total bilirubin (when total bilirubin >1.5 ULN) 
ALT and Total Bilirubin 
ALT > 3 ULN and Total Bilirubin > 2 ULN and baseline ALT≤3 ULN or Total 
bilirubin ≤ 2 ULN 
CPK 
> 3 ULN and ≤ 5 ULN and baseline ≤ 3ULN 
>5 ULN and ≤  10 ULN and baseline ≤ 5 ULN 
>10 ULN and baseline ≤ 10 ULN 
Creatinine 
 150 mol/L (adults) 
 30% from baseline 
 100% from baseline 
CLcr (mL/min) 
(Estimated creatinine 
clearance based on the 
Cokcroft-Gault equation) 
≥15 - <30 (severe decrease in GFR) 
≥30 - < 60 (moderate decrease in GFR) 
≥60 - <90 (mild decrease in GFR) 
≥ 90 (normal GFR) 
eGFR (mL/min/1.73m2) 
(Estimate of GFR based on 
an MDRD equation)  
 
≥15 - <30 (severe decrease in GFR) 
≥30 - < 60 (moderate decrease in GFR) 
≥60 - <90 (mild decrease in GFR) 
≥ 90 (normal GFR) 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 66 of 80 
Parameter 
PCSV 
Uric Acid 
   Hyperuricemia: 
   Hypouricemia: 
 
>408 µmol/L 
<120 µmol/L 
Blood Urea Nitrogen 
≥17 mmol/L 
Chloride 
<80 mmol/L 
>115 mmol/L 
Sodium 
129 mmol/L 
 160 mmol/L 
Potassium 
< 3  mmol/L 
 5.5 mmol/L 
Glucose 
   Hypoglycaemia 
   Hyperglycaemia 
 
 3.9 mmol/L and < LLN 
  7 mmol/L (fasted);  11.1 mmol/L (unfasted) 
HbA1c 
>8% 
Albumin 
≤25 g/L 
CRP 
> 2 ULN or 
 >10 mg/L, if ULN not provided 
Hematology 
WBC 
< 3.0 Giga/L (3000/ mm3) (Non-Black) 
< 2.0 Giga/L (2000/ mm3) (Black) 
≥16.0 Giga/L (16000/ mm3) 
 
Lymphocytes 
>4.0 Giga/L 
Neutrophils 
< 1.5 Giga/L (1500/ mm3) (Non-Black) 
< 1.0 Giga/L (1000/ mm3) (Black) 
Monocytes 
>0.7 Giga/L 
Eosinophils 
> 0.5 Giga/L (500/ mm3) 
or > ULN if ULN  0.5 Giga/L 
Hemoglobin 
≤115 g/L (Male); ≤95 g/L (Female) 
≥185 g/L (Male); ≥165 g/L (Female) 
Decrease from Baseline ≥15 g/L 
Decrease from Baseline ≥20 g/L 
 
Hematocrit 
≤0.37 v/v (Male) ; ≤0.32 v/v (Female) 
≥0.55 v/v (Male) ; ≥0.5 v/v (Female) 
RBC 
≥6 Tera/L 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 67 of 80 
Parameter 
PCSV 
Platelets 
< 100 Giga/L (100 000/mm3) 
≥700 Giga/L (700000/mm3) 
Urinalysis 
pH 
≤4.6 
≥8 
Vital signs 
HR 
 50 bpm and decrease from baseline  20 bpm 
 120 bpm and increase from baseline  20 bpm 
SBP 
 95 mmHg and decrease from baseline  20 mmHg 
 160 mmHg and increase from baseline  20 mmHg 
DBP 
Young and elderly patients 
 45 mmHg and decrease from baseline  10 mmHg 
 110 mmHg and increase from baseline  10 mmHg 
Orthostatic Hypotension 
SBP St – Su  - 20 mmHg 
DBP St – Su  - 10 mmHg 
Weight 
5% increase versus baseline 
5% decrease versus baseline 
ECG parameters 
HR 
 50 bpm and decrease from baseline  20 bpm 
 120 bpm and increase from baseline  20 bpm 
PR 
≥220 ms and increase from baseline ≥20 ms 
QRS 
 120 ms 
QTc 
Borderline 
Prolonged* 
Additional 
Absolute values (ms) 
Borderline  
      431-450 ms (Male) 
      451-470 ms (Female) 
Prolonged* 
       > 450 ms (Male)        
       > 470 ms (Female) 
       QTc   ≥500 ms            
 
Increase versus baseline (Males and Females) 
Borderline 
 30-60 ms 
Prolonged * 
 > 60 ms 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 68 of 80 
10.5. 
Detailed Description of the Multiple Imputation Procedure 
The following is a detailed description of the multiple imputation procedure which will be used 
for analysis of the secondary efficacy endpoints. 
In general, the missing pattern is anticipated to be not monotone, a two-step approach will be 
used: 
 Step 1:  the MCMC method will be used in conjunction with the 
IMPUTE=MONOTONE option to create an imputed data set with a monotone 
missing pattern. Set the SEED=1643 option in SAS MI procedure 
 Step 2:  Using the monotone data set from step 1, missing data will be imputed using 
the regression method. Set the SEED=3461 option in SAS MI procedure 
The imputation model for step 1 will include the treatment group and the values of the analyzed 
parameter at baseline and planned time-points up to week 24/week 16. 
The imputation model for step 2 will include the same variables as in step 1 with the following 
additional variables: 
 the randomization strata; 
 age, BMI, and gender (age and BMI included as continuous variables). 
Non-continuous variables included in the imputer’s model (i.e., treatment group, randomization 
strata and gender) are not expected to be missing. 
In addition, for continuous efficacy variables anticipated to have a non-normal distribution 
(i.e. TG and Lp(a)), data will be log-transformed before imputation process and then 
back-transformed to create the imputed data sets using the TRANSFORM statement of SAS MI 
procedure. 
For variables other than those continuous efficacy variables anticipated to have a non-normal 
distribution (i.e. TG and Lp(a)), for each simulation leading to negative imputed value, another 
value will be redrawn using MINIMUM option of SAS MI procedure. 
The number of imputations (100) will be informally verified by replicating sets of 100 
imputations and checking whether the combined results are stable. If not stable, the number of 
imputations will be increased and informally checked as above, and thus continued until stable 
estimates are obtained. 
10.6. 
Detailed Description of Pattern Mixture Model 
As a sensitivity analysis of the primary efficacy endpoint (i.e. percent change from baseline to 
Week 16 in LDL-C), a pattern-mixture model approach will be used, with a different imputation 
strategy applied for missing LDL-C values during the on-treatment period (i.e. within the time 
period from the first double-blind study treatment administration up to the day of the last double-
blind study treatment administration +35 days or to the day before the first open-label study 
treatment administration, whichever comes first for Group B or +14 days for Group A) and 
missing  LDL-C values after treatment discontinuation (i.e. after the day of last study treatment 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 69 of 80 
administration +35 days for Group B or +14 days for Group A) based on the following 
assumptions: 
 Patients within 35 days for Group B or 14 days for Group A of their last study 
treatment administration would continue to show benefit from treatment similar to 
that observed at the scheduled time point. Therefore, LDL-C values missing during 
the on-treatment period will be considered “Missing at Random” and imputed using a 
model estimated using all samples collected on treatment. 
 Patients who stopped taking their study treatment no longer benefited from it in the 
future, and thus tended to have LDL-C values returning to baseline. Thus LDL-C 
values missing after treatment discontinuation will be imputed based on patient’s own 
baseline value. 
The assumptions for this approach are based on the following considerations: 
 Missing values during the on-treatment period are mostly consecutive to: 
 Visits performed outside of the pre-specified time-window  
 No blood sample available although visit was done 
 LDL-C not measurable due to technical reasons 
In addition, these missing data are often intermittent, i.e. followed by LDL-C values 
collected at subsequent visits. It is therefore considered reasonable to assume that these 
missing data were “At Random”. 
Missing LDL-C values will be imputed 100 times to generate 100 complete data sets. The 
percent change from baseline to Week 16 will be derived from observed and imputed LDL-C at 
this time point. The completed data sets will be analyzed using an analysis of covariance 
(ANCOVA) model with treatment group and randomization strata as fixed effects, and the 
baseline LDL-C value as continuous covariate. The results from the 100 analyses will be 
combined using Rubin’s formulae. If necessary, the number of imputations (100) will be 
increased until stable estimates are obtained. 
Imputation of missing data during the on-treatment period 
Missing LDL-C values during the on-treatment period will be imputed from other on-treatment 
measurements assuming Missing At Random, using SAS® MI procedure. 
Only LDL-C values collected during the on-treatment period will be included in the imputation 
model. This way, missing LDL-C values during the on-treatment period will be imputed based 
solely on observed on-treatment LDL-C values. 
The imputation model will include the treatment arm, baseline LDL-C value, and all LDL-C 
values at pre-specified visits. Since the pattern of missing data will necessarily be non-monotone, 
a Monte-Carlo Markov Chain (MCMC) method will be used. A minimum value of 0 will be 
specified in order to avoid negative imputed LDL-C values. 
A sample SAS code is provided below: 
proc mi data=DATAIN out=DATAOUT nimpute=100 minimum=. 0 0 0 0 0 0 0 0 SEED=1643;  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 70 of 80 
  mcmc impute=monotone; 
  var ARM LDL_BASE LDL_W2 LDL_W4 LDL_W8 LDL_W12 LDL_W16; 
run; 
As stated above, the input dataset DATAIN will include only LDL-C values collected during the 
on-treatment period. Any LDL-C values collected during the post-treatment period will be 
excluded from the input dataset. In practice, the MI procedure will generate imputed values for 
all missing values (whether on-treatment or post-treatment), but only imputed values during the-
on-treatment period will be kept in the final datasets that will be analyzed using ANCOVA. 
Imputed values during the post-treatment period will be discarded and replaced by imputed 
values described in the next paragraph. 
Imputation of missing data after treatment discontinuation 
Missing LDL-C values during the post-treatment period will be imputed assuming LDL-C values 
would on average return to baseline values. 
For each patient, missing post-treatment LDL-C values will be imputed 100 times, using a 
random draw from a normal distribution (SEED=3461), with mean equal to patient’s own 
baseline value and variance equal to the conditional variance at the specific time-point, given the 
baseline value. 
Let Y0 and Y1 denote the LDL-C at baseline and at the specific time-point respectively. Since Y0 
and Y1 are assumed to have a bivariate normal distribution, the conditional variance of Y1 given 
Y0 is: 
)
1(
)
(
2
2
1
0
0
1




y
Y
Y
Var
 
Where 
2
1
 denotes the variance of Y1 and ρ the coefficient of correlation between Y0 and Y1. 
The conditional variance will be estimated from observed data within the same treatment arm at 
the specific time-point. 
During the random generation process, a minimum value of 0 will also be applied in order to 
avoid negative imputed LDL-C values.  
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 71 of 80 
10.7. 
Schedule of Time and Events 
Table 1: 
Screening Schedule of Events – Patients Requiring Medication Change or 
Daily Statin Stabilization at Study Entry 
Visit Number 
Visit 1a 
Pre-Screening  
Visit 1 
Full Screening Visit 
Visit Window (Day) 
 
Day -14 to -1 
Week 
 
-2 
Screening/Baseline: 
 
Informed Consent 
X 
 
 
X 
Medication Adjustment 
X 
 
Inclusion/Exclusion 
X 
X 
Medical History/Surgical History, Alcohol Habits, Smoking 
Habits 
 
X 
Demographics 
 
X 
Treatment: 
 
Concomitant Medications 
X 
X 
Query LMT compliance 
X 
X 
Safety: 
 
Height 
 
X 
Weight 
 
X 
Vital Signs 
 
X 
Physical Examination 
 
X 
Electrocardiogram3 
 
X 
Contraception Use Reminder1 
X 
X 
Adverse Events 
X 
X 
Laboratory Testing2: 
 
Hematology 
 
X 
Chemistry 
 
X 
Urinalysis 
 
X 
Core Lipid Panel (8-hour fasting sample) 
X 
X 
HbA1c 
X 
X 
Pregnancy Test 
Urine 
Serum 
Hepatitis B and C serology 
 
X 
TSH 
 
X 
FSH 
 
X 
PK and Ab Samples: 
 
Research Samples (biomarkers) 
 
X 
Other: 
 
 
Review of diet 
X 
X 
 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 72 of 80 
Table 2: 
Screening Schedule of Events – Patients on Stable Statin, PCSK9 Inhibitor 
Antibody and Lipid Modifying Therapy Regimen at Study Entry 
Visit Number 
Visit 1 
Screening Visit 
 
Day-14 to -1 
Screening/Baseline: 
 
Informed Consent 
X 
 
X 
Inclusion/Exclusion 
X 
Medical/Surgical History, Alcohol habits, Smoking habits 
X 
Demographics 
X 
Treatment: 
 
Concomitant Medications 
X 
Query LMT compliance 
X 
Safety: 
 
Height 
X 
Weight 
X 
Vital Signs 
X 
Physical Examination 
X 
Electrocardiogram3 
X 
Contraception Use Reminder1 
X 
Adverse Events 
X 
Laboratory Testing2: 
 
Hematology 
X 
Chemistry 
X 
Urinalysis 
X 
Core Lipid Panel (8-hour fasting sample) 
X 
HbA1c 
X 
Pregnancy Test 
Serum 
Hepatitis B and C serology 
X 
TSH 
X 
FSH 
X 
PK and Ab Samples: 
 
Research samples (biomarkers) 
X 
Other: 
 
Review of diet 
X 
 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
 Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 73 of 80 
Table 3: 
Schedule of Events for SC Treatment Group A 
  
Double-Blind Treatment Period 
  
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 
10 
Visit 
11 
Visit 
12 
Visit 
13 
Visit 
14 
Visit 
15 
Visit 
16 
Visit 
17 
Visit 18/ 
EOT 
Day 
1 
8 
15 
22 
29 
36 
43 
50 
57 
64 
71 
78 
85 
92 
99 
106 
113 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Screening/Baseline: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Randomization 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Treatment: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Administer SC Study Drug4, 7, 8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Weight 
X 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
X 
Vital Signs11 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical Examination 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
Electrocardiogram3 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Laboratory Testing2: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Hematology 
X 
  
X 
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
Chemistry 
X 
  
X 
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
Urinalysis 
X 
  
X 
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
Core Lipid Panel  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
Specialty Lipid Panel  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
X 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
 Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 74 of 80 
  
Double-Blind Treatment Period 
  
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 
10 
Visit 
11 
Visit 
12 
Visit 
13 
Visit 
14 
Visit 
15 
Visit 
16 
Visit 
17 
Visit 18/ 
EOT 
Day 
1 
8 
15 
22 
29 
36 
43 
50 
57 
64 
71 
78 
85 
92 
99 
106 
113 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
HbA1c 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
hs-CRP 
X 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
X 
Pregnancy Test 
U 
  
  
  
U 
  
  
  
U 
  
  
  
U 
  
  
  
U 
PK and Research Samples: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
PK (evinacumab, alirocumab)4, 
ANGPTL3, PCSK9 sample 
X 
 X  
X 
  
X 
  
  
  
X 
  
X 
  
X 
  
  
  
X 
Anti-evinacumab antibody sample 
X 
  
  
  
X 
  
  
  
  
  
  
  
 
  
  
  
X 
Research samples (biomarkers) 
X 
  
  
  
  
  
X 
  
  
  
  
  
X 
  
  
  
X 
LDL-R function sample5 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
X 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Other: 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Review of low fat diet 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
 Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 75 of 80 
Table 4: 
Schedule of Events for IV Treatment Group B 
  
Double Blind Treatment Period 
Open-Label Treatment Period 
  
Visit 2 
Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 
Visit 8 
Visit 9 
End of 
DBTP 
Visit 10 
Visit 11 Visit 12 Visit 13 Visit 14 Visit 15 Visit 16 
Day 
1 
15 
29 
43 
57 
85 
113 
141 
169 
197 
225 
253 
281 
309 
337 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
2 
4 
6 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
Screening/Baseline: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Randomization 
X 
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Treatment: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Administer Double-Blind IV Study Drug4,7 
X 
  
X 
  
X 
X 
X 
X 
 
 
 
 
 
 
 
Administer Open-Label IV Study Drug4,7 
 
 
 
 
 
 
 
 
X# 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital Signs11 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical Examination 
  
  
  
  
  
  
  
  
X 
 
 
 
 
 
 
Electrocardiogram3 
  
  
  
  
  
  
  
  
X 
 
 
 
 
 
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Laboratory Testing2: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Hematology 
X 
X 
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Chemistry 
X 
X 
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Core Lipid Panel  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Specialty Lipid Panel  
X 
  
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
HbA1c 
  
  
  
  
  
X 
  
  
X 
 
 
X 
 
 
X 
hs-CRP 
X 
  
  
  
  
X 
  
  
X 
 
 
X 
 
 
X 
Pregnancy Test 
U 
  
U 
  
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
 Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 76 of 80 
  
Double Blind Treatment Period 
Open-Label Treatment Period 
  
Visit 2 
Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 
Visit 8 
Visit 9 
End of 
DBTP 
Visit 10 
Visit 11 Visit 12 Visit 13 Visit 14 Visit 15 Visit 16 
Day 
1 
15 
29 
43 
57 
85 
113 
141 
169 
197 
225 
253 
281 
309 
337 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
0 
2 
4 
6 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
PK and Research Samples: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
PK (evinacumab, alirocumab)4, 
ANGPTL3, and PCSK9  
X 
X 
X 
X 
X 
  
X 
  
X 
 
 
X 
 
 
X 
Anti-evinacumab antibody sample 
X 
  
 X 
  
  
X 
  
  
X 
 
 
X 
 
 
X 
Research samples (biomarkers) 
X 
  
  
X 
  
X 
  
  
X 
 
 
X 
 
 
X 
LDL-R function sample5 
X 
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
X 
X 
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
X 
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Other: 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
Review of low fat diet 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 77 of 80 
Table 5: 
Schedule of Events for IV Treatment Group B (Continued for Open-Label) 
  
Open-Label Treatment Period - Continued (Group B) 
  
Visit 17 
Visit 18 
Visit 19 
Visit 20 
Visit 21 
End of 
Open-
Label 
Visit 22 
Day 
365 
398 
421 
449 
477 
505 
Visit Window (Day) 
±3 
±3 
±3 
±3 
±3 
±3 
Week 
52 
56 
60 
64 
68 
72 
Treatment: 
 
 
 
 
 
 
Administer Open-Label IV Study Drug4, 7 
X 
X 
X 
X 
X 
 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
Safety: 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
Vital Signs11 
X 
X 
X 
X 
X 
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
Laboratory Testing2: 
 
 
 
 
 
 
Hematology 
 
 
X 
 
 
X 
Chemistry 
 
 
X 
 
 
X 
Urinalysis 
 
 
X 
 
 
X 
Core Lipid Panel  
X 
X 
X 
X 
X 
X 
Specialty Lipid Panel  
 
 
X 
 
 
X 
HbA1c 
 
 
X 
 
 
X 
hs-CRP 
 
 
X 
 
 
X 
Pregnancy Test 
U 
U 
U 
U 
U 
U 
PK and Research Samples: 
 
 
 
 
 
 
PK (evinacumab, alirocumab)4, ANGPTL3, and PCSK9  
 
 
X 
 
 
X 
Anti-evinacumab antibody sample 
 
 
X 
 
 
X 
Research samples (biomarkers) 
 
 
X 
 
 
X 
Other: 
 
 
 
 
 
 
Review of low fat diet 
X 
X 
X 
X 
X 
X 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 78 of 80 
Table 6: 
Follow-up Schedule of Events for SC Treatment Group A 
  
Follow-up Period 
  
Phone10 
Visit 19 
Visit 20 
Phone10 
Visit 21 
Visit 22 
Phone10 
Visit 23 
Visit 24/ 
EOS 
Day 
141 
169 
197 
225 
253 
274 
Visit Window (Day) 
±7 
±7 
±7 
±7 
±7 
±7 
Week 
20 
24 
28 
32 
36 
39 
Treatment: 
  
  
  
  
  
  
Concomitant Medications 
X 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
  
Weight 
  
  
  
  
  
X 
Vital Signs 
  
X 
  
X 
  
X 
Physical Examination 
  
  
  
  
  
X 
Electrocardiogram 
  
  
  
  
  
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
Laboratory Testing: 
  
  
  
  
  
  
Hematology 
  
X 
  
X 
  
X 
Chemistry 
  
X 
  
X 
  
X 
Urinalysis 
  
X 
  
X 
  
X 
Core Lipid Panel  
  
X 
  
X 
  
X 
Specialty Lipid Panel  
  
X 
  
X 
  
X 
HbA1c 
  
X 
  
X 
  
X 
hs-CRP 
  
  
  
  
  
X 
Pregnancy Test 
U (home) 9 
U 
U (home) 9 
U 
U (home) 9 
S 
PK and Research Samples: 
  
  
  
  
  
  
PK (evinacumab, alirocumab), ANGPTL3, 
PCSK9 sample 
  
X 
  
X 
  
X 
Anti-evinacumab antibody sample 
  
  
  
  
  
X 
Research samples (biomarkers) 
  
  
  
  
  
X 
Other: 
  
  
  
  
  
  
Review of low fat diet 
X 
X 
X 
X 
X 
X 
 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 79 of 80 
Table 7: 
Follow-up Schedule of Events for IV Treatment Group B 
  
Follow-up Period 
  
Visit 23 
Phone10 
Visit 24 
Visit 25 
Phone10 
Visit 26 
EOS 
Visit 27 
Day 
533 
561 
589 
617 
645 
Visit Window (Day) 
±7 
±7 
±7 
±7 
±7 
Week 
76 
80 
84 
88 
92 
Treatment: 
  
  
  
  
  
Concomitant Medications 
X 
X 
X 
X 
X 
Query LMT compliance 
X 
X 
X 
X 
X 
Safety: 
  
  
  
  
  
Weight 
  
  
  
  
X 
Vital Signs 
X 
  
X 
  
X 
Physical Examination 
  
  
  
  
X 
Electrocardiogram 
  
  
  
  
X 
Contraception Use Reminder1 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
Laboratory Testing: 
  
  
  
  
  
Hematology 
X 
  
X 
  
X 
Chemistry 
X 
  
X 
  
X 
Urinalysis 
X 
  
X 
  
X 
Core Lipid Panel  
X 
  
X 
  
X 
Specialty Lipid Panel  
X 
  
X 
  
X 
HbA1c 
  
  
X 
  
X 
hs-CRP 
  
  
  
  
X 
Pregnancy Test 
U 
U (home)9 
U 
U (home) 9 
S 
PK and Research Samples: 
  
  
  
  
  
PK (evinacumab, alirocumab), ANGPTL3, and 
PCSK9  
X 
  
X 
  
X 
Anti-evinacumab antibody sample 
  
  
  
  
X 
Research samples (biomarkers) 
  
  
  
  
X 
Other: 
  
  
  
  
  
Review of low fat diet 
X 
X 
X 
X 
X 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Regeneron Pharmaceuticals, Inc. 
Protocol: R1500-CL-1643 
Statistical Analysis Plan 
Date: October 16, 2019 
 
 
CONFIDENTIAL 
Page 80 of 80 
Footnotes for the Schedule of Events Tables  
EOS = end of study; EOT = end of treatment; U = urine; Core lipid panel = TC, calculated 
LDL-C, HDL-C, TGs, and non-HDL-C; Specialty lipid panel = ApoB, ApoA-1, ratio 
ApoB/ApoA-1, and Lp(a). 
1. All patients will be reminded of protocol-specified contraception use and pregnancy 
reporting. 
2. All laboratory samples should be collected before the administration of study drug. All 
samples should be collected following at least an 8-hour fast. 
3. Electrocardiograms should be performed before blood is drawn during visits requiring 
blood draws. 
4. On dosing days, PK collection should occur pre-dose for group A and prior to IV infusion 
and at the end of the IV infusion for group B. 
5. LDL-R function samples will be collected from a sub-set of patients based on enrollment 
and will be determined by IWRS. 
 
 
  
 
 
7. For SC dosing, patients will be observed at the clinical site for at least 30 minutes 
following each SC study drug administration.  For IV dosing, patients will be monitored 
for at least 60 minutes following the end of each IV study drug administration. 
8. Starting at W1 and every odd visit week (ie, W3, W5, W7, etc) thereafter, visiting home 
nurses may administer study drug for those patients randomized to Group A. 
9. WOCBP will be provided urine pregnancy tests with instructions to test for pregnancy at 
home. 
10. All subjects will be contacted by phone to query LMT compliance, inquire about AEs or 
changes to concomitant medications, confirm required contraception use and remind 
patients of pregnancy reporting.  Women of childbearing potential will report the results 
of their home urine pregnancy test.  All patients will also be queried regarding their low 
fat diet.  
11. Vital signs should be recorded prior to SC injection or IV infusion, and 30 minutes and 
60 minutes post-IV infusion. 
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Signature Page for VV-RIM-00090992 v1.0
Signature Page for VV-RIM-00090992 v1.0 Approved
ESig Approval
ESig Approval
ESig Approval
ESig Approval
ESig Approval
ESig Approval
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00


Signature Page for VV-RIM-00090992 v1.0
Signature Page for VV-RIM-00090992 v1.0 Approved
ESig Approval
                                        VV-RIM-00090992-1.0 Approved - 18 Oct 2019 GMT-5:00